Publications and Papers

MIA researchers play a significant role in expanding world knowledge about melanoma. We’ve compiled a list of all recent publications so you can access all MIA research papers in one place.

Pile-of-journals2_2ab4534b0a2984e07d7caeca8808129f

Characterizing Chronic Cutaneous Immune-Related Adverse Events Following Immune Checkpoint Inhibitors.

MIA2025-04-07T11:54:16+10:00March 12th, 2025|

Fletcher KA, Goodman RS, Lawless A, Woodford R, Fa’ak F, Tipirneni A, Patrinely JR, Yeoh HL, Rapisuwon S, Haydon A, Osman I, Mehnert JM, Long GV, Sullivan RJ, Carlino MS, Menzies AM, Dewan AK, Johnson DB. JAMA Dermatol, (Mar 12 2025), doi:10.1001/jamadermatol.2025.0025. ^{TOP 10%}

Erratum: First-Line Nivolumab Plus Relatlimab Versus Nivolumab Plus Ipilimumab in Advanced Melanoma: An Indirect Treatment Comparison Using RELATIVITY-047 and CheckMate 067 Trial Data.

MIA2025-04-07T12:08:39+10:00March 7th, 2025|

Long GV, Lipson EJ, Hodi FS, Ascierto PA, Larkin J, Lao C, Grob J-J, Ejzykowicz F, Moshyk A, Garcia-Horton V, Zhou Z-Y, Xin Y, Palaia J, McDonald L, Keidel S, Salvatore A, Patel D, Sakkal LA, Tawbi H, Schadendorf D. Journal of Clinical Oncology, 0, no. 0, (Mar 07 2025): JCO-25-00452, doi:10.1200/jco-25-00452. ^{TOP 10%}

Association of inherited genetic variants with multiple primary melanoma.

MIA2025-04-07T11:57:25+10:00March 4th, 2025|

Gibbs DC, Small BM, Autuori I, Leong SF, Ali E, Kenney J, Luo L, Kanetsky PA, Busam KJ, Cust AE, Anton-Culver H, Gallagher RP, Zanetti R, Rosso S, Sacchetto L, Edmiston SN, Conway K, Ollila DW, Begg CB, Berwick M, Orlow I, Thomas NE. Cancer Epidemiol Biomarkers Prev, (Mar 4 2025), doi:10.1158/1055-9965.Epi-24-1442.

Safety and efficacy of immune checkpoint therapy for the treatment of patients with cardiac metastasis: a multicenter international retrospective study.

MIA2025-03-27T15:26:42+11:00March 3rd, 2025|

Nassar AH, Abou Alaiwi S, El Zarif T, Denu R, Macaron W, Abdel-Wahab N, Freeman D, Vasbinder A, Hayeck S, Anderson E, Goodman RS, Johnson DB, Grynberg S, Shapira R, Kwan JM, Woodford R, Long GV, Haykal T, Dent S, Kojima Y, Yonemor K, Tandon A, Trevino A, Akhter N, Yang EH, Hui G, Drakaki A, El-Am E, Kozaily E, Al-Hader A, Bou Farhat E, Babu P, Mittra A, Li M, Jones N, Baena J, Juarez Herrera M, Foderaro S, Nana FA, Kim C, Sackstein P, Parikh K, Desai AP, Smith C, Cortellini A, Pinato DJ, Korolewicz J, Lopetegui-Lia N, Funchain P, Choudhary A, Asnani A, Navani V, Meyers D, Stukalin I, Ocejo Gallegos JA, Trent J, Nusrat S, Malvar C, McKay RR, Neilan TG, Choueiri TK, Naqash AR. J Immunother Cancer, 13, no. 3, (Mar 3 2025), doi:10.1136/jitc-2024-009364.

Single-Cell Multi-Omics: Insights into Therapeutic Innovations to Advance Treatment in Cancer.

MIA2025-04-07T14:08:11+10:00March 2nd, 2025|

Guan A, Quek C. International Journal of Molecular Sciences, 26, no. 6, (2025): 2447.

Timing of nivolumab with neoadjuvant carboplatin and paclitaxel for early triple-negative breast cancer (BCT1902/IBCSG 61-20; Neo-N): a non-comparative, open-label, randomised, phase 2 trial.

MIA2025-04-07T14:10:20+10:00March 1st, 2025|

Zdenkowski N, Kuper-Hommel MJJ, Niman SM, Francis PA, Baron-Hay S, Fox W, Menzies AM, Angus R, Punie K, Zardawi S, Regan MM, Loi S. The Lancet Oncology, 26, no. 3, (2025): 367-77, doi:10.1016/S1470-2045(24)00757-5. ^{TOP 10%}

Use of Patient Reported Outcome Measures (PROMs) in Clinical Care: A Community-Based Allied Health Setting.

MIA2025-04-07T13:38:40+10:00March 1st, 2025|

Pain T, Joseph A, Taylor M, Hazelwood G, Nan-Tie S, Dang T, Brooks B, Mistry S, Lindsay D, Morton RL. J Allied Health, 54, no. 1, (Spring 2025): e41-e48.

In vivo reflectance confocal microscopy role for early to advanced lentigo maligna melanoma spectrum: A systematic review and pooled analysis.

MIA2025-04-07T12:26:03+10:00March 1st, 2025|

Melhoranse Gouveia B, Ferguson PM, Lo SN, Collgros H, Martin LK, Sinz C, Smit AK, Gallo B, Ho G, Glanz A, Scolyer RA, Cust AE, Guitera P. J Eur Acad Dermatol Venereol, 39, no. 3, (Mar 2025): 555-65, doi:10.1111/jdv.20389. ^{TOP 10%}

Economic Evaluation of Inguinal Versus Ilio-inguinal Lymphadenectomy for Patients with Stage III Metastatic Melanoma to Groin Lymph Nodes: Evidence from the EAGLE FM Randomized Trial.

MIA2025-03-27T15:00:14+11:00February 27th, 2025|

Mahumud RA, Law CK, Ospino DA, de Wilt JHW, van Leeuwen BL, Allan C, de Lima Vazquez V, Jones RP, Howle J, Spillane AJ, Morton RL. Annals of Surgical Oncology, (Feb 27 2025), doi:10.1245/s10434-025-17040-2.

Neoadjuvant triplet immune checkpoint blockade in newly diagnosed glioblastoma.

MIA2025-03-27T14:52:54+11:00February 27th, 2025|

Long GV, Shklovskaya E, Satgunaseelan L, Mao Y, da Silva IP, Perry KA, Diefenbach RJ, Gide TN, Shivalingam B, Buckland ME, Gonzalez M, Caixeiro N, Vergara IA, Bai X, Rawson RV, Hsiao E, Palendira U, Phan TG, Menzies AM, Carlino MS, Quek C, Grimmond SM, Vissers JHA, Yeo D, Rasko JEJ, Khasraw M, Neyns B, Reardon DA, Ashley DM, Wheeler H, Back M, Scolyer RA, Drummond J, Wilmott JS, Rizos H. Nature Medicine, (Feb 27 2025), doi:10.1038/s41591-025-03512-1. ^{TOP 1%}

Sociodemographic and health factors associated with genetic testing in Australia: insights from a cohort-based study of 45,061 participants.

MIA2025-04-07T12:00:06+10:00February 27th, 2025|

Goldsbury DE, Kang YJ, Tang C, Tanha HM, Smit AK, Dunlop KLA, Petelin L, Ngo P, Hui H, Meagher NS, Merritt MA, Weber M, DeFazio A, Cust AE, Canfell K, Steinberg J. Eur J Hum Genet, (Feb 27 2025), doi:10.1038/s41431-025-01816-x.

Reflectance confocal microscopy: Presurgical margin assessment improves lentigo maligna and lentigo maligna melanoma management.

MIA2025-03-27T16:58:24+11:00February 25th, 2025|

Sinz C, Guitera P. J Eur Acad Dermatol Venereol, 39, no. 3, (Feb 25 2025): 459-60, doi:10.1111/jdv.20549. ^{TOP 10%}

Clinical outcomes and management following progressive disease with anti-PD-(L)1 therapy in patients with advanced Merkel Cell Carcinoma.

MIA2025-03-27T15:17:13+11:00February 25th, 2025|

Mo J, Zaremba A, Inderjeeth A-J, El Zeinaty P, Li A, Wicky A, Della Marta N, Marqueste CG, Bohne A-S, Matias M, McNamee N, Festino L, Chen C, Ch’ng S, van Akkooi ACJ, Meda LD, Park JJ, Ascierto PA, Hauschild A, Lee JH, Grob JJ, Mangana J, Guminski A, Michielin O, Xu W, Lebbe C, Sandhu S, Zimmer L, Menzies AM, Lo SN, Long GV, Carlino MS, da Silva IP. European Journal of Cancer, 217(Feb 25 2025), doi:10.1016/j.ejca.2025.115254.

A scoping review of factors influencing the implementation of liquid biopsy for cancer care.

MIA2025-03-27T16:51:46+11:00February 12th, 2025|

Sheriff S, Saba M, Patel R, Fisher G, Schroeder T, Arnolda G, Luo D, Warburton L, Gray E, Long G, Braithwaite J, Rizos H, Ellis LA. Journal of Experimental & Clinical Cancer Research, 44, no. 1, (Feb 12 2025): 50, doi:10.1186/s13046-025-03322-w. ^{TOP 10%}

Health-related Quality of Life and hospital costs of Finnish melanoma patients participating in the second Multicenter Selective Lymphadenectomy Trial (MSLT-II).

MIA2025-03-27T13:46:28+11:00February 10th, 2025|

Heino PJ, Pappinen J, Thompson JF, Hernberg M, Jahkola TA, Faries MB. Acta Oncologica, 64(Feb 10 2025): 247-56, doi:10.2340/1651-226X.2025.42314.

Strategies to promote the completion of patient-reported outcome measures by culturally and linguistically diverse and Indigenous Peoples in clinical care settings: A systematic review.

MIA2025-04-07T12:40:29+10:00February 8th, 2025|

Nikolovski J, Kim B, Morton RL, Mercieca-Bebber R, Levesque JF, Tinsley M, Sutherland K, Rossiter B, Fagan M, Hartas G, Rutherford C. Qual Life Res, (Feb 8 2025), doi:10.1007/s11136-025-03913-2.

Prognostic and predictive value of metformin in the European Organisation for Research and Treatment of Cancer 1325/KEYNOTE-054 phase III trial of pembrolizumab versus placebo in resected high-risk stage III melanoma.

MIA2025-03-27T13:56:32+11:00February 7th, 2025|

Kennedy OJ, Glassee N, Kicinski M, Bührer E, Valpione S, Gandini S, Suciu S, Blank CU, Long GV, Atkinson VG, Dalle S, Haydon AM, Meshcheryakov A, Khattak A, Carlino MS, Sandhu S, Larkin J, Puig S, Ascierto PA, Rutkowski P, Schadendorf D, Boers-Sonderen M, Di Giacomo AM, van den Eertwegh AJM, Grob J-J, Gutzmer R, Jamal R, van Akkooi ACJ, Robert C, Eggermont AMM, Lorigan P, Mandala M. EJC Skin Cancer, (Feb 07 2025): 100284, doi:https://doi.org/10.1016/j.ejcskn.2025.100284.

Response to han and liu.

MIA2025-03-27T14:16:10+11:00February 6th, 2025|

Lo SN, Varey AHR, Ch’ng S, Scolyer RA, Thompson JF. J Natl Cancer Inst, (Feb 6 2025), doi:10.1093/jnci/djaf026. ^{TOP 10%}

Multiomic profiling of checkpoint inhibitor-treated melanoma: Identifying predictors of response and resistance, and markers of biological discordance.

MIA2025-04-07T12:33:21+10:00February 6th, 2025|

Newell F, Pires da Silva I, Johansson PA, Menzies AM, Wilmott JS, Addala V, Carlino MS, Rizos H, Nones K, Edwards JJ, Lakis V, Kazakoff SH, Mukhopadhyay P, Ferguson PM, Leonard C, Koufariotis LT, Wood S, Blank CU, Thompson JF, Spillane AJ, Saw RPM, Shannon KF, Pearson JV, Mann GJ, Hayward NK, Scolyer RA, Waddell N, Long GV. Cancer Cell, (Feb 06 2025), doi:https://doi.org/10.1016/j.ccell.2025.01.011. ^{TOP 10%}

Phase Ib Study of Immunocytokine Simlukafusp Alfa (FAP-IL2v) Combined with Pembrolizumab for Treatment of Advanced and/or Metastatic Melanoma.

MIA2025-03-27T15:21:31+11:00February 3rd, 2025|

Munoz-Couselo E, Soria Rivas A, Sandhu S, Long GV, Sanmamed MF, Spreafico A, Buchbinder E, Sznol M, Prenen H, Fedenko A, Milhem M, Arance Fernandez AM, Grob JJ, Demidov L, Robert C, Habigt C, Evers S, Sleiman N, Dejardin D, Ardeshir C, Martin N, Boetsch C, Charo J, Teichgraeber V, Kraxner A, Keshelava N, Bechter O. Cancer Res Commun, (Feb 3 2025), doi:10.1158/2767-9764.Crc-24-0601.

Adjuvant Pembrolizumab in Stage II Melanoma: Outcomes by Primary Tumor Location in the Randomized, Double-Blind, Phase III KEYNOTE-716 Trial.

MIA2025-03-31T15:51:39+11:00February 1st, 2025|

Yoon CH, Ross MI, Gastman BR, Luke JJ, Ascierto PA, Long GV, Rutkowski P, Khattak M, Del Vecchio M, de la Cruz Merino L, Mackiewicz J, Chiarion-Sileni V, Schadendorf D, Carlino MS, Zhao Y, Fukunaga-Kalabis M, Krepler C, Eggermont Alexander MM, Gershenwald JE, Sondak VK. Annals of Surgical Oncology, (Feb 01 2025), doi:10.1245/s10434-024-16642-6.

Outcomes With Radiation Therapy as Primary Treatment for Unresectable Cutaneous Head and Neck Squamous Cell Carcinoma.

MIA2025-04-07T14:03:56+10:00February 1st, 2025|

Zhang EJ, Knox M, Veness MJ, Abdul-Razak M, Wong E, Hwang EJ, Carlino M, Sundaresan P. Clin Oncol (R Coll Radiol), 38(Feb 2025): 103739, doi:10.1016/j.clon.2024.103739.

Mohs micrographic surgery for the treatment of invasive melanoma: A systematic review with meta-analyses.

MIA2025-04-07T14:13:25+10:00February 1st, 2025|

Williams GJ, Quinn T, Lo S, Guitera P, Scolyer RA, Thompson JF, Ch’ng S. J Eur Acad Dermatol Venereol, 39, no. 2, (Feb 2025): 416-25, doi:10.1111/jdv.20138. ^{TOP 10%}

Quality and usability of photographs of skin conditions taken in emergency departments for dermatology consultation.

MIA2025-04-07T14:14:53+10:00February 1st, 2025|

Walter S, Koutsis J, Gorji M, Kherlopian A, Wong T, Lo SN, Chiew AL, Martin LK. Emerg Med Australas, 37, no. 1, (Feb 2025): e70019, doi:10.1111/1742-6723.70019.

Experience, knowledge, practices and attitudes of emergency department medical staff regarding teledermatology.

MIA2025-04-07T14:16:34+10:00February 1st, 2025|

Walter S, Chiew AL, Martin LK. Emerg Med Australas, 37, no. 1, (Feb 2025): e14530, doi:10.1111/1742-6723.14530.

Approaches to Surgical Management of Anorectal Melanoma in the Pre- and Post-Immunotherapy Eras.

MIA2025-04-07T13:41:48+10:00February 1st, 2025|

Pasch JA, Liu W, Kabir S, Pennington T. Diseases of the Colon & Rectum, (Feb 2025): 10.1097/DCR.0000000000003690, doi:10.1097/dcr.0000000000003690.

The tumor immune microenvironment in primary cutaneous melanoma.

MIA2025-03-31T15:54:49+11:00January 18th, 2025|

Zilberg C, Ferguson AL, Lyons JG, Gupta R, Damian DL. Archives of Dermatological Research, 317, no. 1, (Jan 18 2025): 273, doi:10.1007/s00403-024-03758-8.

European consensus-based interdisciplinary guideline for melanoma. Part 1: Diagnostics – Update 2024.

MIA2025-03-27T12:29:38+11:00January 17th, 2025|

Garbe C, Amaral T, Peris K, Hauschild A, Arenberger P, Basset-Seguin N, Bastholt L, Bataille V, Brochez L, Del Marmol V, Dréno B, Eggermont AMM, Fargnoli MC, Forsea AM, Höller C, Kaufmann R, Kelleners-Smeets N, Lallas A, Lebbé C, Leiter U, Longo C, Malvehy J, Moreno-Ramirez D, Nathan P, Pellacani G, Saiag P, Stockfleth E, Stratigos AJ, Van Akkooi ACJ, Vieira R, Zalaudek I, Lorigan P, Mandala M. Eur J Cancer, 215(Jan 17 2025): 115152, doi:10.1016/j.ejca.2024.115152.

Cancer cells impair monocyte-mediated T cell stimulation to evade immunity.

MIA2025-04-07T11:50:44+10:00January 16th, 2025|

Elewaut A, Estivill G, Bayerl F, Castillon L, Novatchkova M, Pottendorfer E, Hoffmann-Haas L, Schönlein M, Nguyen TV, Lauss M, Andreatta F, Vulin M, Krecioch I, Bayerl J, Pedde A-M, Fabre N, Holstein F, Cronin SM, Rieser S, Laniti DD, Barras D, Coukos G, Quek C, Bai X, Muñoz i Ordoño M, Wiesner T, Zuber J, Jönsson G, Böttcher JP, Vanharanta S, Obenauf AC. Nature, 637, no. 8046, (Jan 16 2025): 716-25, doi:10.1038/s41586-024-08257-4. ^{TOP 1%}

Real-World Melanoma Miss-Rate In An NHS Hospital Dermatology Service. A Retrospective Study.

MIA2025-04-07T11:43:06+10:00January 16th, 2025|

Anderson ADG, Shirwac HF, Morgan H, Greenish H, Carswell S, Owen V, Heath H, Koutsis J, Guitera P. Br J Dermatol, (Jan 16 2025), doi:10.1093/bjd/ljaf024. ^{TOP 10%}

The impact of surgical margins in managing regional metastases in cutaneous squamous cell carcinoma of the head and neck.

MIA2025-04-07T11:47:25+10:00January 15th, 2025|

Braude R, Manzie TGH, Clark JR, Shannon K, Palme CE, Elliott M, Wykes J, Ch’ng S, Gupta R, Cheung V, Low TH. Laryngoscope, (Jan 15 2025), doi:10.1002/lary.32006.

Harnessing Molecular Insights for Translational Impact: Highlights from the Special Issue Titled “New Insights in Translational Bioinformatics”.

MIA2025-03-27T16:19:49+11:00January 11th, 2025|

Quek C. International Journal of Molecular Sciences, 26, no. 2, (Jan 11 2025): 579.

Letter to Editor: Avoiding statistical pitfalls when assessing the performance of risk prediction nomograms.

MIA2025-03-31T15:40:46+11:00January 8th, 2025|

Varey AHR, Thompson JF, Lo SN. Surgery, (Jan 08 2025), doi:10.1016/j.surg.2024.109015.

Neoadjuvant anti-PD-1 alone or in combination with anti-TIGIT or an oncolytic virus in resectable stage IIIB-D melanoma: a phase 1/2 trial.

MIA2025-03-27T12:17:48+11:00January 7th, 2025|

Dummer R, Robert C, Scolyer RA, Taube JM, Tetzlaff MT, Menzies AM, Hill A, Grob J-J, Portnoy DC, Lebbe C, Khattak MA, Cohen J, Bar-Sela G, Mehmi I, Shapira-Frommer R, Meyer N, Webber AL, Ren Y, Fukunaga-Kalabis M, Krepler C, Long GV. Nature Medicine, (Jan 07 2025), doi:10.1038/s41591-024-03411-x. ^{TOP 1%}

Sex differences in melanoma survival-a GEM study.

MIA2025-04-07T12:28:40+10:00January 3rd, 2025|

Murali T, Schwartz M, Reynolds AZ, Luo L, Ridgeway G, Busam KJ, Cust AE, Anton-Culver H, Gallagher RP, Zanetti R, Rosso S, Sacchetto L, Begg CB, Orlow I, Thomas NE, Berwick M. JNCI Cancer Spectr, 9, no. 1, (Jan 3 2025), doi:10.1093/jncics/pkaf005.

Sentinel Node Biopsy in Melanoma Remains a Valuable Clinical Tool. Comment on Dixon et al. Primary Cutaneous Melanoma-Management in 2024. J. Clin. Med. 2024, 13, 1607.

MIA2025-03-27T15:49:33+11:00January 2nd, 2025|

Pennington TE, Thompson JF. J Clin Med, 14, no. 1, (Jan 2 2025), doi:10.3390/jcm14010215.

Approaches to Surgical Management of Anorectal Melanoma in the Pre- and Post-Immunotherapy Eras.

MIA2025-03-27T15:45:34+11:00January 1st, 2025|

Pasch JA, Liu W, Kabir S, Pennington T. Diseases of the Colon & Rectum, (2025): 10.1097/DCR.0000000000003690, doi:10.1097/dcr.0000000000003690.

Neoadjuvant or perioperative therapy for melanoma metastasis in clinical practice: an international survey.

MIA2025-03-27T13:42:04+11:00January 1st, 2025|

Hauschild A, Garbe C, Ascierto PA, Demidov L, Dreno B, Dummer R, Eggermont A, Forsea A-M, Gebhardt C, Gershenwald JE, Hamid O, Hoeller C, Kandolf L, Kaufmann R, Kirkwood JM, Lebbé C, Long GV, Malvehy J, Martin-Algarra S, McArthur G, Neyns B, Richtig E, Robert C, Schadendorf D, Scolyer R, Sondak VK, Wainstein A, Weichenthal M, Nuti P, Aarts MJB, Arance A, Asher N, Berciano-Guerrero M-A, Berking C, Carlino MS, Dabelić N, Davar D, Espinosa E, Forschner A, Gaide O, Gaudy-Marqueste C, Gavrilova I, Grabbe S, Gutzmer R, Hafner C, Hassel JC, Jacobs C, Jang S, Kähler KC, Kehrer H, Koelblinger P, Leiter U, Lipson EJ, Livingstone E, Luke JJ, Mandalà M, Mangana J, Marić Brozić J, Marquez-Rodas I, Maul LV, Mazilu L, Mehmi I, Meier F, Mesti T, Mitchell TC, Mohr P, Moyers J, Muñoz Couselo E, Najjar YG, Nakamura Y, Ocvirk J, Orlova K, Popescu BC, Popovic A, Posch C, Queirolo P, Ramelyte E, Roberts-Thomson R, Rorive A, Ruhlmann CH, Rutten A, Salama AKS, Samoylenko I, Schilling B, Shalamanova-Deleva G, Siano M, Smithy JW, Stelzhammer P, Suijkerbuijk K, Terheyden P, Teterycz P, Tietze JK, Urbonas V, Utyashev I, van der Veldt AAM, Venter M, Zarour HM, Zimmer L, Zinovev G. The Lancet Oncology, 26, no. 1, (Jan 2025): 12-14, doi:10.1016/S1470-2045(24)00627-2. ^{TOP 10%}

Treatment sequence with tebentafusp and immune checkpoint inhibitors in patients with metastatic uveal melanoma and metastatic GNA11/GNAQ mutant melanocytic tumors.

MIA2025-03-27T11:57:51+11:00January 1st, 2025|

Dimitriou F, Orloff MM, Koch Hein EC, Cheng PF, Hughes IF, Simeone E, Montazeri K, Grover P, Mehmi I, Gerard CL, Gaudy-Marqueste C, Grob J-J, Michielin O, Hamid O, Long GV, Sullivan R, Kapiteijn E, Johnson DB, Ascierto PA, Joshua AM, Carvajal RD, Butler MO, Hassel JC, Dummer R. European Journal of Cancer, 214(Jan 01 2025): 115161, doi:https://doi.org/10.1016/j.ejca.2024.115161.

X and Y Differences in Melanoma Survival Between the Sexes.

MIA2025-04-03T11:35:48+11:00January 1st, 2025|

Hersey P, Tseng HY, Alavi S, Tiffen J. Pigment Cell Melanoma Res, 38, no. 1, (Jan 2025): e13194, doi:10.1111/pcmr.13194.

ASO Author Reflections: Is Sentinel Node Biopsy Still of Value for Patients with High-Risk Primary Melanomas Eligible for Adjuvant Immunotherapy?

MIA2025-03-27T15:54:18+11:00December 27th, 2024|

Pennington TE, Thompson JF, Varey AHR. Annals of Surgical Oncology, (Dec 27 2024), doi:10.1245/s10434-024-16821-5.

Impact of alternative diagnostic labels for melanoma in situ on management choices and psychological outcomes: protocol for an online randomised study.

MIA2025-03-31T15:48:22+11:00December 20th, 2024|

Wu Z, Nickel B, Boroumand F, Elder D, Ferguson PM, Scolyer RA, O’Brien B, Barnhill R, Adamson AS, van Akkooi ACJ, Emery J, Parker L, Low D, Low C, Davies E, Liu S, Lewis S, Spongberg-Ross B, Bell KJ. BMJ Open, 14, no. 12, (Dec 20 2024): e089558, doi:10.1136/bmjopen-2024-089558.

Three-Year Overall Survival With Nivolumab Plus Relatlimab in Advanced Melanoma From RELATIVITY-047.

MIA2025-03-31T15:21:43+11:00December 13th, 2024|

Tawbi HA, Hodi FS, Lipson EJ, Schadendorf D, Ascierto PA, Matamala L, Gutiérrez EC, Rutkowski P, Gogas H, Lao CD, Menezes JJD, Dalle S, Arance AM, Grob J-J, Ratto B, Rodriguez S, Mazzei A, Dolfi S, Long GV. Journal of Clinical Oncology, (Dec 13 2024): JCO.24.01124, doi:10.1200/jco.24.01124.

Phase 1/2 Study of the Indoleamine 2,3-Dioxygenase 1 Inhibitor Linrodostat Mesylate Combined With Nivolumab or Nivolumab and Ipilimumab in Advanced Solid Tumors or Hematologic Malignancies.

MIA2025-04-07T12:12:37+10:00December 13th, 2024|

Luke JJ, Gelmon K, Siu LL, Moreno V, Desai J, Gomez-Roca CA, Carlino MS, Pachynski RK, Cosman R, Chu QS, Damian S, Curigliano G, Tam R, Wang X, Jeyamohan C, Wang L, Zhu L, Santucci-Pereira J, Greenawalt DM, Tabernero J. Clin Cancer Res, (Dec 13 2024), doi:10.1158/1078-0432.Ccr-24-0439. ^{TOP 10%}

The Development and Evaluation of a Convolutional Neural Network for Cutaneous Melanoma Detection in Whole Slide Images.

MIA2025-03-27T11:13:52+11:00December 12th, 2024|

Clarke EL, Magee D, Newton-Bishop J, Merchant W, Insall R, Maher NG, Scolyer RA, Farnworth G, Ali A, O’Shea S, Treanor D. Arch Pathol Lab Med, (Dec 12 2024), doi:10.5858/arpa.2024-0094-OA.

Risk of Death Due to Melanoma and Other Causes in Patients With Thin Cutaneous Melanomas.

MIA2025-03-27T14:20:58+11:00December 11th, 2024|

Lo SN, Williams GJ, Cust AE, Ollila DW, Varey AHR, Ch’ng S, Scolyer RA, Thompson JF. JAMA Dermatol, (Dec 11 2024), doi:10.1001/jamadermatol.2024.4900. ^{TOP 10%}

Clinical significance of intra-thoracic and intra-abdominal sentinel lymph nodes detected on lymphoscintigraphy in truncal melanoma patients.

MIA2025-03-27T15:42:02+11:00December 9th, 2024|

Novis E, Sulaiman A, Stretch J, Chung D, London K, Wong T, Lo SN, Pennington TE, Saw RPM, Ch’ng S, Shannon KF, Spillane AJ, Nieweg OE, Thompson JF, van Akkooi ACJ, Rtshiladze M. Eur J Surg Oncol, 51, no. 2, (Dec 9 2024): 109538, doi:10.1016/j.ejso.2024.109538.

Outcomes following long-term disease control with immune checkpoint inhibitors in patients with advanced melanoma.

MIA2025-03-27T13:34:07+11:00December 8th, 2024|

Handel EE, McKeown J, Wei J, Kankaria RA, Burnette H, Johnson DB, Lawless A, Czapla J, Sullivan RJ, Albrecht LJ, Zimmer L, Mangana J, Dummer R, Kessels JI, Neyns B, Allayous C, Lebbe C, Boatwright C, Mehnert JM, Ottaviano M, Ascierto PA, Czarnecka AM, Rutkowski P, Lo SN, Long GV, Menzies AM, Carlino MS. European Journal of Cancer, (Dec 08 2024), doi:10.1016/j.ejca.2024.115171.

Update of clinical practice guidelines for the management of patients with sarcoma.

MIA2025-03-27T13:27:52+11:00December 8th, 2024|

Gyorki DE, Bae S, Smith RC, Caruso DA, Coker D, Connolly EA, Desai J, Johnston A, Lawless AK, Lazarakis S, Lo H, Maclean F, Mar J, McDonough J, Perianayagam G, Phillips M, Pryor D, Sundaram A, Thompson SR, Zhou DD, Hong AM. ANZ J Surg, (Oct 30 2024), doi:10.1111/ans.19293.

Survival Outcomes in Patients Undergoing Pelvic Exenteration for Pelvic Mucosal Melanomas: Retrospective Single Institution Australian Study.

MIA2025-03-27T14:00:01+11:00December 3rd, 2024|

Kim T-J, Novis E, Lee PJM, Karunaratne S, Cahill M, Austin KKS, Byrne CM, Solomon MJ. Diseases of the Colon & Rectum, (Dec 03 2024): 10.1097/DCR.0000000000003588, doi:10.1097/dcr.0000000000003588.

Adjuvant systemic therapy in melanoma: Relative versus absolute benefit; the number needed to treat (NNT) versus the number needed to harm (NNH)?

MIA2025-04-03T16:56:43+11:00December 1st, 2024|

van Akkooi ACJ, Mandala M, Nathan P, Haydon A, Postow M, Rutkowski P. EJC Skin Cancer, 2(Feb 06 2024): 100021, doi:https://doi.org/10.1016/j.ejcskn.2024.100021.

Short-Term Effectiveness of a Stepped-Care Model to Address Fear of Cancer Recurrence in Patients With Early-Stage Melanoma.

MIA2025-03-31T15:29:52+11:00December 1st, 2024|

Thompson JR, Gomes L, Kouvelis G, Smith AL, Lo SN, Kasparian NA, Saw RPM, Dieng M, Seaman L, Martin LK, Guitera P, Milne D, Schmid H, Cust AE, Bartula I. Psychooncology, 33, no. 12, (Dec 2024): e70041, doi:10.1002/pon.70041.

Editorial Expression of Concern: Temozolomide induces senescence but not apoptosis in human melanoma cells.

MIA2025-03-27T15:10:07+11:00December 1st, 2024|

Mhaidat NM, Zhang XD, Allen J, Avery-Kiejda KA, Scott RJ, Hersey P. Br J Cancer, 131, no. 12, (Dec 2024): 1947, doi:10.1038/s41416-024-02907-0.

Ipilimumab plus nivolumab versus nivolumab alone in patients with melanoma brain metastases (ABC): 7-year follow-up of a multicentre, open-label, randomised, phase 2 study.

MIA2025-03-27T14:40:03+11:00December 1st, 2024|

Long GV, Atkinson V, Lo SN, Guminski AD, Sandhu SK, Brown MP, Gonzalez M, McArthur GA, Menzies AM. The Lancet Oncology, (Feb 17 2025), doi:10.1016/S1470-2045(24)00735-6. ^{TOP 10%}

Patient and Staff Experiences of Embedding Electronic Patient Reported Outcome Measures for Distress Screening and Quality of Life Assessment, Into Routine Melanoma Care: A Mixed-Methods Study.

MIA2025-03-27T11:37:25+11:00December 1st, 2024|

Dempsey K, Saw R, Bartula I, Lo SN, Menzies AM, Long GV, Lawn C, Chung J, Pennington T, Boyle F, Spillane A, Dieng M, Saks D, Lai-Kwon J, Thompson JR, Morton RL. Psychooncology, 33, no. 12, (Dec 2024): e70053, doi:10.1002/pon.70053.

Nivolumab (NIVO) plus relatlimab (RELA) vs. NIVO in previously untreated, metastatic, or unresectable melanoma (RELATIVITY-047): 3- year overall survival (OS) and melanoma-specific survival (MSS) results.

MIA2025-04-03T10:22:00+11:00December 1st, 2024|

Tawbi HA, Hodi S, Lipson EJ, Schadendorf D, Ascierto PA, Matamala L, Castillo Gutiérrez E, Rutkowski P, Gogas HJ, Lao CD, De Menezes JJ, Dalle S, Arance AM, Grob JJ, Ratto B, Rodriguez S, Mazzei A, Dolfi S, Long G. Annals of Dermatology and Venereology – FMC, 4, no. 8, Supplement 1, (Dec 01 2024): A349-A50, doi:https://doi.org/10.1016/j.fander.2024.09.415.

121MO Anti-IL-8 (BMS-986253) in combination with nivolumab (NIVO) plus ipilimumab (IPI) in patients (pts) with advanced melanoma: Final analysis from the randomized part 2 of the phase I/II CA027-002 study.

MIA2025-04-03T10:15:46+11:00December 1st, 2024|

Simonelli M, Butler MO, Ascierto PA, Long GV, Calvo E, Garcia VM, Gebhardt C, Grob JJ, Haydon AM, Quereux G, Walker J, Kumar M, Chakraborty D, Zhu X, Melero I. Immuno-Oncology and Technology, 24(Dec 2024), https://doi.org/10.1016/j.iotech.2024.100750.

Efficacy and safety of nivolumab + relatlimab (NIVO+RELA) versus nivolumab + ipilimuab (NIVO+IPI) in the first-line (1L) treatment of advanced melanoma: updated data from an indirect treatment comparison.

MIA2025-04-03T10:08:56+11:00December 1st, 2024|

Schadendorf D, Tawbi HA, Lipson EJ, Hodi S, Ascierto PA, Larkin J, Lao CD, Grob JJ, Ejzykowicz F, Palaia J, Garcia-Horton V, Zhou ZY, Christensen D, Rosenblatt L, McDonald L, Ratto B, Salvatore A, Patel D, Sakkal LA, Dalle S, Long G. Annals of Dermatology and Venereology – FMC, 4, no. 8, Supplement 1, (Dec 01 2024): A82-A83, doi:https://doi.org/10.1016/j.fander.2024.09.510.

Impact of an online risk prediction tool for sentinel node metastasis on clinical decision-making in melanoma care: A mixed methods study.

MIA2025-04-03T10:00:18+11:00December 1st, 2024|

Salam RA, Lo SN, Varey AHR, Spillane AJ, Henderson MA, Scolyer RA, Mar VJ, Thompson JF, Saw RPM, van Akkooi ACJ, Stretch JR, Button-Sloan A, Hong A, Morton RL, Watts CG, Smith AL, Cust AE. Surgical Oncology Insight, 1, no. 4, (Dec 01 2024): 100111, doi:https://doi.org/10.1016/j.soi.2024.100111.

Nivolumab vs. Placebo in the Adjuvant Treatment of Patients with Stage IIB/C Melanoma: 3-Year Results of the CheckMate 76K (CM 76K) Study.

MIA2025-04-03T09:51:44+11:00December 1st, 2024|

Long G, Del Vecchio M, Hoeller C, Weber J, Grob JJ, Morh P, Grabbe S, Dutriaux C, Chiarion-Sileni V, Mackiewicz J, Rutkowski P, Arenberger P, Quéreux G, Meniawy T, Ascierto PA, Taube J, Nassar A, Wang W, Kirkwood JM. Annals of Dermatology and Venereology – FMC, 4, no. 8, Supplement 1, (Dec 01 2024): A94-A95, doi:https://doi.org/10.1016/j.fander.2024.09.527.

European consensus-based interdisciplinary guideline for melanoma. Part 2: Treatment – Update 2024.

MIA2025-03-27T13:21:02+11:00November 29th, 2024|

Garbe C, Amaral T, Peris K, Hauschild A, Arenberger P, Basset-Seguin N, Bastholt L, Bataille V, Brochez L, del Marmol V, Dréno B, Eggermont AMM, Fargnoli MC, Forsea A-M, Höller C, Kaufmann R, Kelleners-Smeets N, Lallas A, Lebbé C, Leiter U, Longo C, Malvehy J, Moreno-Ramirez D, Nathan P, Pellacani G, Saiag P, Stockfleth E, Stratigos AJ, Van Akkooi ACJ, Vieira R, Zalaudek I, Lorigan P, Mandala M. European Journal of Cancer, (Nov 29 2024): 115153, doi:https://doi.org/10.1016/j.ejca.2024.115153.

The Impact of Preoperative Facial Nerve Weakness and Facial Nerve Outcomes in the Management of Patients With Parotid Metastases of Cutaneous Squamous Cell Carcinoma.

MIA2025-03-27T14:10:13+11:00November 25th, 2024|

Lin V, Zhang M, Gupta R, Elliott MS, Clark JR, Wykes JJ, Ch’ng S, Shannon KF, Palme CE, Low TH. Head Neck, (Nov 25 2024), doi:10.1002/hed.28005.

Impact of personalized response-directed surgery and adjuvant therapy on survival after neoadjuvant immunotherapy in stage III melanoma: Comparison of 3-year data from PRADO and OpACIN-neo.

MIA2025-03-27T16:27:55+11:00November 19th, 2024|

Reijers ILM, Menzies AM, Lopez-Yurda M, Versluis JM, Rozeman EA, Saw RPM, van Houdt WJ, Kapiteijn E, van der Veldt AAM, Suijkerbuijk KPM, Eriksson H, Hospers GAP, Mc Klop W, Acosta AT, Grijpink-Ongering L, Gonzalez M, van der Wal A, Al-Mamgani A, Spillane AJ, Scolyer RA, van de Wiel BA, van Akkooi ACJ, Long GV, Blank CU. European Journal of Cancer, (Nov 19 2024): 115141, doi:https://doi.org/10.1016/j.ejca.2024.115141.

Relapse-free survival with adjuvant dabrafenib/trametinib therapy after relapse on a prior adjuvant CPI in BRAF V600-mutated stage III/IV melanoma.

MIA2025-03-31T15:44:19+11:00November 19th, 2024|

Weber J, Haque W, Markovic SN, Salama AKS, Mehmi I, Sullivan RJ, Najjar YG, van Akkooi ACJ, Menzies AM, Long GV, Taylor AM, Haanen J, Zijlker LP, Davis KL, Karanth S, Norton D, Connolly L. Oncologist, (Nov 19 2024), doi:10.1093/oncolo/oyae289.

Long-term Outcomes among Patients Who Respond within the First Year to Nivolumab plus Ipilimumab or Nivolumab Monotherapy: A Pooled Analysis in 935 Patients.

MIA2025-03-27T16:35:31+11:00November 16th, 2024|

Robert C, Long GV, Larkin J, Wolchok JD, Hassel JC, Schadendorf D, Hodi FS, Lebbé C, Grob JJ, Hyngstrom JR, Wagstaff J, Chesney J, Butler MO, Bechter O, Márquez-Rodas I, Pavlick AC, Durani P, Pe Benito M, Wang P, Postow MA, Ascierto PA. European Journal of Cancer, (Nov 16 2024): 115119, doi:https://doi.org/10.1016/j.ejca.2024.115119.

An updated review of immune checkpoint inhibitors in cutaneous oncology: Beyond melanoma.

MIA2025-03-27T16:16:22+11:00November 16th, 2024|

Pham JP, Staeger R, Joshua AM, Liu J, Da Silva IP, Dummer R, Goldinger SM. European Journal of Cancer, (Nov 16 2024): 115121, doi:https://doi.org/10.1016/j.ejca.2024.115121.

Cutaneous melanoma: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up.

MIA2025-03-27T10:47:19+11:00November 14th, 2024|

Amaral T, Ottaviano M, Arance A, Blank C, Chiarion-Sileni V, Donia M, Dummer R, Garbe C, Gershenwald JE, Gogas H, Guckenberger M, Haanen J, Hamid O, Hauschild A, Höller C, Lebbé C, Lee RJ, Long GV, Lorigan P, Couselo EM, Nathan P, Robert C, Romano E, Schadendorf D, Sondak V, Suijkerbuijk KPM, van Akkooi ACJ, Michelin O, Ascierto PA. Annals of Oncology, (Nov 14 2024), doi:10.1016/j.annonc.2024.11.006. ^{TOP 10%}

In vivo reflectance confocal microscopy role for early to advanced lentigo maligna melanoma spectrum: A systematic review and pooled analysis.

MIA2025-03-27T15:06:23+11:00November 13th, 2024|

Melhoranse Gouveia B, Ferguson PM, Lo SN, Collgros H, Martin LK, Sinz C, Smit AK, Gallo B, Ho G, Glanz A, Scolyer RA, Cust AE, Guitera P. J Eur Acad Dermatol Venereol, (Nov 13 2024), doi:10.1111/jdv.20389. ^{TOP 10%}

A comparison of isolated limb infusion/perfusion, immune checkpoint inhibitors, and intralesional therapy as first-line treatment for patients with melanoma in-transit metastases

MIA2025-03-27T11:48:52+11:00November 10th, 2024|

DePalo DK, Dugan MM, Naqvi SMH, Ollila DW, Hieken TJ, Block MS, van Houdt WJ, Wouters M, Reijers SJM, Asher N, Broman KK, Duncan Z, Anderson M, Gyorki DE, Snow H, Held J, Farma JM, Vetto JT, Hui JYC, Kolbow M, Saw RPM, Lo SN, Long GV, Thompson JF, Kim Y, Karapetyan L, Ny L, van Akkooi ACJ, Bagge RO, Zager JS. Cancer, (Nov 10 2024), doi:10.1002/cncr.35636.

DNA Methylation Classes of Stage II and III Primary Melanomas and Their Clinical and Prognostic Significance.

MIA2025-03-27T11:22:38+11:00November 8th, 2024|

Conway K, Edmiston SN, Vondras A, Reiner A, Corcoran DL, Shen R, Parrish EA, Hao H, Lin L, Kenney JM, Ilelaboye G, Kostrzewa CE, Kuan PF, Busam KJ, Lezcano C, Lee TK, Hernando E, Googe PB, Ollila DW, Moschos S, Gorlov I, Amos CI, Ernstoff MS, Cust AE, Wilmott JS, Scolyer RA, Mann GJ, Vergara IA, Ko J, Rees JR, Yan S, Nagore E, Bosenberg M, Rothberg BG, Osman I, Lee JE, Saenger Y, Bogner P, Thompson CL, Gerstenblith M, Holmen SL, Funchain P, Brunsgaard E, Depcik-Smith ND, Luo L, Boyce T, Orlow I, Begg CB, Berwick M, Thomas NE. JCO Precis Oncol, 8(Nov 2024): e2400375, doi:10.1200/po-24-00375.

Pooled Long-Term Outcomes With Nivolumab Plus Ipilimumab or Nivolumab Alone in Patients With Advanced Melanoma.

MIA2025-03-27T14:47:50+11:00November 6th, 2024|

Long GV, Larkin J, Schadendorf D, Grob J-J, Lao CD, Márquez-Rodas I, Wagstaff J, Lebbé C, Pigozzo J, Robert C, Ascierto PA, Atkinson V, Postow MA, Atkins MB, Sznol M, Callahan MK, Topalian SL, Sosman JA, Kotapati S, Thakkar PK, Ritchings C, Benito MP, Re S, Soleymani S, Hodi FS. Journal of Clinical Oncology, (Nov 06 2024): JCO.24.00400, doi:10.1200/jco.24.00400. ^{TOP 10%}

BET inhibition sensitizes innate checkpoint inhibitor resistant melanoma to anti-CTLA-4 treatment.

MIA2025-03-31T15:33:52+11:00November 1st, 2024|

Tseng HY, Alavi S, Gallagher S, McGuire HM, Hersey P, Al Emran A, Tiffen J. Pigment Cell Melanoma Res, 37, no. 6, (Nov 2024): 744-51, doi:10.1111/pcmr.13174.

Uptake of health economic evaluations alongside clinical trials in Australia: an observational study.

MIA2025-03-27T10:58:18+11:00October 22nd, 2024|

Carrandi A, Wells C, Morton RL, Norman R, Skouteris H, Grove A, Higgins AM. Trials, 25, no. 1, (Oct 22 2024): 705, doi:10.1186/s13063-024-08562-3.

Acceptability and timing considerations when administering patient-reported outcome measures (PROMs) among people with chronic health conditions who are culturally and linguistically diverse (CALD): a qualitative study protocol.

MIA2025-03-27T15:35:45+11:00September 12th, 2024|

Nikolovski J, Morton RL, Mercieca-Bebber R, Armstrong M, Hartas G, Rossiter B, Fagan M, Tinsley M, Snyder C, Aiyegbusi OL, Amin-Korim R, Sutherland K, Rutherford C. BMJ Open, 14, no. 9, (Sep 12 2024): e083346, doi:10.1136/bmjopen-2023-083346.

The effect of a single dose of nivolumab prior to isolated limb perfusion for patients with in-transit melanoma metastases: An interim analysis of a phase Ib/II randomized double-blind placebo-controlled trial (NivoILP trial).

MIA2025-04-03T12:19:53+11:00June 1st, 2024|

Holmberg C-J, Zijlker LP, Katsarelias D, Huibers AE, Wouters MWJM, Schrage Y, Reijers SJM, van Thienen JV, Grünhagen DJ, Martner A, Nilsson JA, van Akkooi ACJ, Ny L, van Houdt WJ, Bagge RO. European Journal of Surgical Oncology, 50, no. 6, (Jun 2024): 108265, doi:https://doi.org/10.1016/j.ejso.2024.108265.

Quality of life outcomes in patients receiving dental implants in vascularised bone flaps for mandibular reconstruction.

MIA2025-03-31T15:37:25+11:00May 23rd, 2024|

Tumuluri V, Charters E, Venchiarutti RL, Leinkram D, Froggatt C, Dunn M, Wykes J, Singh J, Hubert Low TH, Palme CE, Howes D, Ch’ng S, Clark JR. Br J Oral Maxillofac Surg, (May 23 2024), doi:10.1016/j.bjoms.2024.04.017.

Anti-PD-1 alone or in combination with anti-CTLA-4 for advanced melanoma patients with liver metastases.

MIA2025-04-03T11:53:02+11:00May 7th, 2024|

da Silva IP, Li I, Ugurel S, Serra-Bellver P, Andhale A, Burnette H, Aya F, Conway JW, Braden J, Carlino MS, Menzies AM, Weichenthal M, Mohr P, Gutzmer R, Arance AM, Johnson DB, Lorigan P, Schadendorf D, Lo SN, Long GV. European Journal of Cancer, (May 07 2024): 114101, doi:https://doi.org/10.1016/j.ejca.2024.114101, (2).

Merkel-cell carcinoma: ESMO-EURACAN Clinical Practice Guideline for diagnosis, treatment and follow-up.

MIA2025-04-03T15:01:45+11:00April 30th, 2024|

Lugowska I, Becker JC, Ascierto PA, Veness M, Blom A, Lebbe C, Migliano E, Hamming-Vrieze O, Goebeler M, Kneitz H, Nathan P, Rutkowski P, Slowinska M, Schadendorf D, Piulats JM, Petrelli F, van Akkooi ACJ, Berruti A. ESMO Open, (Apr 30 2024), doi:10.1016/j.esmoop.2024.102977.

Full-body skin examination in screening for cutaneous malignancy: a focus on concealed sites and the practices of Australian dermatologists.

MIA2025-04-03T15:37:23+11:00April 29th, 2024|

Pham JP, Allen N, Star P, Cust A, Guitera P, Marghoob AA, Paoli J, Zalaudek I, Smith A. JEADV Clinical Practice, (Apr 29 2024), doi:https://doi.org/10.1002/jvc2.437. ^{TOP 10%}

Neoadjuvant Triplet Immune Checkpoint Blockade in Newly Diagnosed Glioblastoma.

MIA2025-04-03T14:58:02+11:00April 28th, 2024|

Long G, Wilmott J, Shklovskaya E, Satgunseelan L, Mao Y, Perry K, Diefenbach R, Gide T, Shivalingam B, Buckland ME, Gonzalez M, Caixeiro NJ, Vergara I, Bai X, Hsiao E, Rawson R, da Silva I, Palendira U, Phan T, Menzies A, Carlino M, Quek C, Grimmond SM, Vissers J, Yeo D, Rasko JE, Khasraw M, Neytns B, Reardon D, Ashley DM, Wheeler H, Back M, Drummond J, Scolyer R, Rizos H. Nature Portfolio, (Preprint Apr 28 2024), doi:https://doi.org/10.21203/rs.3.rs-4255559/v1.

Interferon-gamma signature as prognostic and predictive marker in macroscopic stage III melanoma.

MIA2025-04-03T16:28:54+11:00April 27th, 2024|

Versluis JM, Blankenstein SA, Dimitriadis P, Wilmott JS, Elens R, Blokx WAM, Houdt Wv, Menzies AM, Schrage YM, Wouters MWJM, Sanders J, Broeks A, Scolyer RA, Suijkerbuijk KPM, Long GV, Akkooi ACJv, Blank CU. Journal for ImmunoTherapy of Cancer, 12, no. 4, (Apr 27 2024): e008125, doi:10.1136/jitc-2023-008125.

Development and validation of a novel model to predict recurrence-free survival and melanoma-specific survival after sentinel lymph node biopsy in patients with melanoma: an international, retrospective, multicentre analysis

MIA2024-05-09T12:04:57+10:00April 25th, 2024|

Stassen RC, Maas CHM, van der Veldt AAM, Lo SN, Saw R, Varey A, Scolyer R, Long G, Thompson J, Rutkowski P, Keilholz U, van Akkooi ACJ, Verhoef C, van Klaveren D, Grünhagen DJ. Lancet Oncology.

Single-Cell Informatics for Tumor Microenvironment and Immunotherapy.

MIA2025-04-07T14:31:53+10:00April 19th, 2024|

Tian J, Bai X, Quek C. Int J Mol Sci. 2024 Apr 19;25(8):4485. doi: 10.3390/ijms25084485. PMID: 38674070; PMCID: PMC11050520.

Society for Immunotherapy of Cancer (SITC) recommendations on intratumoral immunotherapy clinical trials (IICT): from premalignant to metastatic disease.

MIA2025-04-03T15:11:52+11:00April 18th, 2024|

Luke JJ, Davar D, Andtbacka RH, Bhardwaj N, Brody JD, Chesney J, Coffin R, de Baere T, de Gruijl TD, Fury M, Goldmacher G, Harrington KJ, Kaufman H, Kelly CM, Khilnani AD, Liu K, Loi S, Long GV, Melero I, Middleton M, Neyns B, Pinato DJ, Sheth RA, Solomon SB, Szapary P, Marabelle A. J Immunother Cancer, 12, no. 4, (Apr 18 2024), doi:10.1136/jitc-2023-008378.

Understanding the Tumor Microenvironment in Melanoma Patients with In-Transit Metastases and Its Impacts on Immune Checkpoint Immunotherapy Responses.

MIA2025-04-03T16:00:33+11:00April 11th, 2024|

Tian J, Quek C. International Journal of Molecular Sciences, 25, no. 8, (Apr 11 2024): 4243, doi:doi:10.3390/ijms25084243.

The Impact of Next-generation Sequencing on Interobserver Agreement and Diagnostic Accuracy of Desmoplastic Melanocytic Neoplasms

MIA2024-06-13T16:07:01+10:00April 9th, 2024|

Chen A, Sharma N, Patel P, Olivares S, Bahrami A, Barnhill RL, Blokx WAM, Bosenberg M, Busam KJ, de La Fouchardière A, Duncan LM, Elder DE, Ko JS, Landman G, Lazar AJ, Lezcano C, Lowe L, Maher N, Massi D, Messina J, Mihic-Probst D, Parker DC, Redpath M, Scolyer RA, Shea CR, Spatz A, Tron V, Xu X, Yeh I, Jung Yun S, Zembowicz A, Gerami P. Am J Surg Pathol, doi:10.1097/pas.0000000000002226.

Stroma-infiltrating T cell spatiotypes define immunotherapy outcomes in adolescent and young adult patients with melanoma

MIA2024-06-03T17:11:35+10:00April 8th, 2024|

Bai X, Attrill GH, Gide TN, Ferguson PM, Nahar KJ, Shang P, Vergara IA, Palendira U, da Silva IP, Carlino MS, Menzies AM, Long GV, Scolyer RA, Wilmott JS, Quek C. Nature Communications, 15, no. 1: 3014, doi:10.1038/s41467-024-47301-9.

Cancer in general practice research priorities in Australia.

MIA2024-05-09T17:00:13+10:00April 1st, 2024|

Milley K, Druce P, McNamara M, Bergin RJ, Chan RJ, Cust A, Davis N, Fishman G, Jefford M, Rankin N, Yates P, Emery JD. Australian Journal of General Practice.

Development and validation of a novel model to predict recurrence-free survival and melanoma-specific survival after sentinel lymph node biopsy in patients with melanoma: an international, retrospective, multicentre analysis.

MIA2025-04-03T15:56:03+11:00April 1st, 2024|

Stassen RC, Maas CCHM, van der Veldt AAM, Lo SN, Saw RPM, Varey AHR, Scolyer RA, Long GV, Thompson JF, Rutkowski P, Keilholz U, van Akkooi ACJ, Verhoef C, van Klaveren D, Grünhagen DJ. The Lancet Oncology, 25, no. 4, (Apr 01 2024): 509-17, doi:10.1016/S1470-2045(24)00076-7. ^{TOP 10%}

Predicting Recurrence-Free and Overall Survival for Patients With Stage II Melanoma: The MIA Calculator

MIA2024-05-09T15:46:38+10:00April 1st, 2024|

Varey AHR, Li I, El Sharouni M-A, Simon J, Dedeilia A, Ch’ng S, Saw R, Spillane AJ, Shannon K, Pennington T, Rtshiladze M, Stretch JR, Nieweg O, van Akkooi A, Sullivan R, Gershenwald JE, Scolyer RA, Long GV, Thompson JF, Lo SN. Journal of Clinical Oncology.

ASO Author Reflections: Lymphoedema Related to Inguinal and Ilioinguinal Lymphadenectomy for Melanoma.

MIA2025-04-03T14:53:15+11:00March 27th, 2024|

Lee TS, Spillane AJ. Annals of Surgical Oncology, (Mar 27 2024), doi:10.1245/s10434-024-15216-w.

BRAF Mutated and Morphologically Spitzoid Tumors, a Subgroup of Melanocytic Neoplasms Difficult to Distinguish From True Spitz Neoplasms.

MIA2025-04-03T12:00:03+11:00March 25th, 2024|

Gerami P, Chen A, Sharma N, Patel P, Hagstrom M, Kancherla P, Geraminejad T, Olivares S, Biswas A, Bosenberg M, Busam KJ, de La Fouchardière A, Duncan LM, Elder DE, Ko J, Landman G, Lazar AJ, Lowe L, Massi D, Mihic-Probst D, Parker DC, Scolyer RA, Shea CR, Zembowicz A, Yun SJ, Blokx WAM, Barnhill RL. Am J Surg Pathol, (Mar 25 2024), doi:10.1097/pas.0000000000002194. ^{TOP 10%}

Cancer in general practice research priorities in Australia.

MIA2025-04-03T15:30:25+11:00March 22nd, 2024|

Milley K, Druce P, McNamara M, Bergin R, Chan R, Cust A, Davis N, Fishman G, Jefford M, Rankin N, Yates P, Emery J. Australian Journal of General Practice, 4(Mar 22 2024): 227-34.

Neo-Adjuvant Therapy for Metastatic Melanoma.

MIA2025-04-03T14:44:10+11:00March 22nd, 2024|

Kuijpers AMJ, van Akkooi ACJ. Cancers, 16, no. 7, (Mar 22 2024): 1247.

POLARIS: A phase 2 trial of encorafenib plus binimetinib evaluating high-dose and standard-dose regimens in patients with BRAF V600-mutant melanoma with brain metastasis.

MIA2025-04-03T15:21:14+11:00March 18th, 2024|

Menzies AM, Long GV, Kohn A, Tawbi H, Weber J, Flaherty K, McArthur GA, Ascierto PA, Pfluger Y, Lewis K, Tsai KK, Hamid O, Prenen H, Fein L, Wang E, Guenzel C, Zhang F, Kleha JF, di Pietro A, Davies MA. Neuro-Oncology Advances, (Mar 18 2024), doi:10.1093/noajnl/vdae033.

Leg Lymphoedema After Inguinal and Ilio-Inguinal Lymphadenectomy for Melanoma: Results from a Prospective, Randomised Trial.

MIA2025-04-03T14:50:41+11:00March 17th, 2024|

Lee TS, Li I, Peric B, Saw RPM, Duprat JP, Bertolli E, Spillane JB, van Leeuwen BL, Moncrieff M, Sommariva A, Allan CP, de Wilt JHW, Jones RP, Geh JLC, Howle JR, Spillane AJ. Annals of Surgical Oncology, (Mar 17 2024), doi:10.1245/s10434-024-15149-4.

Pembrolizumab versus placebo as adjuvant therapy in resected stage IIB or IIC melanoma: Outcomes in histopathologic subgroups from the randomized, double-blind, phase 3 KEYNOTE-716 trial.

MIA2024-05-09T12:13:11+10:00March 13th, 2024|

Schadendorf D, Luke JJ, Ascierto PA, Long GV, Rutkowski P, Khattak M, Del Vecchio M, de la Cruz Merino L, Mackiewicz J, Chiarion-Sileni V, Kirkwood JM, Robert C, Grob J-J, Dummer R, Carlino MS, Zhao Y, Fukunaga-Kalabis M, Krepler C, Eggermont AMM, Scolyer RA. Journal of Immunotherapy of Cancer.

Pembrolizumab Versus Placebo as Adjuvant Therapy in Resected Stage IIB or IIC Melanoma: Final Analysis of Distant Metastasis-Free Survival in the Phase III KEYNOTE-716 Study.

MIA2025-04-03T15:06:45+11:00March 7th, 2024|

Luke JJ, Ascierto PA, Khattak MA, Merino LdlC, Vecchio MD, Rutkowski P, Spagnolo F, Mackiewicz J, Chiarion-Sileni V, Kirkwood JM, Robert C, Grob J-J, Galitiis Fd, Schadendorf D, Carlino MS, Wu XL, Fukunaga-Kalabis M, Krepler C, Eggermont AMM, Long GV. Journal of Clinical Oncology, 0, no. 0, (Mar 07 2024): JCO.23.02355, doi:10.1200/jco.23.02355. ^{TOP 10%}

Technical considerations for isolated limb perfusion: A consensus paper.

MIA2025-04-03T12:08:25+11:00March 6th, 2024|

Hayes AJ, Coker DJ, Been L, Boecxstaens VW, Bonvalot S, De Cian F, de la Cruz-Merino L, Duarte C, Eggermont A, Farricha V, Fiore M, Grünhagen D, Grützmann R, Honoré C, Jakob J, Hocevar M, van Houdt W, Klauzner J, Kettelhack C, Märten A, Martinez-Said H, Matter M, Michot A, Niethard M, Pennacchioli E, Podleska LE, Rabago G, Rastrelli M, Reijers S, Ribeiro M, Schwarzbach M, Snow HA, Spacek M, Stoldt S, Testori A, Zoras O, Olofsson Bagge R. Eur J Surg Oncol, 50, no. 6, (Mar 6 2024): 108050, doi:10.1016/j.ejso.2024.108050.

Anti-PD-(L)1 plus BRAF/MEK inhibitors (triplet therapy) after failure of immune checkpoint inhibition and targeted therapy in patients with advanced melanoma

MIA2024-06-03T15:46:56+10:00March 1st, 2024|

Albrecht LJ, Dimitriou F, Grover P, Hassel JC, Erdmann M, Forschner A, Johnson DB, Váraljai R, Lodde G, Placke JM, Krefting F, Zaremba A, Ugurel S, Roesch A, Schulz C, Berking C, Pöttgen C, Menzies AM, Long GV, Dummer R, Livingstone E, Schadendorf D, Zimmer L. European Journal of Cancer, doi:10.1016/j.ejca.2024.113976.

Outcomes of patients with resected stage III/IV acral or mucosal melanoma, treated with adjuvant anti-PD-1 based therapy.

MIA2025-04-03T12:31:28+11:00March 1st, 2024|

Jacques SK, McKeown J, Grover P, Johnson DB, Zaremba A, Dimitriou F, Weiser R, Farid M, Namikawa K, Sullivan RJ, Rutkowski P, Lebbe C, Hamid O, Zager JS, Michielin O, Neyns B, Nakamura Y, Robert C, Mehnert J, Ascierto PA, Bhave P, Park B, Zimmer L, Mangana J, Mooradian M, Placzke J, Allayous C, Glitza Oliva IC, Mehmi I, Depalo D, Wicky A, Schwarze JK, Roy S, Boatwright C, Vanella V, Long GV, Menzies AM, Lo SN, Carlino MS. Eur J Cancer, 199(Mar 2024): 113563, doi:10.1016/j.ejca.2024.113563.

International expert recommendations on image acquisition for in vivo reflectance confocal microscopy of cutaneous tumors.

MIA2025-04-03T12:12:48+11:00March 1st, 2024|

Ho G, Gill M, Grant-Kels J, Schwartz RJ, Pellacani G, Gonzalez S, Alessi-Fox C, Guitera P. J Am Acad Dermatol, 90, no. 3, (Mar 2024): 537-44, doi:10.1016/j.jaad.2023.09.086. ^{TOP 1%}

Prognostic and predictive biomarkers in head and neck cancer: something old, something new, something borrowed, something blue and a sixpence in your shoe.

MIA2025-04-03T11:47:47+11:00March 1st, 2024|

Balgobind S, Cheung VKY, Luk P, Low TH, Wykes J, Wu R, Lee J, Ch’ng S, Palme CE, Clark JR, Gupta R. Pathology, 56, no. 2, (Mar 2024): 170-85, doi:10.1016/j.pathol.2023.11.005.

Transmission and Non-transmission of Melanoma From Deceased Solid Organ Donors to Transplant Recipients: Risks and Missed Opportunities.

MIA2025-04-03T15:40:15+11:00February 29th, 2024|

Rosales BM, Hedley J, De La Mata N, Cavazzoni E, Vajdic CM, Thompson JF, Kelly PJ, Wyburn K, Webster AC. Transplantation, (Feb 29 2024), doi:10.1097/tp.0000000000004961. ^{TOP 10%}

PKC-independent PI3K signalling diminishes PKC inhibitor sensitivity in uveal melanoma.

MIA2025-04-03T15:34:09+11:00February 28th, 2024|

Park JJ, Hamad SA, Stewart A, Carlino MS, Lim SY, Rizos H. Oncogenesis, 13, no. 1, (Feb 28 2024): 9, doi:10.1038/s41389-024-00511-8.

Minimum labelling requirements for dermatology artificial intelligence-based Software as Medical Device (SaMD): A consensus statement.

MIA2025-04-03T12:24:33+11:00February 28th, 2024|

Ingvar Å, Oloruntoba A, Sashindranath M, Miller R, Soyer HP, Guitera P, Caccetta T, Shumack S, Abbott L, Arnold C, Lawn C, Button-Sloan A, Janda M, Mar V. Australas J Dermatol, (Feb 28 2024), doi:10.1111/ajd.14222.

Plain language summary of the CheckMate 76K study results: nivolumab given after stage 2B/2C melanoma is removed by surgery.

MIA2025-04-03T12:57:04+11:00February 23rd, 2024|

Kirkwood JM, Vecchio MD, Weber J, Hoeller C, Grob JJ, Mohr P, Loquai C, Dutriaux C, Chiarion-Sileni V, Mackiewicz J, Rutkowski P, Arenberger P, Quereux G, Meniawy TM, Ascierto PA, Menzies AM, Durani P, Lobo M, Campigotto F, Gastman B, Long GV. Future Oncol, (Feb 23 2024), doi:10.2217/fon-2023-0977.

The difficulty with measuring the largest melanoma tumour diameter in sentinel lymph nodes.

MIA2025-04-03T14:47:26+11:00February 20th, 2024|

Laeijendecker AE, El Sharouni MA, Stathonikos N, Spoto CPE, van de Wiel BA, Eijken EJE, Mulder M, Mooyaart AL, Szumera-Cieckiewicz A, Mihic-Probst D, Massi D, Cook M, Koljenovic S, Alos L, van Diest PJ, van Akkooi ACJ, Blokx W. J Clin Pathol, (Feb 20 2024), doi:10.1136/jcp-2023-209354.

Implementation considerations for risk-tailored cancer screening in the population: A scoping review

MIA2024-06-13T16:11:42+10:00February 18th, 2024|

Dunlop KLA, Singh N, Robbins HA, Zahed H, Johansson M, Rankin NM, Cust AE. Prev Med, 181: 107897, doi:10.1016/j.ypmed.2024.107897.

Individualised neoantigen therapy mRNA-4157 (V940) plus pembrolizumab versus pembrolizumab monotherapy in resected melanoma (KEYNOTE-942): a randomised, phase 2b study.

MIA2025-04-03T16:32:40+11:00February 17th, 2024|

Weber JS, Carlino MS, Khattak A, Meniawy T, Ansstas G, Taylor MH, Kim KB, McKean M, Long GV, Sullivan RJ, Faries M, Tran TT, Cowey CL, Pecora A, Shaheen M, Segar J, Medina T, Atkinson V, Gibney GT, Luke JJ, Thomas S, Buchbinder EI, Healy JA, Huang M, Morrissey M, Feldman I, Sehgal V, Robert-Tissot C, Hou P, Zhu L, Brown M, Aanur P, Meehan RS, Zaks T. Lancet, 403, no. 10427, (Feb 17 2024): 632-44, doi:10.1016/s0140-6736(23)02268-7. ^{TOP 1%}

Commentary: Real-world post-deployment performance of a novel machine learning-based digital health technology for skin lesion assessment and suggestions for post-market surveillance

MIA2024-06-03T16:06:40+10:00February 6th, 2024|

Anderson ADG, Lo SN, Guitera P. Front Med (Lausanne), 1345659, doi:10.3389/fmed.2024.1345659.

A review of skin cancer primary prevention activities in primary care settings.

MIA2024-05-09T12:10:38+10:00February 6th, 2024|

Singh N, Dunlop KLA, Woolley N, Wills VT, Damian DL, Vuong K, Cust AE, Smit AK. Public Health Res Pract.

Predicting Recurrence-Free and Overall Survival for Patients With Stage II Melanoma: The MIA Calculator.

MIA2025-04-03T16:08:04+11:00February 5th, 2024|

Varey AHR, Li I, El Sharouni MA, Simon J, Dedeilia A, Ch’ng S, Saw RPM, Spillane AJ, Shannon KF, Pennington TE, Rtshiladze M, Stretch JR, Nieweg OE, van Akkooi A, Sullivan RJ, Boland GM, Gershenwald JE, van Diest PJ, Scolyer RA, Long GV, Thompson JF, Lo SN. J Clin Oncol, (Feb 5 2024): Jco2301020, doi:10.1200/jco.23.01020. ^{TOP 10%}

Health Economic Consequences Associated With COVID-19-Related Delay in Melanoma Diagnosis in Europe.

MIA2025-04-03T15:16:08+11:00February 5th, 2024|

Maul LV, Jamiolkowski D, Lapides RA, Mueller AM, Hauschild A, Garbe C, Lorigan P, Gershenwald JE, Ascierto PA, Long GV, Wang-Evers M, Scolyer RA, Saravi B, Augustin M, Navarini AA, Legge S, Németh IB, Jánosi Á J, Mocellin S, Feller A, Manstein D, Zink A, Maul JT, Buja A, Adhikari K, Roider E. JAMA Netw Open, 7, no. 2, (Feb 5 2024): e2356479, doi:10.1001/jamanetworkopen.2023.56479. ^{TOP 10%}

Smoking Status and Survival in Patients With Early-Stage Primary Cutaneous Melanoma.

MIA2025-04-03T12:27:19+11:00February 5th, 2024|

Jackson KM, Jones PC, Fluke LM, Fischer TD, Thompson JF, Cochran AJ, Stern SL, Faries MB, Hoon DSB, Foshag LJ. JAMA Netw Open, 7, no. 2, (Feb 5 2024): e2354751, doi:10.1001/jamanetworkopen.2023.54751. ^{TOP 10%}

Pathology: the narrative continues.

MIA2025-04-03T17:01:54+11:00February 1st, 2024|

Scolyer RA. Pathology, (Feb 1 2024), doi:10.1016/j.pathol.2024.01.001.

Synchronous collision metastasis of melanoma and squamous cell carcinoma in a parotid lymph node: a very rare occurrence and literature review.

MIA2025-04-03T16:38:40+11:00February 1st, 2024|

Wu M, Scolyer RA, Maher N, Menzies AM, Pennington TE. Pathology, 56(Feb 2024): S85, doi:10.1016/j.pathol.2023.12.288.

Prognostic and predictive value of non-steroidal anti-inflammatory drugs in the EORTC 1325/KEYNOTE-054 phase III trial of pembrolizumab versus placebo in resected high-risk stage III melanoma.

MIA2025-04-03T12:50:35+11:00February 1st, 2024|

Kennedy OJ, Glassee N, Kicinski M, Blank CU, Long GV, Atkinson VG, Dalle S, Haydon AM, Meshcheryakov A, Khattak A, Carlino MS, Sandhu S, Larkin J, Puig S, Ascierto PA, Rutkowski P, Schadendorf D, Boers-Sonderen M, Giacomo AMD, van den Eertwegh AJM, Grob JJ, Gutzmer R, Jamal R, van Akkooi ACJ, Gandini S, Buhrer E, Suciu S, Robert C, Eggermont AMM, Mandala M, Lorigan P, Valpione S. Eur J Cancer, 201(Feb 1 2024): 113585, doi:10.1016/j.ejca.2024.113585.

Cutaneous malignancies in chronic lymphocytic leukemia.

MIA2025-04-03T16:43:23+11:00January 31st, 2024|

Zilberg C, Ferguson AL, Lyons JG, Gupta R, Fuller SJ, Damian DL. The Journal of Dermatology, 51, no. 3, (Jan 31 2024): 353-64, doi:https://doi.org/10.1111/1346-8138.17126.

Management of infliximab refractory immune checkpoint inhibitor gastrointestinal toxicity: a multicenter case series.

MIA2025-04-03T12:05:17+11:00January 31st, 2024|

Harvey C, Nahar KJ, McKeown J, Lo SN, Farag S, Yousaf N, Young K, Tas L, Meerveld-Eggink A, Blank C, Thomas A, McQuade J, Schilling B, Johnson DB, Huertas RM, Arance A, Lee J, Zimmer L, Long GV, Carlino MS, Wang Y, Menzies AM. J Immunother Cancer, 12, no. 1, (Jan 31 2024), doi:10.1136/jitc-2023-008232.

Rethinking the urgency priority system in round hole detachments, which should be done first? Macula on or macula off.

MIA2025-04-03T12:34:46+11:00January 26th, 2024|

Javed A, Qadir MO, Lee S, Mitra A, Tyagi A, Sharma A, Lett K, Ch’ng S. Eye (Lond), (Jan 26 2024), doi:10.1038/s41433-024-02930-8.

Associations between patient-level health literacy and diagnostic time intervals for head and neck cancer: A prospective cohort study.

MIA2025-04-03T16:19:53+11:00January 11th, 2024|

Venchiarutti RL, Clark JA, Palme CE, Dwyer P, Tahir ARM, Hill J, Ch’ng S, Elliott MS, Young JM. Head Neck, (Jan 11 2024), doi:10.1002/hed.27633.

Author Correction: Adjuvant nivolumab in resected stage IIB/C melanoma: primary results from the randomized, phase 3 CheckMate 76K trial.

MIA2025-04-03T12:53:08+11:00January 4th, 2024|

Kirkwood JM, Del Vecchio M, Weber J, Hoeller C, Grob JJ, Mohr P, Loquai C, Dutriaux C, Chiarion-Sileni V, Mackiewicz J, Rutkowski P, Arenberger P, Quereux G, Meniawy TM, Ascierto PA, Menzies AM, Durani P, Lobo M, Campigotto F, Gastman B, Long GV. Nat Med, (Jan 4 2024), doi:10.1038/s41591-023-02775-w. ^{TOP 1%}

Implementing systematic melanoma risk assessment and risk-tailored surveillance in a skin cancer focussed dermatology clinic: A qualitative study of feasibility and acceptability to patients and clinic staff.

MIA2025-04-03T15:50:11+11:00January 1st, 2024|

Smith AL, Smit AK, Laginha BI, Singh N, Gallo B, Martin L, Cust AE. Cancer Med, 13, no. 2, (Jan 2024): e6976, doi:10.1002/cam4.6976.

Prognostic and predictive biomarkers in head and neck cancer: something old, something new, something borrowed, something blue and a sixpence in your shoe

MIA2024-06-03T17:22:07+10:00December 19th, 2023|

Balgobind S, Cheung VKY, Luk P, Low TH, Wykes J, Wu R, Lee J, Ch’ng S, Palme CE, Clark JR, Gupta R. Pathology, 56, no. 2: 170-85, doi:10.1016/j.pathol.2023.11.005.

Extended Follow-Up of Chronic Immune-Related Adverse Events Following Adjuvant Anti-PD-1 Therapy for High-Risk Resected Melanoma.

MIA2025-04-24T13:49:19+10:00August 3rd, 2023|

Goodman RS, Lawless A, Woodford R, Fa’ak F, Tipirneni A, Patrinely JR, Yeoh HL, Rapisuwon S, Haydon A, Osman I, Mehnert JM, Long GV, Sullivan RJ, Carlino MS, Menzies AM, Johnson DB. JAMA Network Open, 6, no. 8, (Aug 03 2023): e2327145-e45, doi:10.1001/jamanetworkopen.2023.27145. ^{TOP 10%}

European consensus-based interdisciplinary guideline for invasive cutaneous squamous cell carcinoma. Part 1: Diagnostics and prevention-Update 2023.

MIA2025-04-24T14:51:04+10:00July 28th, 2023|

Stratigos AJ, Garbe C, Dessinioti C, Lebbe C, van Akkooi A, Bataille V, Bastholt L, Dreno B, Dummer R, Fargnoli MC, Forsea AM, Harwood CA, Hauschild A, Hoeller C, Kandolf-Sekulovic L, Kaufmann R, Kelleners-Smeets NWJ, Lallas A, Leiter U, Malvehy J, del Marmol V, Moreno-Ramirez D, Pellacani G, Peris K, Saiag P, Tagliaferri L, Trakatelli M, Ioannides D, Vieira R, Zalaudek I, Arenberger P, Eggermont AMM, Rocken M, Grob J-J, Lorigan P. European Journal of Cancer, (Jul 28 2023), doi:10.1016/j.ejca.2023.113251.

Implementing structured pathology reporting protocol for non-melanocytic skin cancers: practical considerations.

MIA2025-04-24T13:54:51+10:00July 28th, 2023|

Gupta R, Selinger CI, Ashford B, Chua MST, Clark JR, Damian DL, Jackett LA, James C, Johnson S, Ladwa R, Lambie D, McKenzie C, Tan ST, Scolyer RA. Pathology, (Jul 28 2023), doi:https://doi.org/10.1016/j.pathol.2023.07.003.

Perspectives in Melanoma: meeting report from the Melanoma Bridge (December 1st-3rd, 2022-Naples, Italy).

MIA2025-04-24T12:41:18+10:00July 28th, 2023|

Ascierto PA, Agarwala SS, Warner AB, Ernstoff MS, Fox BA, Gajewski TF, Galon J, Garbe C, Gastman BR, Gershenwald JE, Kalinski P, Krogsgaard M, Leidner RS, Lo RS, Menzies AM, Michielin O, Poulikakos PI, Weber JS, Caracò C, Osman I, Puzanov I, Thurin M. Journal of Translational Medicine, 21, no. 1, (Jul 28 2023): 508, doi:10.1186/s12967-023-04325-x.

Looking beyond workforce parity: addressing gender inequity in pathology.

MIA2025-04-24T14:19:46+10:00July 25th, 2023|

McKenzie CA, Gupta R, Jackett L, Anderson L, Chen V, Dahlstrom JE, Dray M, Farshid G, Hemmings C, Karim R, Kench JG, Klebe S, Kramer N, Kumarasinghe P, Maclean F, Morey A, Nguyen MA, O’Toole S, Rowbotham B, Salisbury ELC, Scolyer RA, Stewart K, Waring L, Cooper CL, Cooper WA. Pathology, (Jul 25 2023), doi:https://doi.org/10.1016/j.pathol.2023.07.002.

Cutaneous melanoma

MIA Media2023-08-16T11:29:16+10:00July 24th, 2023|

Georgina V Long, Susan M Swetter, Alexander M Menzies, Jeffrey E Gershenwald, Richard A Scolyer. Lancet 2023 Jul 24;S0140-6736(23)00821-8. doi: 10.1016/S0140-6736(23)00821-8.

Towards modulating the gut microbiota to enhance the efficacy of immune-checkpoint inhibitors

MIA Media2024-05-09T10:38:40+10:00July 24th, 2023|

Rebecca C. Simpson, Erin R. Shanahan, Richard A. Scolyer & Georgina V. Long. Nature Reviews Clinical Oncology volume 20, pages 697–715 (2023)

Acceptability of risk-tailored cancer screening among Australian GPs: a qualitative study.

MIA2025-04-24T13:41:11+10:00July 17th, 2023|

Dunlop KLA, Smit AK, Keogh L, Newson AJ, Rankin NM, Cust A. British Journal of General Practice, (Jul 17 2023): BJGP.2023.0117, doi:10.3399/bjgp.2023.0117. ^{TOP 1%}

Multiomics analysis reveals a Type III driven immune response in immunotherapy-induced toxicity in melanoma and identifies potential new therapeutic targets.

MIA2024-05-09T16:16:51+10:00July 10th, 2023|

Levesque M, Dimitriou F, Cheng P, Saltari A, Schaper-Gerhardt K, Staeger R, Haunerdinger V, Sella F, Tastanova A, Urban C, Dettwiler S, Mihic-Probst D, Michielin O, Gutzmer R, Long G, Becher B, Dummer R. Preprint from Research Square.

Efficacy of immune checkpoint inhibitors for the treatment of advanced melanoma in patients with concomitant chronic lymphocytic leukemia.

MIA2025-04-24T12:59:04+10:00July 4th, 2023|

Cass SH, Tobin JWD, Seo YD, Gener-Ricos G, Keung EZ, Burton EM, Davies MA, McQuade JL, Lazar AJ, Mason R, Millward M, Sandhu S, Khoo C, Warburton L, Guerra V, Haydon A, Dearden H, Menzies AM, Carlino M, Smith JL, Mollee P, Burgess M, Mapp S, Keane C, Atkinson V, Parikh SA, Markovic SN, Ding W, Call TG, Hampel PJ, Long GV, Wargo JA, Ferrajoli A. Ann Oncol, (Jul 4 2023), doi:10.1016/j.annonc.2023.06.007. ^{TOP 10%}

Delphi Consensus Among International Experts on the Diagnosis, Management, and Surveillance for Lentigo Maligna.

MIA2025-04-24T14:12:14+10:00July 1st, 2023|

Longo C, Navarrete-Dechent C, Tschandl P, Apalla Z, Argenziano G, Braun RP, Bataille V, Cabo H, Hoffmann-Wellhenhof R, Forsea AM, Garbe C, Guitera P, Raimond K, Marghoob AA, Malvehy J, Del Marmol V, Moreno D, Nehal KS, Nagore E, Paoli J, Pellacani G, Peris K, Puig S, Soyer HP, Swetter S, Stratigos A, Stolz W, Thomas L, Tiodorovic D, Zalaudek I, Kittler H, Lallas A. Dermatol Pract Concept, 13, no. 3, (Jul 1 2023), doi:10.5826/dpc.1303a244.

The association of dermatologist demographic density with melanoma survival in New South Wales, Australia.

MIA2025-04-24T12:52:46+10:00June 24th, 2023|

Blake SC, Guitera P, Cust AE, Galea C, Lo SN, Scolyer RA, Armstrong BK, Thompson JF, Menzies SW, Madronio C, Morton RL, Mann GJ, Watts CG. Australas J Dermatol, (Jun 24 2023), doi:10.1111/ajd.14113.

Preferences for Adjuvant Immunotherapy in Adults with Resected Stage III Melanoma-A Discrete Choice Experiment.

MIA2025-04-24T14:10:10+10:00June 23rd, 2023|

Livingstone A, Howard K, Menzies AM, Long GV, Stockler MR, Morton RL. The Patient – Patient-Centered Outcomes Research, (23 Jun 2023), doi:10.1007/s40271-023-00635-w.

Seven-Year Follow-Up of the Phase III KEYNOTE-006 Study: Pembrolizumab Versus Ipilimumab in Advanced Melanoma.

MIA2025-04-24T14:39:04+10:00June 22nd, 2023|

Robert C, Carlino MS, McNeil C, Ribas A, Grob J-J, Schachter J, Nyakas M, Kee D, Petrella TM, Blaustein A, Lotem M, Arance A, Daud AI, Hamid O, Larkin J, Anderson J, Krepler C, Grebennik D, Long GV. Journal of Clinical Oncology, (22 Jun 2023): JCO.22.01599, doi:10.1200/jco.22.01599. ^{TOP 10%}

Inter-rater concordance of basal cell carcinoma subtypes: influences on reporting format and opportunities for further classification modifications.

MIA2025-04-24T14:15:12+10:00June 7th, 2023|

Maher NG, Prosser N, Aivazian K, Colebatch AJ, Ferguson PM, Karim RZ, McKenzie CA, Rawson RV, Lo SN, Scolyer RA. Pathology, (Jun 07 2023), doi:https://doi.org/10.1016/j.pathol.2023.04.003.

Melanoma In Situ—Getting the Diagnosis and Prognosis Right.

MIA2025-04-24T13:01:55+10:00June 7th, 2023|

Cust AE, Scolyer RA. JAMA Dermatology, (Jun 07 2023), doi:10.1001/jamadermatol.2023.1485. ^{TOP 1%}

Health-related quality of life in patients with melanoma brain metastases treated with immunotherapy.

MIA2025-04-24T15:00:31+10:00June 3rd, 2023|

Thompson JR, Lai-Kwon J, Morton RL, Guminski AD, Gonzalez M, Atkinson V, Sandhu S, Brown MP, Menzies AM, McArthur GA, Lo SN, Long GV, Bartula I. Immunotherapy, (May 2 2023), doi:10.2217/imt-2022-0262.

Modeling Methods in Craniofacial Virtual Surgical Planning.

MIA2025-04-24T14:36:42+10:00June 1st, 2023|

Riordan E, Yung A, Cheng K, Lim L, Clark J, Rtshiladze M, Ch’ng S. J Craniofac Surg, 34, no. 4, (Jun 1 2023): 1191-98, doi:10.1097/scs.0000000000009187.

Epidemiology, staging and management of mucosal melanoma of the head and neck: a narrative review.

MIA2025-04-24T14:02:13+10:00June 1st, 2023|

Jeong YJ, Thompson JF, Ch’ng S. Chinese clinical oncology, 12, no. 3, (Jun 01 2023): 28, doi:10.21037/cco-23-16.

Definitive treatment with PD-1 blockade and radiation therapy of unresected primary desmoplastic melanoma of the nose.

MIA2025-04-24T13:46:42+10:00June 1st, 2023|

Gjorup CA, Pires da Silva I, Martin L, Stretch JR, Scolyer RA, Long GV, Hong A. Melanoma Research, (Aug 03 9900): 10.1097/CMR.0000000000000905, doi:10.1097/cmr.0000000000000905.

Reply to: ‘Melanoma diagnosis at a specialist dermatology practice without the use of photographic surveillance’.

MIA2025-04-24T12:44:40+10:00May 25th, 2023|

Adler NR, Cust AE, Mar VJ, Martin LK, Guitera P. Australas J Dermatol, (May 25 2023), doi:10.1111/ajd.14087.

Molecular and clinical correlates of HER3 expression highlights its potential role as a therapeutic target in melanoma.

MIA2025-04-24T14:44:58+10:00May 16th, 2023|

Shteinman ER, Vergara IA, Rawson RV, Lo SN, Maeda N, Koyama K, Pires da Silva I, Long GV, Scolyer RA, Wilmott JS, Menzies AM. Pathology, (May 16 2023), doi:https://doi.org/10.1016/j.pathol.2023.03.007.

Neoadjuvant immunotherapy for melanoma is now ready for clinical practice.

MIA2025-04-24T13:43:51+10:00May 16th, 2023|

Garbe C, Dummer R, Amaral T, Amaria RN, Ascierto PA, Burton EM, Dreno B, Eggermont AMM, Hauschild A, Hoeller C, Kaufmann R, Lebbe C, Mandala M, Menzies AM, Moreno D, Michielin O, Nathan P, Patel SP, Robert C, Schadendorf D, Lorigan PC, Scolyer RA, Tawbi HA, van de Wiel BA, Blank C, Long GV. Nature Medicine, (May 16 2023), doi:10.1038/s41591-023-02336-1. ^{TOP 1%}

Adjuvant therapy for stage II melanoma: the need for further studies.

MIA2025-04-24T14:06:47+10:00May 8th, 2023|

Lee R, Mandala M, Long GV, Eggermont AMM, van Akkooi ACJ, Sandhu S, Garbe C, Lorigan P. European Journal of Cancer, (May 08 2023), doi:https://doi.org/10.1016/j.ejca.2023.05.003.

Regarding: Predicting Regional Lymph Node Recurrence in The Modern Age of Tumor-Positive Sentinel Node Melanoma.

MIA2025-04-24T14:54:48+10:00May 6th, 2023|

Thompson JF, Hyngstrom J, Caracò C, Zager JS, Jahkola T, Bowles TL, Pennacchioli E, Hoekstra HJ, Moncrieff M, Ingvar C, van Akkooi A, Sabel MS, Levine EA, Henderson M, Dummer R, Rossi CR, Kane JM, Trocha S, Wright F, Byrd DR, Matter M, MacKenzie-Ross A, Kelley MC, Terheyden P, Huston TL, Wayne JD, Neuman H, Smithers BM, Desai D, Gershenwald JE, Schneebaum S, Gesierich A, Jacobs LK, Lewis JM, O’Donoghue C, Sardi A, McKinnon JG, Slingluff CL, Farma JM, Schultz E, Scheri RP, Vidal-Sicart S, Testori AAE, Scolyer RA, Elashoff DE, Cochran AJ, Faries MB. Annals of Surgical Oncology, (May 06 2023), doi:10.1245/s10434-023-13570-9.

ASO Author Reflections: The Clinical Relevance of Sentinel Nodes in Minor Lymph Node Fields Such as the Triangular Intermuscular Space in Patients with Melanoma.

MIA2025-04-24T14:41:42+10:00May 3rd, 2023|

Schoenfeldt T, Chakera AH, Nieweg OE, Thompson JF. Annals of Surgical Oncology, (May 03 2023), doi:10.1245/s10434-023-13443-1.

Systemic LRG1 expression in melanoma is associated with disease progression and recurrence.

MIA Media2023-05-15T21:28:45+10:00April 20th, 2023|

Esmee P. Hoefsmit, Franziska Völlmy, Elisa A. Rozeman, Irene L. M. Reijers, Judith M. Versluis, Liesbeth Hoekman, Alexander C. J. van Akkooi, Georgina V. Long, Dirk Schadendorf, Reinhard Dummer, Maarten Altelaar, Christian U. Blank. Cancer Research Communications 2023; https://doi.org/10.1158/2767-9764.CRC-23-0015

Comparing Genomic Landscapes of Oral and Cutaneous Squamous Cell Carcinoma of the Head and Neck: Quest for Novel Diagnostic Markers.

MIA2025-04-24T13:58:51+10:00April 18th, 2023|

Gupta R, Strbenac D, Satgunaseelan L, Cheung VK, Narayanappa H, Ashford B, Mitchell J, Thind A, Palme CE, Ch’ng S, Low TH, Wykes J, Willet CE, Chew T, Yang J, Ranson M, Clark JR. Mod Pathol, 36, no. 8, (Apr 18 2023): 100190, doi:10.1016/j.modpat.2023.100190. ^{TOP 10%}

Baseline ultrasound and FDG-PET/CT imaging in Merkel cell carcinoma.

MIA Media2023-05-15T21:45:01+10:00April 1st, 2023|

Zijlker LP, Bakker M, van der Hiel B, Bruining A, Klop WMC, Zuur CL, Wouters MWJM, van Akkooi ACJ. J Surg Oncol. 2023 Apr;127(5):841-847. doi: 10.1002/jso.27193. Epub 2022 Dec 27. PMID: 36573839.

ASO Visual Abstract: Prognostic Significance and Management of Sentinel Nodes in the Triangular Intermuscular Space of Patients with Melanoma.

MIA Media2023-05-15T20:55:49+10:00April 1st, 2023|

Schoenfeldt T, Thompson JF, Lo S, Drzewiecki KT, Stretch J, Saw RPM, Spillane A, Shannon K, Uren RF, Chakera AH, Nieweg OE. Ann Surg Oncol. 2023 Apr;30(4):2362-2363. doi: 10.1245/s10434-022-12889-z. PMID: 36525209.

Study protocol for a randomised controlled trial to evaluate the use of melanoma surveillance photography to the Improve early detection of MelanomA in ultra-hiGh and high-risk patiEnts (the IMAGE trial).

MIA Media2023-05-15T22:05:53+10:00March 29th, 2023|

Yan MK, Cust AE, Soyer HP, Janda M, Loewe K, Byars G, Fishburn P, White P, Mahumud RA, Saw RPM, Herschtal A, Fernandez-Penas P, Guitera P, Morton RL, Kelly J, Wolfe R, Mar VJ. Trials. 2023 Mar 29;24(1):236. doi: 10.1186/s13063-023-07203-5. PMID: 36991460; PMCID: PMC10061902

Chemotherapy in Cutaneous Melanoma: Is There Still a Role?

MIA Media2023-05-15T21:56:24+10:00March 29th, 2023|

Pham JP, Joshua AM, da Silva IP, Dummer R, Goldinger SM. Curr Oncol Rep. 2023 Mar 29. doi: 10.1007/s11912-023-01385-6. Epub ahead of print. PMID: 36988735.

Time to reconsider the role of sentinel lymph node biopsy in melanoma

MIA Media2023-05-14T20:21:10+10:00March 28th, 2023|

Faries MB, Cochran AJ, Thompson JF. J Am Acad Dermatol. 2023 Jan;88(1):e25-e26. doi: 10.1016/j.jaad.2019.03.064. Epub 2019 Mar 28. PMID: 30928469

Adjuvant radiotherapy after salvage surgery for melanoma recurrence in a node field following a previous lymph node dissection.

MIA Media2023-05-14T17:04:34+10:00March 27th, 2023|

Holtkamp LHJ, Lo SN, Thompson JF, Spillane AJ, Stretch JR, Saw RPM, Shannon KF, Nieweg OE, Hong AM. J Surg Oncol. 2023 Mar 27. doi: 10.1002/jso.27245. Epub ahead of print. PMID: 36971691

Measuring the quality of skin cancer management in primary care: A scoping review.

MIA Media2023-05-15T21:21:59+10:00March 24th, 2023|

Spanos S, Singh N, Laginha BI, Arnolda G, Wilkinson D, Smith AL, Cust AE, Braithwaite J. Australas J Dermatol. 2023 Mar 24. doi: 10.1111/ajd.14023. Epub ahead of print. PMID: 36960976.

Human Genetics Society of Australasia Position Statement: Use of Polygenic Scores in Clinical Practice and Population Health. Twin Res Hum Genet.

Jane Varley2023-05-15T21:18:31+10:00March 23rd, 2023|

Young MA, Yanes T, Cust AE, Dunlop K, Limb S, Newson AJ, Purvis R, Thiyagarajan L, Scott RJ, Verma K, James PA, Steinberg J. Twin Res Hum Genet. 2023 Mar 23:1-9. doi: 10.1017/thg.2023.10. Epub ahead of print. PMID: 36950972.

Junctional Nevus and Early Melanoma on Sun-Damaged Skin of the Head/Neck: a Clinico-Pathologic Challenge.

Jane Varley2023-05-15T19:55:10+10:00March 22nd, 2023|

Moscarella E, Guitera P, Scolyer RA, Rocha L, Thomas L, Ronchi A, Scharf C, Brancaccio G, Argenziano G. Dermatol Pract Concept. 2023 Mar 22;13(2). doi: 10.5826/dpc.1302a122. Epub ahead of print. PMID: 36947065.

Risk of developing a second primary melanoma after a first primary melanoma in a population-based Australian cohort.

MIA Media2023-05-15T19:50:56+10:00March 22nd, 2023|

Ni Y, Watts CG, Scolyer RA, Madronio C, Armstrong BK, Morton RL, Menzies SW, Mann GJ, Thompson JF, Lo SN, Cust AE. Br J Dermatol. 2023 Mar 22:ljad076. doi: 10.1093/bjd/ljad076. Epub ahead of print. PMID: 36946230.

Overall Survival and Response with Nivolumab and Relatlimab in Advanced Melanoma.

MIA Media2023-05-15T19:45:14+10:00March 22nd, 2023|

Long GV, Hodi FS, Lipson EJ, Schadendorf D, Ascierto PA, Matamala L, Salman P, Gutierrez EC, Rutkowski P, Gogas HJ Lao CD, De Menezes JJ, Dalle S, Arance A, Grob J-J, Keidel S, Shaikh A, Sobiesk AM, Dolfi S, Tawbi HA, NEJM Evidence, 2023 Mar 22, doi:10.1056/EVIDoa2200239

Health-related quality of life with nivolumab plus Relatlimab versus nivolumab monotherapy in patients with previously untreated unresectable or metastatic melanoma: RELATIVITY-047 trial.

MIA Media2023-05-15T18:07:21+10:00March 22nd, 2023|

Schadendorf D, Tawbi H, Lipson EJ, Hodi FS, Rutkowski P, Gogas H, Lao CD, Grob J-J, Moshyk A, Lord-Bessen J, Hamilton M, Guo S, Shi L, Keidel S, Long GV, Eur J Cancer, 2023 Mar 22; doi: httpsL//doi.org/10.1016/j.ejca.2023.03.014

Role of reflectance confocal microscopy for in vivo investigation of oral disorders: White, red and pigmented lesions.

MIA Media2023-05-15T20:49:52+10:00March 20th, 2023|

Franceschini C, Mandel VD, Peterson G, Manciocco V, Guitera P, Rajadhyaksha M, Ardigò M. Exp Dermatol. 2023 Jan 29. doi: 10.1111/exd.14758. Epub ahead of print. PMID: 36710524.

The molecular and functional landscape of resistance to immune checkpoint blockade in melanoma.

MIA Media2023-05-14T20:06:52+10:00March 18th, 2023|

Lim SY, Shklovskaya E, Lee JH, Pedersen B, Stewart A, Ming Z, Irvine M, Shivalingam B, Saw RPM, Menzies AM, Carlino MS, Scolyer RA, Long GV, Rizos H. Nat Commun. 2023 Mar 18;14(1):1516. doi: 10.1038/s41467-023-36979-y. PMID: 36934113; PMCID: PMC10024679.

REPLY to MS#JAAD-D-23-00002R1.

MIA Media2023-05-15T20:05:54+10:00March 17th, 2023|

El Sharouni MA, Lo SN, Scolyer RA, van Gils CH, Thompson JF. J Am Acad Dermatol. 2023 Mar 17:S0190-9622(23)00440-1. doi: 10.1016/j.jaad.2023.03.008. Epub ahead of print. PMID: 36935017.

Has the advent of modern adjuvant systemic therapy for melanoma rendered sentinel node biopsy unnecessary?

MIA Media2023-05-14T20:01:30+10:00March 17th, 2023|

Varey AHR, Thompson JF, Howle JR, Lo SN, Ch’ng S, Carlino MS. European Journal of Cancer, 2023 Mar 17; DOI: https://doi.org/10.1016/j.ejca.2023.03.011

Spatial mapping reveals granuloma diversity and histopathological superstructure in human tuberculosis.

MIA Media2023-05-15T19:36:53+10:00March 15th, 2023|

Sawyer AJ, Patrick E, Edwards J, Wilmott JS, Fielder T, Yang Q, Barber DL, Ernst JD, Britton WJ, Palendira U, Chen X, Feng CG. J Exp Med. 2023 Jun 5;220(6):e20221392. doi: 10.1084/jem.20221392. Epub 2023 Mar 15. PMID: 36920308; PMCID: PMC10035589.

IFN-γ signature enables selection of neoadjuvant treatment in patients with stage III melanoma.

MIA Media2023-05-14T19:44:01+10:00March 15th, 2023|

Reijers ILM, Rao D, Versluis JM, Menzies AM, Dimitriadis P, Wouters MW, Spillane AJ, Klop WMC, Broeks A, Bosch LJW, Lopez-Yurda M, van Houdt WJ, Rawson RV, Grijpink-Ongering LG, Gonzalez M, Cornelissen S, Bouwman J, Sanders J, Plasmeijer E, Elshot YS, Scolyer RA, van de Wiel BA, Peeper DS, van Akkooi ACJ, Long GV, Blank CU. J Exp Med. 2023 May 1;220(5):e20221952. doi: 10.1084/jem.20221952. Epub 2023 Mar 15. PMID: 36920329; PMCID: PMC10037109.

Lentigo maligna/lentigo maligna melanoma in young patients in Australian tertiary centres.

MIA Media2023-05-14T19:48:17+10:00March 14th, 2023|

Huang C, Burke H, Scolyer RA, Guitera P. Clin Exp Dermatol. 2023 Mar 14:llad089. doi: 10.1093/ced/llad089. Epub ahead of print. PMID: 36916530.

Efficacy of ipilimumab 3mn/kg following progression on low-dose ipilimumab in metastatic melanoma.

MIA Media2023-05-15T21:13:35+10:00March 11th, 2023|

Lai-Kwon J, Hacques S, Carlino M, Benannoune N, Robert C, Baroudjian B, Lebbe C, Zinner L, Eroglu Z, Topcu TO, Dimitriou F, Haydon A, Lo SN, Menzies AM, Long GV, European Journal of Cancer, 2023 Mar 10, doi: 10.1016/j.ejca.2023.03.006

Rare immune-related adverse events in patients with melanoma: incidence, spectrum, and clinical presentations.

Jane Varley2023-05-14T17:58:28+10:00March 8th, 2023|

Park BC, Narayanan S, Gavraldis A, Ye F, Fan R, Sullivan RJ, Boland G, Reynolds KL, Balko JM, Carlino MS, Long GV, Zubiri L, Menzies AM, Johnson DB. Oncoimmunology. 2023 Mar 8;12(1):2188719. doi: 10.1080/2162402X.2023.2188719. PMID: 36926262; PMCID: PMC10012911.

Surgical outcomes of lymph node dissections for stage III melanoma after neoadjuvant systemic therapy are not inferior to upfront surgery.

Jane Varley2023-05-14T18:55:39+10:00March 7th, 2023|

Zijlker LP, van der Burg SJC, Blank CU, Zuur CL, Klop WMC, Wouters MWMJ, van Houdt WJ, van Akkooi ACJ. Eur J Cancer. 2023 Mar 7;185:131-138. doi: 10.1016/j.ejca.2023.03.003. Epub ahead of print. PMID: 36989829.

MC1R ‘r’ allele does not increase melanoma risk in MITF E318K carriers.

MIA Media2023-05-15T20:42:49+10:00March 5th, 2023|

Wallingford CK, Demeshko A, Krishnankutty Krishnakripa A, Smit DJ, Duffy DL, Betz-Stablein B, Pflugfelder A, Jagirdar K, Holland E, Mann GJ, Primiero CA, Yanes T, Malvehy J, Badenas C, Carrera C, Aguilera P, Olsen CM, Ward SV, Haass NK, Sturm RA, Puig S, Whiteman DC, Law MH, Cust AE, Potrony M, Soyer HP, McInerney-Leo AM. Br J Dermatol. 2023 Mar 5:ljad041. doi: 10.1093/bjd/ljad041. Epub ahead of print. PMID: 36879448.

Melanotransferrin Functions as a Pro-Oncogenic WNT Agonist: A Yin-Yang Relationship in Melanoma with the WNT Antagonist and Metastasis Suppressor, NDRG1.

MIA2024-05-09T12:17:43+10:00March 3rd, 2023|

Paluncic J, Gholam Azad M, Lane DJR, Skoda J, Park KC, Chiang S, Bae DH, Scolyer R, Afroz R, Babu G, Wilmott J, Loh K, Jansson PJ, Dharmasivam M, Huang ML, Zhao X, Kovacevic Z, Richardson DR. bioRxiv, doi:10.1101/2023.02.27.530353.

Nicotinamide for Skin-Cancer Chemoprevention in Transplant Recipients.

Jane Varley2023-05-14T17:39:43+10:00March 2nd, 2023|

Allen NC, Martin AJ, Snaidr VA, Eggins R, Chong AH, Fernandéz-Peñas P, Gin D, Sidhu S, Paddon VL, Banney LA, Lim A, Upjohn E, Schaider H, Ganhewa AD, Nguyen J, McKenzie CA, Prakash S, McLean C, Lochhead A, Ibbetson J, Dettrick A, Landgren A, Allnutt KJ, Allison C, Davenport RB, Mumford BP, Wong B, Stagg B, Tedman A, Gribbin H, Edwards HA, De Rosa N, Stewart T, Doolan BJ, Kok Y, Simpson K, Low ZM, Kovitwanichkanont T, Scolyer RA, Dhillon HM, Vardy JL, Chadban SJ, Bowen DG, Chen AC, Damian DL. N Engl J Med. 2023 Mar 2;388(9):804-812. doi: 10.1056/NEJMoa2203086. PMID: 36856616.

Common toxicities associated with immune checkpoint inhibitors and targeted therapy in the treatment of melanoma: A systematic scoping review

MIA Media2023-05-15T21:38:39+10:00March 1st, 2023|

Egeler MD, van Leeuwen M, Fraterman I, van den Heuvel NMJ, Boekhout AH, Lai-Kwon J, Wilthagen EA, Eriksson H, Haanen JB, Wilgenhof S, Ascierto PA, van Akkooi ACJ, van de Poll-Franse LV. Crit Rev Oncol Hematol. 2023 Mar;183:103919. doi: 10.1016/j.critrevonc.2023.103919. Epub 2023 Feb 1. PMID: 36736511.

Clinical features and outcomes of cardiac involvement in patients with cancer treated with immune checkpoint inhibitors.

MIA Media2023-05-14T19:23:51+10:00March 1st, 2023|

Sarah Abou Alaiwi, Amin Nassar, Talal Zarif, Edward El-Am, Ryan Denu, Walid Macaron, Carmel Malvar, Alessio Cortellini, James Korolewicz, Paul Sackstein, Frank Aboubakar Nana, Rachel Woodford, Georgina V. Long, Jennifer Kwan, Shirly Grynberg, Ronnie Shapira, Mercedes Herrera-Juárez, Simone Foderaro, Alexi Vasbinder, Aarti Asnani, Ankita Tandon, Salim Hayek, Tomas G. Neilan, Toni Choueiri, and Abdul-Rafeh Naqash. J Am Coll Cardiol. 2023 Mar, 81 (8_Supplement) 2338.https://doi.org/10.1016/S0735-1097(23)02782-1

In vivo reflectance confocal microscopy can detect the invasive component of lentigo maligna melanoma: Prospective analysis and case-control study.

Jane Varley2023-05-14T17:43:30+10:00February 28th, 2023|

Gouveia BM, Carlos G, Wadell A, Sinz C, Ahmed T, Lo SN, Rawson RV, Ferguson PM, Scolyer RA, Guitera P. J Eur Acad Dermatol Venereol. 2023 Feb 28. doi: 10.1111/jdv.18998. Epub ahead of print. PMID: 36855833.

A sheep in wolf’s clothing: Agminated blue naevi masquerading as in-transit melanoma metastases.

MIA Media2023-05-15T20:15:26+10:00February 25th, 2023|

Allen NC, Paver EC, Agar N, Scolyer RA, Moloney FJ. Australas J Dermatol. 2023 Feb 25. doi: 10.1111/ajd.14002. Epub ahead of print. PMID: 36840895.

Challenges in oncology career: are we closing the gender gap? Results of the new ESMO Women for Oncology Committee survey.

MIA Media2023-05-14T17:31:03+10:00February 24th, 2023|

Linardou H, Adjei AA, Bajpai J, Banerjee S, Berghoff AS, Mathias CC, Choo SP, Dent R, Felip E, Furness AJS, Garassino MC, Garralda E, Konsoulova-Kirova A, Letsch A, Menzies AM, Mukherji D, Peters S, Sessa C, Tsang J, Yang JC, Garrido P. ESMO Open. 2023 Feb 24;8(2):100781. doi: 10.1016/j.esmoop.2023.100781. Epub ahead of print. PMID: 36842299.

Case series: Immune checkpoint inhibitor-induced transverse myelitis.

MIA Events2023-05-14T17:35:09+10:00February 21st, 2023|

Chatterton S, Xi S, Jia JX, Krause M, Long GV, Atkinson V, Menzies AM, Fernando SL, Boyle T, Kwok S, Duggins A, Karikios D, Parratt JDE. Front Neurol. 2023 Feb 21;14:1130313. doi: 10.3389/fneur.2023.1130313. PMID: 36895912; PMCID: PMC9989185.

Reply to A. Mangla and E. Hindié.

Jane Varley2023-05-15T13:34:42+10:00February 20th, 2023|

Moncrieff MD, Sondak VK, Thompson JF, Zager JS. J Clin Oncol. 2023 Feb 20;41(6):1326-1327. doi: 10.1200/JCO.22.02218. Epub 2022 Dec 1. PMID: 36455171.

Intratumoral CD16+ macrophages are associated with clinical outcomes of patients with metastatic melanoma treated with combination anti-PD-1 and anti-CTLA-4 therapy.

MIA Media2023-05-15T20:22:46+10:00February 15th, 2023|

Lee H, Ferguson AL, Quek C, Vergara IA, Pires daSilva I, Allen R, Gide TN, Conway JW, Koufariotis LT, Hayward NK, Waddell N, Carlino MS, Menzies AM, Saw RPM, Shklovskaya E, Rizos H, Lo S, Scolyer RA, Long GV, Palendira U, Wilmott JS. Clin Cancer Res. 2023 Feb 15:CCR-22-2657. doi: 10.1158/1078-0432.CCR-22-2657. Epub ahead of print. PMID: 36790412.

Longitudinal trajectory of quality of life for patients with melanoma brain metastases: A secondary analysis from a whole brain radiotherapy randomized clinical trial.

MIA Media2023-05-14T17:00:47+10:00February 15th, 2023|

Bartula I, Anh D. Tran, Anna K. Nowak, Tasnia Ahmed, Rachael L. Morton, Bryan H. Burmeister, Kari Dolven-Jacobsen, Jenny Nobes, John F. Thompson, Gerald B. Fogarty, Serigne N Lo, Angela M. Hong. Clinical and Translational Radiation Oncology,
2. 2023, 100597, ISSN 2405-6308, https://doi.org/10.1016/j.ctro.2023.100597

Nivolumab and Relatlimab in Patients With Advanced Melanoma That Had Progressed on Anti–Programmed Death-1/Programmed Death Ligand 1 Therapy: Results From the Phase I/IIa RELATIVITY-020 Trial

MIA Media2023-05-14T16:06:01+10:00February 13th, 2023|

Ascierto PA, Lipson EJ, Dummer R, Larkin J, Long GV, Sanborn RE, Chiarion-Sileni V, Dréno B, Dalle S, Schadendorf D, Callahan MK, Nyakas M, Atkinson V, Gomez-Roca CA, Yamazaki N, Tawbi HA, Sarkis N, Warad D, Dolfi S, Mitra P, Suryawanshi S, Grob J-J. Journal of Clinical Oncology, (Feb 13 2023): JCO.22.02072, doi:10.1200/jco.22.02072.

Efficacy and toxicity of adjuvant radiotherapy in recurrent melanoma after adjuvant immunotherapy.

MIA Media2023-05-14T17:55:27+10:00February 11th, 2023|

Bhave P, Hong A, Lo SN, Johnson R, Mangana J, Johnson DB, Dulgar O, Eroglu Z, Yeoh HL, Haydon A, Lodde GC, Livingstone E, Khattak A, Kähler K, Hausschild A, McArthur GA, Menzies AM, Long G, Wang W, Carlino MS. J Immunother Cancer. 2023 Mar;11(3):e006629. doi: 10.1136/jitc-2022-006629. PMID: 36889810; PMCID: PMC10008434.

Plain Language Summary – Development and validation of risk calculators for people with “thin” melanomas on their skin to predict the likelihood that their cancer will return.

Jane Varley2023-05-14T16:44:45+10:00February 10th, 2023|

Sharouni M-AE, Lo SN, Varey AH, Elias SG, Witkamp AJ, Sigurdsson V, Suijkerbuijk KP, van Diest PJ, van Gils CH, Blokx WA, Scolyer RA, Thompson JF. Future oncology (London, England), (Feb 10 2023), doi:10.2217/fon-2022-0525.

Author Correction: Reversal of pre-existing NGFR-driven tumor and immune therapy resistance.

MIA Media2023-05-15T21:32:50+10:00February 7th, 2023|

Boshuizen J, Vredevoogd DW, Krijgsman O, Ligtenberg MA, Blankenstein S, de Bruijn B, Frederick DT, Kenski JCN, Parren M, Brüggemann M, Madu MF, Rozeman EA, Song JY, Horlings HM, Blank CU, van Akkooi ACJ, Flaherty KT, Boland GM, Peeper DS. Nat Commun. 2023 Feb 7;14(1):672. doi: 10.1038/s41467-023-35852-2. Erratum for: Nat Commun. 2020 Aug 7;11(1):3946. PMID: 36750559; PMCID: PMC9905532.

Lichen sclerosus and immune checkpoint inhibitors: A case and review of the literature.

MIA Media2023-05-14T17:51:01+10:00February 1st, 2023|

Truong K, Jones-Caballero M, Chou S, Carlino MS, Consuegra-Romero G, Araujo RR. Australas J Dermatol. 2023 Feb;64(1):158-161. doi: 10.1111/ajd.13941. Epub 2022 Oct 31. PMID: 36310527.

Clinical Features Associated with Outcomes and Biomarker Analysis of Dabrafenib plus Trametinib Treatment in Patients with BRAF-Mutant Melanoma Brain Metastases.

MIA Media2023-05-14T16:54:39+10:00February 1st, 2023|

Wilmott JS, Tawbi H, Engh JA, Amankulor NM, Shivalingam B, Banerjee H, Vergara IA, Lee H, Johansson PA, Ferguson PM, Saiag P, Robert C, Grob JJ, Butterfield LH, Scolyer RA, Kirkwood JM, Long GV, Davies MA. Clin Cancer Res, 29, no. 3, (Feb 1 2023): 521-31, doi:10.1158/1078-0432.Ccr-22-2581

IFNγ signaling sensitizes melanoma cells to BH3 Mimetics.

MIA Media2023-05-14T16:40:18+10:00February 1st, 2023|

Ming Z, Lim SY, Stewart A, Pedersen B, Shklovskaya E, Menzies AM, Carlino MS, Kefford RF, Lee JH, Scolyer RA, Long GV, Rizos H. Journal of Investigative Dermatology, (Feb 01 2023), doi:https://doi.org/10.1016/j.jid.2023.01.017.

ASO Visual Abstract: Is a History of Optimal Staging by SLNB in the Era Prior to Adjuvant Therapy Associated with Improved Outcome Once Melanoma Patients have Progressed to Advanced Disease?

MIA Media2023-05-15T21:52:04+10:00January 30th, 2023|

Blankenstein SA, Bonenkamp JJ, Aarts MJB, van den Berkmortel FWPJ, Blank CU, Blokx WAM, Boers-Sonderen MJ, van den Eertwegh AJM, Franken MG, de Groot JWB, Haanen JBAG, Hospers GAP, Kapiteijn EW, van Not OJ, Piersma D, van Rijn RS, Suijkerbuijk KPM, van der Veldt AAM, Vreugdenhil G, Westgeest HM, Wouters MWJM, van Akkooi ACJ. Ann Surg Oncol. 2023 Jan;30(1):587-588. doi: 10.1245/s10434-022-12719-2. PMID: 36319872.

Durability of response to immune checkpoint inhibitors in metastatic Merkel cell carcinoma after treatment cessation.

MIA Media2023-05-14T16:49:40+10:00January 28th, 2023|

Weppler AM, Da Meda L, Pires da Silva I, Xu W, Grignani G, Menzies AM, Carlino MS, Long GV, Lo SN, Nordman I, Steer CB, Lyle M, Trojaniello C, Ascierto PA, Lebbe C, Sandhu S. European Journal of Cancer, (Jan 28 2023), doi:10.1016/j.ejca.2023.01.016

Association of Germline Variants in Telomere Maintenance Genes (POT1, TERF2IP, ACD, TERT) with Spitzoid Morphology in Familial Melanoma: A Multi-Center Case Series.

Jane Varley2023-05-14T16:36:38+10:00January 28th, 2023|

Goldstein AM, Qin R, Chu EY, Elder DE, Massi D, Adams DJ, Harms PW, Robles-Espinoza CD, Newton-Bishop JA, Bishop DT, Harland M, Holland EA, Cust AE, Schmid H, Mann GJ, Puig S, Potrony M, Alos L, Nagore E, Millán-Esteban D, Hayward NK, Broit N, Palmer JM, Nathan V, Berry EG, Astiazaran-Symonds E, Yang XR, Tucker MA, Landi MT, Pfeiffer RM, Sargen MR. JAAD International, (Jan 28 2023), doi:10.1016/j.jdin.2023.01.013.

Survival update of neoadjuvant ipilimumab plus nivolumab in macroscopic stage III melanoma in the OpACIN and OpACIN-neo trials.

MIA Media2023-05-14T16:01:42+10:00January 18th, 2023|

Versluis JM, Menzies AM, Sikorska K, Rozeman EA, Saw RPM, van Houdt WJ, Eriksson H, Klop WMC, Ch’ng S, van Thienen JV, Mallo H, Gonzalez M, Torres Acosta A, Grijpink-Ongering LG, van der Wal A, Bruining A, van de Wiel BA, Scolyer RA, Haanen J, Schumacher TN, van Akkooi ACJ, Long GV, Blank CU. Ann Oncol, (Jan 18 2023), doi:10.1016/j.annonc.2023.01.004

Genetics and Genomics of Melanoma: Current Progress and Future Directions.

MIA Media2023-05-14T15:27:17+10:00January 16th, 2023|

Quek C. Genes. 14, no. 1, (Jan 16 2023): 232.

Interobserver agreement in the histopathological classification of desmoplastic melanomas

Jane Varley2023-05-14T14:59:32+10:00January 16th, 2023|

Lezcano C, Berwick M, Luo L, Barnhill R, Duncan LM, Gerami P, Lowe L, Messina JL, Scolyer RA, Wood B, Yeh I, Zembovicz A, Busam KJ. Pathology, 2023, ISSN 0031-3025.

Neo-Adjuvant Immunotherapy emerges as best medical practice and will be the new standard of care for macroscopic stage III Melanoma.

MIA Media2023-05-14T15:08:22+10:00January 11th, 2023|

van Akkooi ACJ, Blank C, Eggermont AMM. European Journal of Cancer, (Jan 11 2023),

Author Correction: Androgen receptor blockade promotes response to BRAF/MEK-targeted therapy.

MIA Media2023-05-14T15:15:25+10:00January 10th, 2023|

Vellano CP, White MG, Andrews MC, Chelvanambi M, Witt RG, Daniele JR, Titus M, McQuade JL, Conforti F, Burton EM, Lastrapes MJ, Ologun G, Cogdill AP, Morad G, Prieto P, Lazar AJ, Chu Y, Han G, Khan MAW, Helmink B, Davies MA, Amaria RN, Kovacs JJ, Woodman SE, Patel S, Hwu P, Peoples M, Lee JE, Cooper ZA, Zhu H, Gao G, Banerjee H, Lau M, Gershenwald JE, Lucci A, Keung EZ, Ross MI, Pala L, Pagan E, Segura RL, Liu Q, Borthwick MS, Lau E, Yates MS, Westin SN, Wani K, Tetzlaff MT, Haydu LE, Mahendra M, Ma X, Logothetis C, Kulstad Z, Johnson S, Hudgens CW, Feng N, Federico L, Long GV, Futreal PA, Arur S, Tawbi HA, Moran AE, Wang L, Heffernan TP, Marszalek JR, Wargo JA. Nature, (Jan 10 2023), doi:10.1038/s41586-022-05632-x.

Biology and genetics of acquired and congenital melanocytic naevi

MIA Media2023-05-14T11:07:21+10:00January 10th, 2023|

Maher NG, Scolyer RA, Colebatch AJ Pathology, 2022, ISSN 0031-3025

A phase I trial of LXS196, a protein kinase C (PKC) inhibitor, for metastatic uveal melanoma.

Jane Varley2023-05-14T17:46:58+10:00January 9th, 2023|

Piperno-Neumann S, Carlino MS, Boni V, Loirat D, Speetjens FM, Park JJ, Calvo E, Carvajal RD, Nyakas M, Gonzalez-Maffe J, Zhu X, Shirley MD, Ramkumar T, Fessehatsion A, Burks HE, Yerramilli-Rao P, Kapiteijn E. Br J Cancer. 2023 Apr;128(6):1040-1051. doi: 10.1038/s41416-022-02133-6. Epub 2023 Jan 9. PMID: 36624219; PMCID: PMC10006169.

Genomic profiling of metastatic basal cell carcinoma reveals candidate drivers of disease and therapeutic targets.

MIA Media2023-05-14T15:31:46+10:00January 9th, 2023|

Vergara IA, Aivazian K, Carlino MS, Guminski AD, Maher NG, Shannon KF, Ch’ng S, Saw RPM, Long GV, Wilmott JS, Scolyer RA. Modern Pathology, (Jan 10 2023): 100099, doi:https://doi.org/10.1016/j.modpat.2023.100099.

Alternatives and Reduced need for Sentinel Lymph Node Biopsy (SLNB) Staging for Melanoma

MIA Media2023-05-14T15:00:10+10:00January 9th, 2023|

van Akkooi ACJ, Schadendorf D, Eggermont AMM, European Journal of Cancer, 2022, ISSN 0959-8049, https://doi.org/10.1016/j.ejca.2022.12.022.

Efficacy and safety of immune checkpoint inhibitors in young adults with metastatic melanoma

MIA Media2023-05-14T11:12:23+10:00January 9th, 2023|

Wong SK, Blum SM, Sun X, Pires Da Silva I, Zubiri L, Ye F, Bai K, Zhang K, Ugurel S, Zimmer L, Livingstone E, Schadendorf D, Serra-Bellver P, Muñoz-Couselo E, Ortiz C, Lostes J, Huertas RM, Arance A, Pickering L, Long GV, Carlino MS, Buchbinder EI, Vázquez-Cortés L, Jara-Casas D, Márquez-Rodas I, González-Espinoza IR, Balko JM, Menzies AM, Sullivan RJ, Johnson DB. European Journal of Cancer, 2022, ISSN 0959-8049

Representativeness of initial skin biopsies showing pure desmoplastic melanoma: implications for management

MIA Media2023-04-03T10:30:41+10:00January 6th, 2023|

R.V. Rawson, I.A. Vergara, J.R. Stretch, R.P.M. Saw, J.F. Thompson, S.N. Lo, R.A. Scolyer, K.J. Busam Pathology, 2023, ISSN 0031-3025

Management of basal cell carcinoma with pulmonary metastasis.

MIA Media2023-05-14T15:05:21+10:00January 4th, 2023|

Fordham SA, Shao EX, Banney L, Azer M, Dettrick A. BMJ Case Rep. 2023 Jan 4;16(1):e251700. doi: 10.1136/bcr-2022-251700. PMID: 36599494; PMCID: PMC9815043.

Neoadjuvant Relatlimab and Nivolumab for Resectable Melanoma.

MIA Media2023-05-15T12:01:22+10:00January 4th, 2023|

Franke V, van Akkooi ACJ. Advanced Melanoma, (Jan 04 2023).

Revision of the Melanocytic Pathology Assessment Tool and Hierarchy for Diagnosis Classification Schema for Melanocytic Lesions: A Consensus Statement

MIA Media2023-04-03T10:14:47+10:00January 3rd, 2023|

Barnhill RL, Elder DE, Piepkorn MW, Knezevich SR, Reisch LM, Eguchi MM, Bastian BC, Blokx W, Bosenberg M, Busam KJ, Carr R, Cochran A, Cook MG, Duncan LM, Elenitsas R, de la Fouchardière A, Gerami P, Johansson I, Ko J, Landman G, Lazar AJ, Lowe L, Massi D, Messina J, Mihic-Probst D, Parker DC, Schmidt B, Shea CR, Scolyer RA, Tetzlaff M, Xu X, Yeh I, Zembowicz A, Elmore JG. JAMA Netw Open. 2023 Jan 3;6(1):e2250613. doi: 10.1001/jamanetworkopen.2022.50613. PMID: 36630138.

Interobserver agreement in the histopathological classification of desmoplastic melanomas.

MIA Media2023-05-14T15:19:25+10:00January 2nd, 2023|

Lezcano C, Berwick M, Luo L, Barnhill R, Duncan LM, Gerami P, Lowe L, Messina JL, Scolyer RA, Wood B, Yeh I, Zembowicz A, Busam KJ. Pathology (Jan 2 2023), doi:10.1016/j.pathol.2022.12.347.

Hypercalcaemia secondary to hypophysitis and cortisol deficiency: another immunotherapy-related adverse event.

MIA Media2023-05-14T15:23:22+10:00January 1st, 2023|

Miller SR, Kumar S, Yuile A, Menzies AM. Endocrinol Diabetes Metab Case Rep. 2023 (Jan 1 2023), doi:10.1530/edm-22-0375.

Views of the Australian public on the delivery of risk-stratified cancer screening in the population: a qualitative study.

MIA2025-04-24T13:04:49+10:00January 1st, 2023|

Dunlop K, Rankin N, Smit A, Newson A, Keogh L, Cust A. Public Health Research & Practice, (2023).

Biology and genetics of acquired and congenital melanocytic naevi.

MIA Media2023-05-15T21:02:50+10:00December 29th, 2022|

Maher NG, Scolyer RA, Colebatch AJ. Pathology. 2023 Mar;55(2):169-177. doi: 10.1016/j.pathol.2022.12.344. Epub 2022 Dec 29. PMID: 36635156.

Diagnostic biopsies of suspected skin cancer in general practice from 2010 to 2017 in Victoria, Australia

MIA Media2023-04-03T10:21:11+10:00December 22nd, 2022|

So C, McCarthy D, Watts CG, Kearney C, Reyes-Marcelino G, Goldsbury DE, Mcloughlin K, Emery J, Cust AE British Journal of Dermatology, 2022 ljac111

Embedding electronic patient-reported outcome measures into routine care for patients with stage III MELanoma (ePROMs-MEL): protocol for a prospective, longitudinal, mixed-methods pilot study.

MIA Media2023-05-15T13:41:18+10:00December 20th, 2022|

Dempsey K, Saw R, Bartula I, Lo S, Lawn C, Pennington T, Spillane A, Boyle F, Dong S, Dieng M, Milne D, Seaman L, Saks D, Lai-Kwon J, Thompson JR, Morton R. BMJ Open. 2022 Dec 20;12(12):e066852. doi: 10.1136/bmjopen-2022-066852. PMID: 36600423; PMCID: PMC9772660.

Perspectives and Experiences of Patient-Led Melanoma Surveillance Using Digital Technologies From Clinicians Involved in the MEL-SELF Pilot Randomized Controlled Trial: Qualitative Interview Study

MIA Media2023-05-14T10:58:25+10:00December 20th, 2022|

Drabarek D, Habgood E, Ackermann D, Hersch J, Janda M, Morton RL, Guitera P, Soyer HP, Collgros H, Cust AE, Saw RP, Emery J, Mar V, Dieng M, Azzi A, Lilleyman A, Bell KJ
JMIR Dermatol 2022;5(4):e40623

Talimogene Laherparepvec in Combination with Immunotherapy, A Viable Option?

MIA Media2023-04-03T10:20:26+10:00December 15th, 2022|

Zager, J. & van Akkooi, Alexander. (2022). Annals of Surgical Oncology. 10.1245/s10434-022-12940-z.

Melanomas in children and adolescents: clinicopathologic features and survival outcomes.

MIA Media2023-01-21T22:02:19+11:00December 9th, 2022|

El Sharouni MA, Rawson RV, Potter AJ, Paver EC, Wilmott JS, Witkamp AJ, Sigurdsson V, van Diest PJ, Scolyer RA, Thompson JF, Lo SN, van Gils CH. J Am Acad Dermatol. 2022 Dec 9:S0190-9622(22)03176-0. doi: 10.1016/j.jaad.2022.08.067. Epub ahead of print. PMID: 36509217.

Tumor-Infiltrating Lymphocyte Therapy or Ipilimumab in Advanced Melanoma.

MIA Media2023-01-21T22:32:20+11:00December 8th, 2022|

Rohaan MW, Borch TH, van den Berg JH, Met Ö, Kessels R, Geukes Foppen MH, Stoltenborg Granhøj J, Nuijen B, Nijenhuis C, Jedema I, van Zon M, Scheij S, Beijnen JH, Hansen M, Voermans C, Noringriis IM, Monberg TJ, Holmstroem RB, Wever LDV, van Dijk M, Grijpink-Ongering LG, Valkenet LHM, Torres Acosta A, Karger M, Borgers JSW, Ten Ham RMT, Retèl VP, van Harten WH, Lalezari F, van Tinteren H, van der Veldt AAM, Hospers GAP, Stevense-den Boer MAM, Suijkerbuijk KPM, Aarts MJB, Piersma D, van den Eertwegh AJM, de Groot JB, Vreugdenhil G, Kapiteijn E, Boers-Sonderen MJ, Fiets WE, van den Berkmortel FWPJ, Ellebaek E, Hölmich LR, van Akkooi ACJ, van Houdt WJ, Wouters MWJM, van Thienen JV, Blank CU, Meerveld-Eggink A, Klobuch S, Wilgenhof S, Schumacher TN, Donia M, Svane IM, Haanen JBAG. N Engl J Med. 2022 Dec 8;387(23):2113-2125. doi: 10.1056/NEJMoa2210233. PMID: 36477031.

Clinical features associated with outcomes and biomarker analysis of dabrafenib plus trametinib treatment in patients with BRAF-mutant melanoma brain metastases.

MIA Media2023-01-21T22:57:07+11:00December 7th, 2022|

Wilmott JS, Tawbi H, Engh JA, Amankulor NM, Shivalingam B, Banerjee H, Vergara IA, Lee H, Johansson PA, Ferguson PM, Saiag P, Robert C, Grob JJ, Butterfield LH, Scolyer RA, Kirkwood JM, Long GV, Davies MA. Clin Cancer Res. 2022 Dec 7:CCR-22-2581. doi: 10.1158/1078-0432.CCR-22-2581. Epub ahead of print. PMID: 36477181.

Incorporating carbon into health care: adding carbon emissions to health technology assessments.

MIA Media2023-01-21T22:11:16+11:00December 6th, 2022|

McAlister S, Morton RL, Barratt A. Lancet Planet Health. 2022 Dec;6(12):e993-e999. doi: 10.1016/S2542-5196(22)00258-3. PMID: 36495894.

Prognostic Significance and Management of Sentinel Nodes in the Triangular Intermuscular Space of Patients with Melanoma.

MIA Media2023-01-21T22:38:49+11:00December 3rd, 2022|

Schoenfeldt T, Thompson JF, Lo S, Drzewiecki KT, Stretch J, Saw RPM, Spillane A, Shannon K, Uren RF, Chakera AH, Nieweg OE. Ann Surg Oncol. 2022 Dec 3. doi: 10.1245/s10434-022-12840-2. Epub ahead of print. PMID: 36463358.

Talimogene laherparepvec monotherapy for head and neck melanoma patients.

MIA Media2025-04-24T10:43:17+10:00November 29th, 2022|

Franke V, Stahlie EHA, Klop WMC, Zuur CL, Berger DMS, van der Hiel B, van de Wiel BA, Wouters MWJM, van Houdt WJ, van Akkooi ACJ. Melanoma Res. 2022 Nov 29. doi: 10.1097/CMR.0000000000000866. Epub ahead of print. PMID: 36454284.

Genomic and proteomic findings in early melanoma and opportunities for early diagnosis.

MIA Media2023-04-03T10:20:54+10:00November 28th, 2022|

Teh R, Azimi A, Pupo GM, Ali M, Mann GJ, Fernández-Peñas P. Exp Dermatol. 2022 Nov 14. doi: 10.1111/exd.14705. Epub ahead of print. PMID: 36373875.

Reflectance confocal microscopy in Australia: Perspectives on barriers to implementation and uptake.

MIA Media2022-12-10T21:33:50+11:00November 22nd, 2022|

Ho G, Smith A, Cust AE, Melhoranse-Gouveia B, Collgros H, Martin L, Guitera P. Australas J Dermatol. 2022 Nov 22. doi: 10.1111/ajd.13954. Epub ahead of print. PMID: 36412240.

Five-year survival and clinical correlates among patients with advanced non-small cell lung cancer, melanoma and renal cell carcinoma treated with immune check-point inhibitors in Australian tertiary oncology centres.

MIA Media2022-12-10T21:45:50+11:00November 20th, 2022|

Brown LJ, da Silva IP, Moujaber T, Gao B, Hui R, Gurney H, Carlino M, Nagrial A. Cancer Med. 2022 Nov 20. doi: 10.1002/cam4.5468. Epub ahead of print. PMID: 36404632.

The effect of organ-specific tumor microenvironments on response patterns to immunotherapy.

MIA Media2022-11-20T14:43:45+11:00November 17th, 2022|

Conway Jordan W., Braden Jorja, Wilmott James S., Scolyer Richard A., Long Georgina V., Pires da Silva Inês. Frontiers in Immunology, 2022. https://www.frontiersin.org/articles/10.3389/fimmu.2022.1030147; DOI=10.3389/fimmu.2022.1030147, ISSN=1664-3224

Informing a position statement on the use of artificial intelligence in dermatology in Australia.

MIA Media2022-12-10T21:28:53+11:00November 15th, 2022|

Caffery LJ, Janda M, Miller R, Abbott LM, Arnold C, Caccetta T, Guitera P, Shumack S, Fernández-Peñas P, Mar V, Soyer HP. Australas J Dermatol. 2022 Nov 15. doi: 10.1111/ajd.13946. Epub ahead of print. PMID: 36380357.

BRAF inhibitor cessation prior to disease progression in metastatic melanoma: long term outcomes.

MIA Media2022-11-20T14:37:39+11:00November 9th, 2022|

J. Lee, T. Ahmed, A. Maurichi, L. Di Guardo, A.M. Stagno, L. Warburton, A. Taylor, E. Livingstone, S. Rehman, A. Khattak, K. Kahler, V. Vanella, V. Atkinson, M. Millward, D. Schadendorf, D.B. Johnson, P.A. Ascierto, A. Hauschild, S.N. Lo, G.V. Long, A.M. Menzies, M.S. Carlino. European Journal of Cancer, 2022, ISSN 0959-8049, https://doi.org/10.1016/j.ejca.2022.11.009.

Toripalimab vs High-Dose Interferon-α2b as Adjuvant Therapy for Resected Mucosal Melanoma.

MIA Media2022-12-10T21:40:04+11:00November 9th, 2022|

Franke V, van Akkooi, ACJ. Advanced Melanoma 2022 Nov 09.

Which strategies support the effective use of clinical practice guidelines and clinical quality registry data to inform health service delivery? A systematic review.

MIA Media2022-12-10T21:18:07+11:00November 9th, 2022|

Dempsey K, Ferguson C, Walczak A, Middleton S, Levi C, Morton RL; Australian Health Research Alliance (AHRA) Health System Improvement and Sustainability Working Group members. Syst Rev. 2022 Nov 9;11(1):237. doi: 10.1186/s13643-022-02104-1. PMID: 36352475; PMCID: PMC9644489.

Phase 1b Study of Cobimetinib Plus Atezolizumab in Patients with Advanced BRAFV600 Wild-Type Melanoma Progressing on Prior Anti–Programmed Death-1 Therapy.

MIA Media2022-11-20T14:24:20+11:00November 2nd, 2022|

Sandhu S, Atkinson V, Cao MG, Medina T, Rivas AS, Menzies AM, Caro I, Roberts L, Song Y, Yan Y, Guo Y, Xue C, Long GV. European Journal of Cancer. 2022 Nov 02; doi: 10.1016/j.ejca.2022.10.019.

Dataset for the Reporting of Merkel Cell Carcinoma: Recommendations From the International Collaboration on Cancer Reporting (ICCR).

MIA Media2022-11-20T10:22:19+11:00November 1st, 2022|

Busam KJ, Judge MJ, Bichakjian CK, Coit D, Kutzner H, Requena L, Scolyer RA, Stefanato CM, Wood BA, Walsh NM. Am J Surg Pathol. 2022 Nov 1;46(11):1583-1591. doi: 10.1097/PAS.0000000000001959. Epub 2022 Aug 25. PMID: 36001458.

Utility of next generation sequencing for differentiating malignant PEComa from metastatic melanoma.

MIA Media2022-11-20T14:08:23+11:00October 29th, 2022|

Paver E, Aivazian K, Maclean F, Long GV, Spillane AJ, Wilmott JS, Scolyer RA. Pathology. 2022 Oct 29.

ASO Visual Abstract: Predictors of Sentinel Lymph Node Metastasis in Patients with Thin Melanoma-An International Multi-institutional Collaboration.

MIA Media2022-11-20T10:33:10+11:00October 29th, 2022|

Walker RJB, Look Hong NJ, Moncrieff M, van Akkooi ACJ, Jost E, Nessim C, van Houdt WJ, Stahlie EHA, Seo C, Quan ML, McKinnon JG, Wright FC, Mavros MN. Ann Surg Oncol. 2022 Oct;29(11):7018. doi: 10.1245/s10434-022-12050-w. Epub 2022 Jul 9. PMID: 35810221.

Tertiary lymphoid structures accompanied by fibrillary matrix morphology impact anti-tumor immunity in basal cell carcinomas.

MIA Media2022-12-10T21:19:18+11:00October 27th, 2022|

Byers C, Gill M, Kurtansky NR, Alessi-Fox C, Harman M, Cordova M, Gonzalez S, Guitera P, Rotemberg V, Marghoob A, Chen CJ, Dy J, Kose K, Rajadhyaksha M, Sahu A. Front Med (Lausanne). 2022 Oct 27;9:981074. doi: 10.3389/fmed.2022.981074. PMID: 36388913; PMCID: PMC9647637.

Combination of the STING Agonist MIW815 and PD-1 Inhibitor Spartalizumab in Advanced/Metastatic Solid Tumors or Lymphomas: An Open-label, Multicenter, Phase Ib Study.

MIA Media2022-11-20T14:01:27+11:00October 25th, 2022|

Meric-Bernstam F, Sweis RF, Kasper S, Hamid O, Bhatia S, Dummer R, Stradella A, Long GV, Spreafico A, Shimizu T, Steeghs N, Luke JJ, McWhirter SM, Müller T, Nair N, Lewis N, Chen X, Bean A, Kattenhorn L, Pelletier M, Sandhu S. Clin Cancer Res. 2022 Oct 25:CCR-22-2235. doi: 10.1158/1078-0432.CCR-22-2235. Epub ahead of print. PMID: 36282874.

Discussion of costs and financial burden in clinical practice: A survey of medical oncologists in Australia.

MIA Media2022-11-20T13:54:33+11:00October 21st, 2022|

Agarwal A, Karikios DJ, Stockler MR, Morton RL. PLoS One. 2022 Oct 21;17(10):e0273620. doi: 10.1371/journal.pone.0273620. PMID: 36269711; PMCID: PMC9586404.

Pembrolizumab versus placebo as adjuvant therapy in resected stage IIB or IIC melanoma (KEYNOTE-716): distant metastasis-free survival results of a multicentre, double-blind, randomised, phase 3 trial.

MIA Media2022-11-20T09:47:33+11:00October 18th, 2022|

Long GV, Luke JJ, Khattak MA, de la Cruz Merino L, Del Vecchio M, Rutkowski P, Spagnolo F, Mackiewicz J, Chiarion-Sileni V, Kirkwood JM, Robert C, Grob J-J, de Galitiis F, Schadendorf D, Carlino MS, Mohr P, Dummer R, Gershenwald JE, Yoon CH, Wu XL, Fukunaga-Kalabis M, Krepler C, Eggermont AMM, Ascierto PA. The Lancet Oncology, (Oct 18 2022)

Clinical Management of Melanocytic Tumours of Uncertain Malignant Potential (MelTUMPs), including Melanocytomas: A Systematic Review and Meta-Analysis.

MIA Media2022-11-20T10:15:57+11:00October 17th, 2022|

Varey, A.H.R., Williams, G.J., Lo, S.N., Taing, C.Y., Maurichi, A., Santinami, M., Scolyer, R.A. and Thompson, J.F. J Eur Acad Dermatol Venereol.

Motivations and Barriers to Participation in a Randomized Trial on Melanoma Genomic Risk: A Mixed-Methods Analysis.

MIA Media2022-11-20T09:08:20+11:00October 12th, 2022|

Mercado G, Newson AJ, Espinoza D, The Managing Your Risk Study Group, Cust AE, Smit AK. Journal of Personalized Medicine. 2022; 12(10):1704.

Real-world outcomes with ipilimumab and nivolumab in advanced melanoma: a multicentre retrospective study.

MIA Media2022-11-20T13:34:01+11:00October 7th, 2022|

Serra-Bellver P, Versluis JM, Oberoi HK, Zhou C, Slattery TD, Khan Y, Patrinely JR, Pires da Silva I, Martínez-Vila C, Cook N, Graham DM, Carlino MS, Menzies AM, Arance AM, Johnson DB, Long GV, Pickering L, Larkin JMG, Blank CU, Lorigan P. Eur J Cancer. 2022 Oct 7;176:121-132. doi: 10.1016/j.ejca.2022.09.004. Epub ahead of print. PMID: 36215945.

Causes, consequences and clinical significance of aneuploidy across melanoma subtypes.

MIA Media2022-11-20T14:18:45+11:00October 6th, 2022|

Shteinman ER, Wilmott JS, da Silva IP, Long GV, Scolyer RA, Vergara IA. Front Oncol. 2022 Oct 6;12:988691. doi: 10.3389/fonc.2022.988691. PMID: 36276131; PMCID: PMC9582607.

Is a History of Optimal Staging by Sentinel Lymph Node Biopsy in the Era Prior to Adjuvant Therapy Associated with Improved Outcome Once Melanoma Patients have Progressed to Advanced Disease?

MIA Media2022-11-20T09:27:24+11:00October 6th, 2022|

Blankenstein SA, Bonenkamp JJ, Aarts MJB, van den Berkmortel FWPJ, Blank CU, Blokx WAM, Boers-Sonderen MJ, van den Eertwegh AJM, Franken MG, de Groot JWB, Haanen JBAG, Hospers GAP, Kapiteijn EW, van Not OJ, Piersma D, van Rijn RS, Suijkerbuijk KPM, van der Veldt AAM, Vreugdenhil G, Westgeest HM, Wouters MWJM, van Akkooi ACJ. Ann Surg Oncol. 2022 Oct 6. doi: 10.1245/s10434-022-12600-2. Epub ahead of print. PMID: 36203067.

Exploring the Integration of Environmental Impacts in the Cost Analysis of the Pilot MEL-SELF Trial of Patient-Led Melanoma Surveillance.

MIA Media2022-11-20T09:34:27+11:00October 5th, 2022|

Williams JTW, Bell KJL, Morton RL, Dieng M. Appl Health Econ Health Policy. 2022 Oct 5. doi: 10.1007/s40258-022-00765-6. Epub ahead of print. PMID: 36195819.

Adjuvant pembrolizumab versus placebo in resected high-risk stage II melanoma: Health-related quality of life from the randomized phase 3 KEYNOTE-716 study.

MIA Media2022-11-19T22:44:45+11:00October 3rd, 2022|

Muhammad A. Khattak, Jason J. Luke, Georgina V. Long, Paolo A. Ascierto, Piotr Rutkowski, Dirk Schadendorf, Caroline Robert, Jean-Jacques Grob, Luis de la Cruz Merino, Michele Del Vecchio, Francesco Spagnolo, Jacek Mackiewicz, Vanna Chiarion-Sileni, Matteo S. Carlino, Peter Mohr, Federica De Galitiis, Merrick I. Ross, Zeynep Eroglu, Ke Chen, Ruixuan Jiang, Mizuho Fukunaga-Kalabis, Clemens Krepler, Alexander M.M. Eggermont, John M. Kirkwood. European Journal of Cancer, 2022, ISSN 0959-8049

Metastasizing and non-metastasizing thick melanoma: clinicopathological predictors and molecular profiling.

MIA Media2022-12-10T22:01:22+11:00October 1st, 2022|

Güvenç C, Antoranz A, Szumera-Cieckiewicz A, Teterycz PP, Rutkowski P, Rawson RV, Scolyer RA, Thompson JF, Newton-Bishop , Stas M, Boecxstaens V, Bechter O, Vercauteren J, Garmyn M, van den Oord J, Bosisio FM. Dutch Journal of Dermatology and Venereology. 2022 Oct

Factors influencing acceptance, adoption and adherence to sentinel node biopsy recommendations in the Australian Melanoma Management Guidelines: a qualitative study using an implementation science framework.

MIA Media2022-11-20T09:22:58+11:00October 1st, 2022|

Smith AL, Watts CG, Henderson M, Long GV, Rapport F, Saw RPM, Scolyer RA, Spillane AJ, Thompson JF, Cust AE. Implement Sci Commun. 2022 Oct 1;3(1):103. doi: 10.1186/s43058-022-00351-w. PMID: 36183121; PMCID: PMC9526940.

Causes, consequences and clinical significance of aneuploidy across melanoma subtypes.

MIA Media2022-11-20T09:15:44+11:00October 1st, 2022|

Shteinman Eva R., Wilmott James S., da Silva Ines Pires, Long Georgina V., Scolyer Richard A., Vergara Ismael A. Frontiers in Oncology. 2022; 12 doi=10.3389/fonc.2022.988691

Obesity is associated with altered tumor metabolism in metastatic melanoma.

MIA Media2022-11-19T22:24:52+11:00September 27th, 2022|

Hahn AW, Menk AV, Rivadeneira DB, Augustin RC, Xu M, Li J, Wu X, Mishra AK, Gide TN, Quek C, Zang Y, Spencer CN, Menzies AM, Daniel CR, Hudgens CW, Nowicki T, Haydu LE, Khan MAW, Gopalakrishnan V, Burton EM, Malke J, Simon JM, Bernatchez C, Putluri N, Woodman SE, Gopal Y N V, Guerrieri R, Fischer GM, Wang J, Wani KM, Thompson JF, Lee JE, Hwu P, Ajami N, Gershenwald JE, Long GV, Scolyer RA, Tetzlaff MT, Lazar AJ, Schadendorf D, Wargo JA, Kirkwood JM, DeBerardinis RJ, Liang H, Futreal A, Zhang J, Wilmott JS, Peng W, Davies MA, Delgoffe GM, Najjar YG, McQuade JL. Clin Cancer Res. 2022 Sep 27:CCR-22-2661. doi: 10.1158/1078-0432.CCR-22-2661. Epub ahead of print. PMID: 36166093.

Hypoxia controls the glycome signature and galectin-8 – ligand axis to promote pro-tumorigenic properties of metastatic melanoma.

MIA Media2022-11-19T22:31:02+11:00September 26th, 2022|

Chakraborty A, Perez M, Carroll JD, Antonopoulos A, Dell A, Ortega L, Mohammed NBB, Wells M, Staudinger C, Griswold A, Chandler KB, Marrero C, Jimenez R, Tani Y, Wilmott JS, Thompson JF, Wang W, Sackstein R, Scolyer RA, Murphy GF, Haslam SM, Dimitroff CJ. J Invest Dermatol. 2022 Sep 26:S0022-202X(22)01931-5. doi: 10.1016/j.jid.2022.07.033. Epub ahead of print. PMID: 36174713.

Adjuvant Therapy of Nivolumab Combined With Ipilimumab Versus Nivolumab Alone in Patients With Resected Stage IIIB-D or Stage IV Melanoma (CheckMate 915).

MIA Media2022-11-19T22:17:24+11:00September 26th, 2022|

Weber JS, Schadendorf D, Del Vecchio M, Larkin J, Atkinson V, Schenker M, Pigozzo J, Gogas H, Dalle S, Meyer N, Ascierto PA, Sandhu S, Eigentler T, Gutzmer R, Hassel JC, Robert C, Carlino MS, Di Giacomo AM, Butler MO, Muñoz-Couselo E, Brown MP, Rutkowski P, Haydon A, Grob JJ, Schachter J, Queirolo P, de la Cruz-Merino L, van der Westhuizen A, Menzies AM, Re S, Bas T, de Pril V, Braverman J, Tenney DJ, Tang H, Long GV. J Clin Oncol. 2022 Sep 26:JCO2200533. doi: 10.1200/JCO.22.00533. Epub ahead of print. PMID: 36162037.

Communicating Personal Melanoma Polygenic Risk Information: Participants’ Experiences of Genetic Counseling in a Community-Based Study.

MIA Media2022-11-19T21:54:58+11:00September 26th, 2022|

Smit AK, Espinoza D, Fenton GL, Kirk J, Innes JS, McGovern M, Limb S, on behalf of the Managing Your Risk Study Group, Turbitt E, Cust AE. Journal of Personalized Medicine. 2022; 12(10):1581.

Validation of self-reported sun exposure against electronic ultraviolet radiation dosimeters.

MIA Media2022-11-19T22:02:54+11:00September 24th, 2022|

Zhang R, Smit AK, Espinoza D, Allen M, Reyes-Marcelino G, Kimlin MG, Lo SN, Sharman AR, Law MH, Kanetsky PA, Mann GJ, Cust AE. Int J Epidemiol. 2022 Sep 24:dyac179. doi: 10.1093/ije/dyac179. Epub ahead of print. PMID: 36153755.

Recursive Partitioning to Determine Order of Significance of Regional Metastasis Characteristics in Head and Neck Cutaneous Squamous Cell Carcinoma.

MIA Media2022-11-19T22:04:45+11:00September 24th, 2022|

Hurrell MJL, Heller GZ, Elliott MS, Gao K, Ebrahimi A, Clark JR, Shannon K, Palme CE, Wykes J, Gupta R, Ch’ng S, Nguyen KM, Low TH. Ann Surg Oncol. 2022 Oct 29(11):7000-7001. doi: 10.1245/s10434-022-12061-7. PMID: 35907993.

Neurological adverse effects associated with anti-PD1 antibodies alone or in combination with ipilimumab: a multicenter case series.

MIA Media2022-11-19T22:01:59+11:00September 23rd, 2022|

Smith JL, Menzies AM, Cohen JV, Mut-Lloret M, Ozgun A, Spain L, Park J, Quach HT, Pallan L, McQuade J, Feng S, Sandhu S, Atkinson V, Tsai K, Long GV, Larkin J, Eroglu Z, Johnson DB, Sullivan R, Herkes GK, Henderson A, Carlino MS. Melanoma Res. 2022 Sep 23. doi: 10.1097/CMR.0000000000000825. Epub ahead of print. PMID: 36164923.

Characteristics of immune checkpoint inhibitor-induced encephalitis and comparison with HSV-1 and anti-LGI1 encephalitis: A retrospective multicentre cohort study.

MIA Media2022-11-19T22:37:15+11:00September 22nd, 2022|

Müller-Jensen L, Zierold S, Versluis JM, Boehmerle W, Huehnchen P, Endres M, Mohr R, Compter A, Blank CU, Hagenacker T, Meier F, Reinhardt L, Gesierich A, Salzmann M, Hassel JC, Ugurel S, Zimmer L, Banks P, Spain L, Soon JA, Enokida T, Tahara M, Kähler KC, Seggewiss-Bernhardt R, Harvey C, Long GV, Schöberl F, von Baumgarten L, Hundsberger T, Schlaak M, French LE, Knauss S, Heinzerling LM. CEur J Cancer. 2022 Sep 22;175:224-235. doi: 10.1016/j.ejca.2022.08.009. Epub ahead of print. PMID: 36155116.

Feasibility, acceptability, and utility of a nurse-led survivorship program for people with metastatic melanoma (MELCARE).

MIA Media2022-11-19T21:55:24+11:00September 22nd, 2022|

Lai-Kwon J, Kelly B, Lane S, Biviano R, Bartula I, Brennan F, Kivikoski I, Thompson J, Dhillon HM, Menzies A, Long GV. Support Care Cancer. 2022 Sep 22:1–10. doi: 10.1007/s00520-022-07360-4. Epub ahead of print. PMID: 36136246; PMCID: PMC9492451.

Navigating the cellular landscape in tissue: Recent advances in defining the pathogenesis of human disease.

MIA Media2022-10-23T19:59:56+11:00September 15th, 2022|

Chen HY, Palendira U, Feng CG. Computational and Structural Biotechnology Journal, Volume 20, 2022 Sep 15, Pages 5256-5263, ISSN 2001-0370, doi: 10.1016/j.csbj.2022.09.005.

Comparative genomics provides etiological and biological insights into melanoma subtypes

MIA Media2022-10-09T21:35:02+11:00September 13th, 2022|

Newell F, Johansson PA, Wilmott JS, Nones K, Lakis V, Pritchard AL, Lo SN, Rawson RV, Kazakoff SH, Colebatch AJ, Koufariotis LT, Ferguson PM, Wood S, Leonard C, Law MH, Brooks KM, Broit N, Palmer JM, Couts KL, Vergara IA, Long GV, Barbour AP, Nieweg OE, Shivalingam B, Robinson WA, Stretch JR, Spillane AJ, Saw RPM, Shannon KF, Thompson JF, Mann GJ, Pearson JV, Scolyer RA, Waddell N, Hayward NK. Cancer Discov. 2022 Sep 13:CD-22-0603. doi: 10.1158/2159-8290.CD-22-0603. Epub ahead of print. PMID: 36098958.

Unveiling the tumor immune microenvironment of organ-specific melanoma metastatic sites.

MIA Media2022-10-09T21:38:54+11:00September 10th, 2022|

Conway JW, Rawson RV, Lo S, Ahmed T, Vergara IA, Gide TN, Attrill GH, Carlino MS, Saw RPM, Thompson JF, Spillane AJ, Shannon KF, Shivalingam B, Menzies AM, Wilmott JS, Long GV, Scolyer RA, Pires da Silva I. J Immunother Cancer. 2022 Sep;10(9):e004884. doi: 10.1136/jitc-2022-004884. PMID: 36096531.

Five-Year Analysis of Adjuvant Pembrolizumab or Placebo in Stage III Melanoma.

MIA Media2022-10-23T20:07:40+11:00September 10th, 2022|

Eggermont AMM, Kicinski M, Blank CU, Mandala M, Long GV, Atkinson V, Dalle S, Haydon A, Meshcheryakov A, Khattak A, Carlino MS, Sandhu S, Larkin J, Puig S, Ascierto PA, Rutkowski P, Schadendorf D, Boers-Sonderen M, Di Giacomo AM, van den Eertwegh AJM, Grob J-J, Gutzner R, Jamal R, van Akkooi ACJ, Lorigan P, Grebennik D, Krepler C, Marreaud S, Suciu S, Robert C. NEJM Evidence. 2022 Sep 10. doi: 10.1056/EVIDoa2200214. Epub ahead of print.

In vivo tumor immune microenvironment phenotypes correlate with inflammation and vasculature to predict immunotherapy response.

MIA Media2022-10-23T19:14:26+11:00September 9th, 2022|

Sahu A, Kose K, Kraehenbuehl L, Byers C, Holland A, Tembo T, Santella A, Alfonso A, Li M, Cordova M, Gill M, Fox C, Gonzalez S, Kumar P, Wang AW, Kurtansky N, Chandrani P, Yin S, Mehta P, Navarrete-Dechent C, Peterson G, King K, Dusza S, Yang N, Liu S, Phillips W, Guitera P, Rossi A, Halpern A, Deng L, Pulitzer M, Marghoob A, Chen CJ, Merghoub T, Rajadhyaksha M. Nat Commun. 2022 Sep 9;13(1):5312. doi: 10.1038/s41467-022-32738-7. PMID: 36085288; PMCID: PMC9463451.

Views of the Australian public on the delivery of risk-stratified cancer screening in the population: a qualitative study.

MIA Media2022-10-09T21:40:00+11:00September 6th, 2022|

Kate LA Dunlop, Nicole M Rankin, Amelia K Smit, Ainsley J Newson, Louise A Keogh, Anne E Cust. Public Health Res Pract. 2022 Sep 6:32232213. doi: 10.17061/phrp32232213. Epub ahead of print. PMID: 36065020.

Higher polygenic risk for melanoma is associated with improved survival in a high ultraviolet radiation setting.

MIA Media2022-10-09T21:41:43+11:00September 5th, 2022|

Seviiri M, Scolyer RA, Bishop DT, Newton-Bishop JA, Iles MM, Lo SN, Stretch JR, Saw RPM, Nieweg OE, Shannon KF, Spillane AJ, Gordon SD, Olsen CM, Whiteman DC, Landi MT, Thompson JF, Long GV, MacGregor S, Law MH. J Transl Med. 2022 Sep 5;20(1):403. doi: 10.1186/s12967-022-03613-2. PMID: 36064556; PMCID: PMC9446843.

Assessing the value of precision medicine health technologies to detect and manage melanoma.

MIA Media2022-10-10T21:52:53+11:00September 4th, 2022|

Mahumud RA, Janda M, Soyer HP, Fernández-Peñas P, Mar VJ, Morton RL. Med J Aust. 2022 Sep 4. doi: 10.5694/mja2.51696. Epub ahead of print. PMID: 36057953.

Utility of optical coherence tomography in basal cell naevus syndrome: A case report

MIA Media2022-10-23T19:56:19+11:00September 2nd, 2022|

Ho G, Schwartz RJ, Melhoranse-Gouveia B, Guitera P, O’Sullivan NA, Cheung VKY, Ch’ng S, Martin LK. Australas J Dermatol. 2022 Sep 20. doi: 10.1111/ajd.13921. Epub ahead of print. PMID: 36125195.

Diet-driven microbial ecology underpins associations between cancer immunotherapy outcomes and the gut microbiome.

MIA Media2022-10-23T19:53:17+11:00September 1st, 2022|

Simpson RC, Shanahan ER, Batten M, Reijers ILM, Read M, Silva IP, Versluis JM, Ribero R, Angelatos AS, Tan J, Adhikari C, Menzies AM, Saw RPM, Gonzalez M, Shannon KF, Spillane AJ, Velickovic R, Lazar AJ, Damania AV, Mishra AK, Chelvanambi M, Banerjee A, Ajami NJ, Wargo JA, Macia L, Holmes AJ, Wilmott JS, Blank CU, Scolyer RA, Long GV. Nat Med 2022 Sep 22. doi: 10.1038/s41591-022-01965-2. Epub ahead of print.

Developing an Australian Melanoma Clinical Outcomes Registry (MelCOR): a protocol paper.

MIA Media2022-10-09T21:42:39+11:00September 1st, 2022|

Jobson D, Roffey B, Best R, Button-Sloan A, Cossio D, Evans S, Shang C, Moore J, Arnold C, Mann G, Shackleton M, Soyer HP, Morton RL, Zalcberg J, Mar V. BMJ Open 2022;12:e062139. doi: 10.1136/bmjopen-2022-062139

Survival outcomes of perineural spread in head and neck cutaneous squamous cell carcinoma.

MIA Media2022-10-23T20:13:59+11:00September 1st, 2022|

Phung D, Ahmadi N, Gupta R, Clark JR, Wykes J, Ch’ng S, Elliott MS, Palme CE, Shannon K, Wu R, Lee JH, Low TH. ANZ J Surg. 2022 Sep;92(9):2299-2304. doi: 10.1111/ans.17908. Epub 2022 Jul 22. PMID: 35866314.

KEYNOTE – D36: personalized immunotherapy with a neoepitope vaccine, EVX-01 and pembrolizumab in advanced melanoma.

MIA Media2022-10-09T21:43:26+11:00September 1st, 2022|

Long GV, Ferrucci PF, Khattak A, Meniawy TM, Ott PA, Chisamore M, Trolle T, Hyseni A, Heegaard E. Future Oncol. 2022 Sep 1. doi: 10.2217/fon-2022-0694. Epub ahead of print. PMID: 36047545.

High-dimensional and spatial analysis reveals immune landscape dependent progression in cutaneous squamous cell carcinoma

MIA Media2022-10-23T20:17:17+11:00August 31st, 2022|

Ferguson AL, Sharman AR, Allen RO, Ye T, Lee JH, Low TH, Ch’ng S, Palme CE, Ashford B, Ranson M, Clark JR, Patrick E, Gupta R, Palendira U. Clin Cancer Res. 2022 Aug 31:CCR-22-1332. doi: 10.1158/1078-0432.CCR-22-1332. Epub ahead of print. PMID: 36044477.

Sentinel node biopsy: linchpin of melanoma management.

MIA Media2022-11-20T14:13:04+11:00August 29th, 2022|

Smithers BM, Scolyer RA, Thompson JF. InSight+ MJA. 2022 Aug 29. Vol 33.

Response to ‘Multicentre Selective Lymphadenectomy Trial 1: key primary data remain unavailable.

MIA Media2022-11-20T13:48:23+11:00August 20th, 2022|

Faries MB, Cochran AJ, Thompson JF. Br J Dermatol. 2022 Aug 20. doi: 10.1111/bjd.21841. Epub ahead of print. PMID: 35988015.

Neoadjuvant nivolumab + T-VEC combination therapy for resectable early stage or metastatic (IIIB-IVM1a) melanoma with injectable disease: study protocol of the NIVEC trial.

MIA Media2022-11-20T13:34:53+11:00August 4th, 2022|

Rohaan MW, Stahlie EHA, Franke V, Zijlker LP, Wilgenhof S, van der Noort V, van Akkooi ACJ, Haanen JBAG. BMC Cancer. 2022 Aug 4;22(1):851. doi: 10.1186/s12885-022-09896-4. PMID: 35927710; PMCID: PMC9351098.

Whole genome analysis reveals the genomic complexity in metastatic cutaneous squamous cell carcinoma.

MIA Media2022-10-23T20:21:48+11:00August 2nd, 2022|

Thind AS, Ashford B, Strbenac D, Mitchell J, Lee J, Mueller SA, Minaei E, Perry JR, Ch’ng S, Iyer NG, Clark JR, Gupta R, Ranson M. Front Oncol. 2022 Aug 2;12:919118. doi: 10.3389/fonc.2022.919118. PMID: 35982973; PMCID: PMC9379253.

Diagnosis and treatment of Merkel cell carcinoma: European consensus-based interdisciplinary guideline – Update 2022.

MIA Media2022-11-20T10:26:50+11:00August 1st, 2022|

Gauci ML, Aristei C, Becker JC, Blom A, Bataille V, Dreno B, Del Marmol V, Forsea AM, Fargnoli MC, Grob JJ, Gomes F, Hauschild A, Hoeller C, Harwood C, Kelleners-Smeets N, Kaufmann R, Lallas A, Malvehy J, Moreno-Ramirez D, Peris K, Pellacani G, Saiag P, Stratigos AJ, Vieira R, Zalaudek I, van Akkooi ACJ, Lorigan P, Garbe C, Lebbé C; European Dermatology Forum (EDF), the European Association of Dermato-Oncology (EADO) and the European Organization for Research and Treatment of Cancer (EORTC). Eur J Cancer. 2022 Aug;171:203-231. doi: 10.1016/j.ejca.2022.03.043. Epub 2022 Jun 19. PMID: 35732101.

Benchmarking Survival Outcomes Following Surgical Management of pT3 and pT4 Cutaneous Squamous Cell Carcinoma of the Head and Neck.

MIA Media2022-10-23T20:57:14+11:00August 1st, 2022|

Yung AE, Crouch G, Varey AHR, Lo S, Elliott MS, Lee J, Rawson R, Gupta R, Hong AM, Clark JR, Ch’ng S. Ann Surg Oncol. 2022 Aug;29(8):5124-5138. doi: 10.1245/s10434-022-11669-z. Epub 2022 Apr 13. PMID: 35419758; PMCID: PMC9246815.

Melanoma In Situ: A Critical Review and Re-Evaluation of Current Excision Margin Recommendations.

MIA Media2022-07-25T21:52:45+10:00July 25th, 2022|

Friedman EB, Scolyer RA, Williams GJ, Thompson JF. Adv Ther. (Epub 28 May 2021).

Phase Ib/II Trial of Ribociclib in Combination with Binimetinib in Patients with NRAS-mutant Melanoma.

MIA Media2022-10-23T19:41:23+11:00July 15th, 2022|

Schuler M, Zimmer L, Kim KB, Sosman JA, Ascierto PA, Postow MA, De Vos FYFL, van Herpen CML, Carlino MS, Johnson DB, Berking C, Reddy MB, Harney AS, Berlin JD, Amaria RN. Clin Cancer Res. 2022 Jul 15;28(14):3002-3010. doi: 10.1158/1078-0432.CCR-21-3872. PMID: 35294522.

Protein-based classification of melanoma differentiation subtypes.

MIA Media2022-10-23T20:24:48+11:00July 1st, 2022|

Lim SY, Pedersen B, Rizos H. Pigment Cell Melanoma Res. 2022 Jul;35(4):471-473. doi: 10.1111/pcmr.13041. Epub 2022 May 15. PMID: 35452161.

Re-induction ipilimumab following acquired resistance to combination ipilimumab and anti-PD-1 therapy.

MIA Media2022-07-25T21:40:02+10:00June 28th, 2022|

Hepner A, Atkinson VG, Larkin J, Burrell RA, Carlino MS, Johnson DB, Zimmer L, Tsai KK, Klein O, Lo SN, Haydon A, Bhave P, Lyle M, Pallan L, Pires da Silva I, Gerard C, Michielin O, Long GV, Menzies AM. Eur J Cancer. 2021 Jun 28;153:213-222.

MHC Class I Deficiency in Solid Tumors and Therapeutic Strategies to Overcome It

MIA Media2022-10-23T21:04:26+11:00June 23rd, 2022|

Shklovskaya E, Rizos H. Int J Mol Sci. 2021 Jun 23;22(13):6741. doi: 10.3390/ijms22136741. PMID: 34201655; PMCID: PMC8268865.

Outcomes after definitive treatment for head and neck angiosarcoma.

MIA Media2022-10-23T20:28:59+11:00June 1st, 2022|

Irawati N, Moghadam A, Abdul-Razak M, Strach M, Elliott M, Ch’ng S, Shannon K, Palme CE, Clark J, Wykes J, Low TH. ANZ J Surg. 2022 Jun;92(6):1407-1414. doi: 10.1111/ans.17695. Epub 2022 May 9. PMID: 35531880.

The role of regional chemotherapy for advanced limb melanoma in the era of potentially effective systemic therapies.

MIA Media2022-07-25T22:06:08+10:00May 25th, 2022|

Read RL, Thompson JF. Melanoma Res. (Epub 25 May 2021)

Changes in sun protection behaviours, sun exposure and shade availability among adults, children and adolescents in New South Wales, 2003-2016.

MIA Media2022-07-25T22:08:51+10:00May 24th, 2022|

Liew AY, Cust AE. Aust N Z J Public Health. (Epub 24 May 2021)

Repurposing Melanoma Chemotherapy to Activate Inflammasomes in the Treatment of BRAF/MAPK Inhibitor Resistant Melanoma.

MIA Media2022-10-23T21:01:03+11:00May 1st, 2022|

Ahmed F, Tseng HY, Ahn A, Gunatilake D, Alavi S, Eccles M, Rizos H, Gallagher SJ, Tiffen JC, Hersey P, Emran AA. J Invest Dermatol. 2022 May;142(5):1444-1455.e10. doi: 10.1016/j.jid.2021.09.030. Epub 2021 Oct 22. PMID: 34695412

Nicotinamide Inhibits T Cell Exhaustion and Increases Differentiation of CD8 Effector T Cells.

MIA Media2022-11-20T13:43:47+11:00January 10th, 2022|

Alavi S, Emran AA, Tseng HY, Tiffen JC, McGuire HM, Hersey P. Cancers (Basel). 2022 Jan 10;14(2):323. doi: 10.3390/cancers14020323. PMID: 35053490; PMCID: PMC8774026.

Pyrexia in patients treated with dabrafenib plus trametinib across clinical trials in BRAF-mutant cancers.

MIA Media2022-11-20T13:44:10+11:00December 21st, 2021|

Hersey P. Eur J Cancer. 2022 Feb;162:241-242. doi: 10.1016/j.ejca.2021.10.037. Epub 2021 Dec 20. PMID: 34949515.

A survey of surgical management of the sentinel node positive melanoma patient in the post-MSLT2 era.

MIA Media2022-07-23T17:42:30+10:00December 1st, 2021|

Downs JS, Subramaniam S, Henderson MA, Paton E, Spillane AJ, Mathy JA, Gyorki DE. J Surg Oncol. 2021 Dec;124(8):1544-1550.

Impact of Next-generation Sequencing on Interobserver Agreement and Diagnosis of Spitzoid Neoplasms.

MIA Media2022-07-23T17:39:25+10:00December 1st, 2021|

Benton S, Zhao J, Zhang B, Bahrami A, Barnhill RL, Busam K, Cerroni L, Cook MG, de la Fouchardière A, Elder DE, Johansson I, Landman G, Lazar A, LeBoit P, Lowe L, Massi D, Duncan LM, Messina J, Mihic-Probst D, Mihm MC Jr, Piepkorn MW, Schmidt B, Scolyer RA, Shea CR, Tetzlaff MT, Tron VA, Xu X, Yeh I, Yun SJ, Zembowicz A, Gerami P. Am J Surg Pathol. 2021 Dec 1;45(12):1597-1605

Assessing the Potential for Patient-led Surveillance After Treatment of Localized Melanoma (MEL-SELF): A Pilot Randomized Clinical Trial.

MIA Media2022-07-23T17:22:11+10:00November 24th, 2021|

Ackermann DM, Dieng M, Medcalf E, Jenkins MC, van Kemenade CH, Janda M, Turner RM, Cust AE, Morton RL, Irwig L, Guitera P, Soyer HP, Mar V, Hersch JK, Low D, Low C, Saw RPM, Scolyer RA, Drabarek D, Espinoza D, Azzi A, Lilleyman AM, Smit AK, Murchie P, Thompson JF, Bell KJL. JAMA Dermatol. (Epub 24 Nov 2021)

Long-Term Outcomes With Nivolumab Plus Ipilimumab or Nivolumab Alone Versus Ipilimumab in Patients With Advanced Melanoma.

MIA Media2022-07-23T17:15:22+10:00November 24th, 2021|

Wolchok JD, Chiarion-Sileni V, Gonzalez R, Grob JJ, Rutkowski P, Lao CD, Cowey CL, Schadendorf D, Wagstaff J, Dummer R, Ferrucci PF, Smylie M, Butler MO, Hill A, Márquez-Rodas I, Haanen JBAG, Guidoboni M, Maio M, Schöffski P, Carlino MS, Lebbé C, McArthur G, Ascierto PA, Daniels GA, Long GV, Bas T, Ritchings C, Larkin J, Hodi FS. J Clin Oncol. (Epub 24 Nov 2021)

Adaptive designs for clinical trials have potential advantages, but statistical challenges lurk!

MIA Media2022-07-23T17:31:02+10:00November 22nd, 2021|

Lo SN, Thompson JF. Br J Dermatol. (Epub 22 Nov 2021)

Multi-trait genetic analysis identifies auto-immune loci associated with cutaneous melanoma.

MIA Media2022-07-23T17:26:41+10:00November 20th, 2021|

Liyanage U, MacGregor S, Bishop DT, Shi J, An J, Ong JS, Han X, Scolyer RA, Martin NG, Medland SE, Byrne EM, Green AC, Saw RPM, Thompson JF, Stretch J, Spillane A, Jiang Y, Tian C; 23andMe Research Team, Gordon SG, Duffy DL, Olsen CM, Whiteman DC, Long GV, Iles MM, Landi MT, Law MH. J Invest Dermatol. (Epub 20 Nov 2021)

KEYNOTE-022: Pembrolizumab with trametinib in patients with BRAF wild-type melanoma or advanced solid tumours irrespective of BRAF mutation.

MIA Media2022-07-23T17:04:44+10:00November 17th, 2021|

Maio M, Carlino MS, Joshua AM, McWhirter E, Ribas A, Ascierto PA, Miller WH Jr, Butler MO, Ferrucci PF, Zielinski RR, Del Vecchio M, Gasal E, Ghori R, Diede SJ, Croydon E, Hamid O. Eur J Cancer. 2021 Nov 17:S0959-8049(21)00621-3.

Optical coherence tomography features of a tumour of the follicular infundibulum.

MIA Media2022-07-23T17:10:03+10:00November 10th, 2021|

Koutsis JJ, Cachia AR, Guitera PA, Martin LK. Australas J Dermatol. (Epub 4 Nov 2021)

Unravelling Checkpoint Inhibitor Associated Autoimmune Diabetes: From Bench to Bedside.

MIA Media2022-07-23T17:34:37+10:00November 5th, 2021|

Wu L, Tsang VHM, Sasson SC, Menzies AM, Carlino MS, Brown DA, Clifton-Bligh R, Gunton JE. Front Endocrinol (Lausanne). 2021 Nov 5;12:764138.

Case report of a challenging medium-sized congenital melanocytic nevus (CMN): Highlighting a role for reflectance confocal microscopy (RCM) for evaluating changing CMN in children.

MIA Media2022-07-23T16:50:47+10:00November 4th, 2021|

Haefliger S, Guitera P, Melhoranse Gouveia B, Colebatch AJ, Scolyer RA, Rtshiladze M, Martin LK. Pediatr Dermatol. (Epub 4 Nov 2021)

Association Between Melanoma Detected During Routine Skin Checks and Mortality.

MIA Media2022-07-23T16:56:23+10:00November 3rd, 2021|

Watts CG, McLoughlin K, Goumas C, van Kemenade CH, Aitken JF, Soyer HP, Fernandez Peñas P, Guitera P, Scolyer RA, Morton RL, Menzies SW, Caruana M, Kang YJ, Mann GJ, Chakera AH, Madronio CM, Armstrong BK, Thompson JF, Cust AE. JAMA Dermatol. (Epub 4 Nov 2021)

Complex melanoma of the scalp: Diagnosis and management aided by confocal microscopy.

MIA Media2022-07-23T16:32:33+10:00October 26th, 2021|

Regio Pereira A, Guitera P, Ferguson PM, Ch’ng S, Hirata S. Australas J Dermatol. (Epub 26 Oct 2021)

Review BRAF inhibition and the spectrum of granulomatous reactions.

MIA Media2022-07-23T16:23:30+10:00October 26th, 2021|

Pham JP, Star P, Phan K, Loh Y, Joshua AM, Smith A. J Am Acad Dermatol. (Epub 26 Oct 2021)

Antitumor Activity of Ipilimumab or BRAF ± MEK Inhibition After Pembrolizumab in Patients With Advanced Melanoma: Analysis from KEYNOTE-006.

MIA Media2022-07-23T16:27:18+10:00October 25th, 2021|

Long GV, Arance A, Mortier L, Lorigan P, Blank C, Mohr P, Schachter J, Grob JJ, Lotem M, Middleton MR, Neyns B, Steven N, Ribas A, Walpole E, Carlino MS, Lebbe C, Sznol M, Jensen E, Leiby MA, Ibrahim N, Robert C. Ann Oncol. (Epub 26 Oct 2021)

Repurposing Melanoma Chemotherapy to Activate Inflammasomes in the Treatment of BRAF/MAPK Inhibitor Resistant Melanoma.

MIA Media2022-07-23T16:39:59+10:00October 22nd, 2021|

Ahmed F, Tseng HY, Ahn A, Gunatilake D, Alavi S, Eccles M, Rizos H, Gallagher S, Tiffen J, Hersey P, Al Emran A. J Invest Dermatol. (Epub 26 Oct 2021)

Acute bilateral phrenic nerve neuropathy causing hypercapnic respiratory associated with checkpoint inhibitor immunotherapy.

MIA Media2022-07-23T16:47:19+10:00October 21st, 2021|

Srinivasan M, Taylor AM, Long GV, Herkes G, King GG. Respir Med Case Rep. 2021 Oct 21;34:101533.

Grade 4 Neutropenia Secondary to Immune Checkpoint Inhibition – A Descriptive Observational Retrospective Multicenter Analysis.

Jane Varley2022-07-23T16:44:16+10:00October 21st, 2021|

Zaremba A, Kramer R, De Temple V, Bertram S, Salzmann M, Gesierich A, Reinhardt L, Baroudjian B, Sachse MM, Mechtersheimer G, Johnson DB, Weppler AM, Spain L, Loquai C, Dudda M, Pföhler C, Hepner A, Long GV, Menzies AM, Carlino MS, Lebbé C, Enokida T, Tahara M, Bröckelmann PJ, Eigentler T, Kähler KC, Gutzmer R, Berking C, Ugurel S, Stadtler N, Sucker A, Becker JC, Livingstone E, Meier F, Hassel JC, Schadendorf D, Hanoun M, Heinzerling L, Zimmer L. Front Oncol. (21 Oct 2021)

High-Dimensional Single-Cell Transcriptomics in Melanoma and Cancer Immunotherapy

MIA Media2022-07-23T16:19:32+10:00October 16th, 2021|

Quek C, Bai X, Long GV, Scolyer RA, Wilmott JS. Genes (Basel). (Oct 16 2021)

Combined presentation and immunogenicity analysis reveals a recurrent RAS.Q61K neoantigen in melanoma.

MIA Media2022-07-23T20:29:32+10:00October 15th, 2021|

Peri A, Greenstein E, Alon M, Pai JA, Dingjan T, Reich-Zeliger S, Barnea E, Barbolin C, Levy R, Arnedo-Pac C, Kalaora S, Dassa B, Feldmesser E, Shang P, Greenberg P, Levin Y, Benedek G, Levesque MP, Adams DJ, Lotem M, Wilmott JS, Scolyer RA, Jönsson GB, Admon A, Rosenberg SA, Cohen CJ, Niv MY, Lopez-Bigas N, Satpathy AT, Friedman N, Samuels Y. J Clin Invest. 2021 Oct 15;131(20):e129466.

Interventions to Increase Sunscreen Use in Adults: A Review of the Literature.

MIA Media2022-07-23T20:32:51+10:00October 12th, 2021|

Allen N, Damian DL. Health Educ Behav. (Epub 12 Oct 2021)

Immune checkpoint inhibitors in patients with pre-existing psoriasis: safety and efficacy

Jane Varley2022-07-23T20:38:01+10:00October 11th, 2021|

Halle BR, Betof Warner A, Zaman FY, Haydon A, Bhave P, Dewan AK, Ye F, Irlmeier R, Mehta P, Kurtansky NR, Lacouture ME, Hassel JC, Choi JS, Sosman JA, Chandra S, Otto TS, Sullivan R, Mooradian MJ, Chen ST, Dimitriou F, Long G, Carlino M, Menzies A, Johnson DB, Rotemberg VM. J Immunother Cancer. (Epub 11 Oct 2021)

Melanoma brain metastases that progress on BRAF-MEK inhibitors demonstrate resistance to ipilimumab-nivolumab that is associated with the Innate PD-1 Resistance Signature (IPRES).

MIA Media2022-07-23T20:20:49+10:00October 8th, 2021|

Lau PKH, Feran B, Smith L, Lasocki A, Molania R, Smith K, Weppler A, Angel C, Kee D, Bhave P, Lee B, Young RJ, Iravani A, Yeang HA, Vergara IA, Kok D, Drummond K, Neeson PJ, Sheppard KE, Papenfuss T, Solomon BJ, Sandhu S, McArthur GA. J Immunother Cancer. (Epub 8 Oct 2021)

Road to Metastasis: The TWEAK Pathway as a Discriminant between Metastasizing and Non-Metastasizing Thick Melanomas

MIA Media2022-07-23T20:16:25+10:00September 29th, 2021|

Güvenç C, Antoranz A, Szumera-Ciećkiewicz A, Teterycz PP, Rutkowski PR, Rawson RV, Scolyer RA, Thompson JF, Newton-Bishop J, Stas M, Boecxstaens V, Bechter O, Vercauteren J, Garmyn M, van den Oord J, Bosisio FM. Int J Mol Sci. (Epub 29 Sept 2021)

Long-term outcomes in patients with advanced melanoma who had initial stable disease with pembrolizumab in KEYNOTE-001 and KEYNOTE-006.

MIA Media2022-07-23T20:08:01+10:00September 24th, 2021|

Hamid O, Robert C, Daud A, Carlino MS, Mitchell TC, Hersey P, Schachter J, Long GV, Hodi FS, Wolchok JD, Arance A, Grob JJ, Joshua AM, Weber JS, Mortier L, Jensen E, Diede SJ, Moreno BH, Ribas A. Eur J Cancer. (Epub 24 Sept 2021)

Irregular Sleep/Wake Patterns Are Associated With Reduced Quality of Life in Post-treatment Cancer Patients: A Study Across Three Cancer Cohorts

MIA Media2022-07-23T20:03:08+10:00September 22nd, 2021|

Trivedi R, Man H, Madut A, Mather M, Elder E, Dhillon HM, Brand A, Howle J, Mann G, DeFazio A, Amis T, Cain SW, Phillips AJK, Kairaitis K. Front Neurosci. (Epub 22 Sept 2021)

A practical guide on the use of Imiquimod cream for Lentigo Maligna.

MIA Media2022-07-23T19:40:49+10:00September 16th, 2021|

Guitera P, Waddell A, Paton E, Fogarty GB, Hong A, Scolyer RA, Stretch JR, O’Donnell BA, Pellacani G. Australas J Dermatol. (Epub 16 Sept 2021)

Interleukin-6 blockade for prophylaxis and management of immune-related adverse events in cancer immunotherapy.

MIA Media2022-07-23T19:38:03+10:00September 15th, 2021|

Dimitriou F, Hogan S, Menzies AM, Dummer R, Long GV. Eur J Cancer. (Epub 15 Sept 2021)

Immune checkpoint inhibitors in melanoma

MIA Media2022-07-23T19:51:12+10:00September 11th, 2021|

Carlino MS, Larkin J, Long GV. Lancet. (Epub 11 Sept 2021)

Adjuvant immunotherapy recommendations for stage III melanoma: physician and nurse interviews.

MIA Media2022-07-23T19:30:18+10:00September 10th, 2021|

Livingstone A, Dempsey K, Stockler MR, Howard K, Long GV, Carlino MS, Menzies AM, Morton RL. BMC Cancer. (Epub 10 Sept 2021)

PARP Inhibitors in Melanoma-An Expanding Therapeutic Option?

MIA Media2022-07-23T19:56:37+10:00September 8th, 2021|

Chan WY, Brown LJ, Reid L, Joshua AM. Cancers (Basel). (Epub 8 Sept 2021)

Skin cancer classification via convolutional neural networks: systematic review of studies involving human experts.

MIA Media2022-07-23T19:23:39+10:00September 8th, 2021|

Haggenmüller S, Maron RC, Hekler A, Utikal JS, Barata C, Barnhill RL, Beltraminelli H, Berking C, Betz-Stablein B, Blum A, Braun SA, Carr R, Combalia M, Fernandez-Figueras MT, Ferrara G, Fraitag S, French LE, Gellrich FF, Ghoreschi K, Goebeler M, Guitera P, Haenssle HA, Haferkamp S, Heinzerling L, Heppt MV, Hilke FJ, Hobelsberger S, Krahl D, Kutzner H, Lallas A, Liopyris K, Llamas-Velasco M, Malvehy J, Meier F, Müller CSL, Navarini AA, Navarrete-Dechent C, Perasole A, Poch G, Podlipnik S, Requena L, Rotemberg VM, Saggini A, Sangueza OP, Santonja C, Schadendorf D, Schilling B, Schlaak M, Schlager JG, Sergon M, Sondermann W, Soyer HP, Starz H, Stolz W, Vale E, Weyers W, Zink A, Krieghoff-Henning E, Kather JN, von Kalle C, Lipka DB, Fröhling S, Hauschild A, Kittler H, Brinker TJ. Eur J Cancer. (Epub 8 Sept 2021)

Position statement on classification of basal cell carcinomas. Part 1: unsupervised clustering of experts as a way to build an operational classification of advanced basal cell carcinoma based on pattern recognition.

MIA Media2022-07-23T19:11:07+10:00August 25th, 2021|

Grob JJ, Guminski A, Malvehy J, Basset-Seguin N, Bertrand B, Fernandez-Penas P, Kaufmann R, Zalaudek I, Gaudy-Marqueste C, Fargnoli MC, Tagliaferri L, Fertil B, Del Marmol V, Stratigos A, Garbe C, Peris K. J Eur Acad Dermatol Venereol. (Epub 25 Aug 2021)

Position statement on classification of basal cell carcinomas. Part 2: EADO proposal for new operational staging system adapted to basal cell carcinomas.

MIA Media2022-07-23T19:14:13+10:00August 23rd, 2021|

Grob JJ, Gaudy-Marqueste C, Guminski A, Malvehy J, Basset-Seguin N, Bertrand B, Fernandez-Penas P, Kaufmann R, Zalaudek I, Fargnoli MC, Tagliaferri L, Fertil B, Del Marmol V, Stratigos A, Garbe C, Peris K. J Eur Acad Dermatol Venereol. (Epub 23 Aug 2021)

Metastatic acral melanoma treatment outcomes: a systematic review and meta-analysis.

MIA Media2022-07-23T19:06:20+10:00August 23rd, 2021|

Cho KK, Cust AE, Foo YM, Long GV, Menzies AM, Eslick GD. Melanoma Res. (Epub 23 Aug 2021)

Cutaneous clear cell sarcoma with an epidermal component mimicking melanoma.

MIA Media2022-07-23T19:17:56+10:00August 19th, 2021|

Potter AJ, Dimitriou F, Karim RZ, Mahar A, Chan C, Long GV, Scolyer RA. Pathology. (Epub 19 Aug 2021)

Strengthening melanoma prevention and early detection among people with type 2 diabetes.

MIA Media2022-07-23T18:56:44+10:00August 18th, 2021|

Cust AE. Br J Dermatol. (Epub 18 Aug 2021)

A survey of surgical management of the sentinel node positive melanoma patient in the post-MSLT2 era.

MIA Media2022-07-23T18:54:18+10:00August 18th, 2021|

Downs JS, Subramaniam S, Henderson MA, Paton E, Spillane AJ, Mathy JA, Gyorki DE. J Surg Oncol. (Epub 18 Aug 2021)

TMB and Inflammatory Gene Expression Associated With Clinical Outcomes Following Immunotherapy in Advanced Melanoma

MIA Media2022-07-23T18:25:33+10:00August 13th, 2021|

Hodi FS, Wolchok JD, Schadendorf D, Larkin J, Long GV, Qian X, Saci A, Young TC, Srinivasan S, Chang H, Tang H, Wind-Rotolo M, Rizzo JI, Jackson DG, Ascierto PA. Cancer Immunol Res. (Epub 13 Aug 2021)

Residual melanoma in wide local excision specimens after ‘complete’ excision of primary cutaneous in situ and invasive melanomas.

MIA Media2022-07-23T18:59:17+10:00August 12th, 2021|

Jackett LA, Satgunaseelan L, Roper E, Lo SN, Thompson JF, Scolyer RA. Pathology. (Epub 12 Aug 2021)

Impact of personal genomic risk information on melanoma prevention behaviors and psychological outcomes: a randomized controlled trial

MIA Media2022-07-23T18:31:09+10:00August 12th, 2021|

Smit AK, Allen M, Beswick B, Butow P, Dawkins H, Dobbinson SJ, Dunlop KL, Espinoza D, Fenton G, Kanetsky PA, Keogh L, Kimlin MG, Kirk J, Law MH, Lo S, Low C, Mann GJ, Reyes-Marcelino G, Morton RL, Newson AJ, Savard J, Trevena L, Wordsworth S, Cust AE. Genet Med. (Epub 12 Aug 2021)

The concepts of rechallenge and retreatment with immune checkpoint blockade in melanoma patients

MIA Media2022-07-23T18:20:00+10:00August 12th, 2021|

Zaremba A, Eggermont AMM, Robert C, Dummer R, Ugurel S, Livingstone E, Ascierto PA, Long GV, Schadendorf D, Zimmer L. Eur J Cancer. (Epub 12 Aug 2021)

Early use of high-dose-glucocorticoid for the management of irAE is associated with poorer survival in patients with advanced melanoma treated with anti-PD-1 monotherapy

MIA Media2022-07-23T18:42:02+10:00August 10th, 2021|

Bai X, Hu J, Betof Warner A, Quach HT, Cann CG, Zhang MZ, Si L, Tang B, Cui C, Yang X, Wei X, Pallan L, Harvey C, Manos MP, Ouyang O, Kim MS, Kasumova G, Cohen JV, Lawrence DP, Freedman C, Fadden RM, Rubin KM, Sharova T, Frederick DT, Flaherty KT, Rahma OE, Long GV, Menzies AM, Guo J, Shoushtari AN, Johnson DB, Sullivan RJ, Boland GM. Clin Cancer Res. (Epub 10 Aug 2021)

Survival Outcomes of Salvage Metastasectomy after Failure of Modern-Era Systemic Therapy for Melanoma

MIA Media2022-07-23T18:38:50+10:00August 10th, 2021|

Li AT, Vakharia K, Lo SN, Varey AHR, Carlino MS, Saw RPM, Shannon KF, Howle JR, Pennington TE, Stretch JR, Nieweg OE, Spillane AJ, Long GV, Menzies AM, Scolyer RA, Thompson JF, Ch’ng S. Ann Surg Oncol. (Epub 10 Aug 2021)

ASO Author Reflections: Surgical Resection May Improve the Outcome for Patients with Residual Metastatic Melanoma When Modern Systemic Therapies Have Not Achieved Complete Disease Control

MIA Media2022-07-23T18:45:23+10:00August 9th, 2021|

Ch’ng S, Scolyer RA, Thompson JF. Ann Surg Oncol. (Epub 9 Aug 2021)

In Sentinel Node-Positive Melanoma Patients, Does Omission of Completion Lymph Node Dissection Make More Intensive Follow-Up Necessary, and Does Adjuvant Systemic Therapy Permit Less Intensive Follow-Up?

MIA Media2022-07-23T21:02:51+10:00August 7th, 2021|

Thompson JF. Ann Surg Oncol. (Epub 7 Aug 2021)

Confocal microscopy, dermoscopy, and histopathology features of atypical intraepidermal melanocytic proliferations associated with evolution to melanoma in situ

MIA Media2022-05-16T16:27:08+10:00August 5th, 2021|

Rocha LKFL, Vilain RE, Scolyer RA, Lo SN, Drummond M, Star P, Fogarty GB, Hong AM, Guitera P. Int J Dermatol. (Epub 5 Aug 2021)

Correction to: Histological regression in melanoma: impact on sentinel lymph node status and survival.

MIA Media2022-07-23T21:07:37+10:00August 4th, 2021|

Aivazian K, Ahmed T, El Sharouni MA, Stretch JR, Saw RPM, Spillane AJ, Shannon KF, Ch’ng S, Nieweg OE, Thompson JF, Lo SN, Scolyer RA. Mod Pathol. (Epub 4 Aug 2021)

Survival Outcomes of Salvage Metastasectomy After Failure of Modern-Era Systemic Therapy for Melanoma

MIA Media2022-05-16T16:29:17+10:00August 4th, 2021|

Ipilimumab versus ipilimumab plus anti-PD-1 for metastatic melanoma – Authors’ reply

MIA Media2022-07-23T18:49:18+10:00August 1st, 2021|

da Silva IP, Ahmed T, Reijers ILM, Warner AB, Patrinely JR, Serra-Bellver P, Allayous C, Mangana J, Zimmer L, Trojaniello C, Klein O, Gerard CL, Michielin O, Haydon A, Ascierto PA, Carlino MS, Lebbe C, Lorigan P, Johnson DB, Sandhu S, Lo SN, Menzies AM, Long GV. Lancet Oncol. 22(8):e343-e344.

Surveillance of patients with thin melanoma.

MIA Media2022-07-23T20:46:53+10:00July 22nd, 2021|

Ribero S, Cust AE. Australas J Dermatol. (Epub 22 July 2021)

Contemporary management of locoregionally advanced melanoma in Australia and New Zealand and the role of adjuvant systemic therapy.

MIA Media2022-07-23T20:52:26+10:00July 20th, 2021|

Smithers BM, Saw RPM, Gyorki DE, Martin RCW, Atkinson V, Haydon A, Roberts-Thomson R, Thompson JF. ANZ J Surg. (Epub 20 July 2021)

Deep Learning for Basal Cell Carcinoma Detection for Reflectance Confocal Microscopy.

MIA Media2022-07-23T20:42:26+10:00July 12th, 2021|

Campanella G, Navarrete-Dechent C, Liopyris K, Monnier J, Aleissa S, Minas B, Scope A, Longo C, Guitera P, Pellacani G, Kose K, Halpern AC, Fuchs TJ, Jain M. J Invest Dermatol. (Epub 12 July 2021)

Histological regression in melanoma: impact on sentinel lymph node status and survival.

MIA Media2022-07-23T21:19:27+10:00July 10th, 2021|

Aivazian K, Ahmed T, El Sharouni MA, Stretch JR, Saw RPM, Spillane AJ, Shannon KF, Ch’ng S, Nieweg OE, Thompson JF, Lo SN, Scolyer RA. Mod Pathol. (Epub 10 July 2021)

Knowledge, views and expectations for cancer polygenic risk testing in clinical practice: a cross-sectional survey of health professionals.

MIA Media2022-07-23T21:11:35+10:00July 3rd, 2021|

Smit AK, Sharman AR, Espinoza D, Wallingford C, Young MA, Dunlop K, Tiller J, Newson AJ, Meiser B, Cust AE, Yanes T. Clin Genet. (Epub 3 July 2021)

Pyrexia in patients treated with dabrafenib plus trametinib across clinical trials in BRAF-mutant cancers.

MIA Media2022-07-23T21:22:36+10:00July 2nd, 2021|

Schadendorf D, Robert C, Dummer R, Flaherty KT, Tawbi HA, Menzies AM, Banerjee H, Lau M, Long GV. Eur J Cancer. (Epub 2 July 2021)

Standard-Dose Pembrolizumab Plus Alternate-Dose Ipilimumab in Advanced Melanoma: KEYNOTE-029 Cohort 1C, a Phase 2 Randomized Study of Two Dosing Schedules.

MIA Media2022-07-23T21:15:41+10:00July 1st, 2021|

Long GV, Robert C, Butler MO, Couture F, Carlino MS, O’Day S, Atkinson V, Cebon JS, Brown MP, Dalle S, Hill AG, Gibney GT, McCune S, Menzies AM, Niu C, Ibrahim N, Homet Moreno B, Diab A. Clin Cancer Res. (Epub 1 July 2021)

Melanoma In Situ: A Critical Review and Re-Evaluation of Current Excision Margin Recommendations.

MIA Media2022-07-23T20:59:19+10:00July 1st, 2021|

Friedman EB, Scolyer RA, Williams GJ, Thompson JF. Adv Ther. 2021 Jul;38(7):3506-3530.

A multicentre study of naevus-associated melanoma vs. de novo melanoma, tumour thickness and body site differences.

MIA Media2022-07-23T20:56:30+10:00July 1st, 2021|

Dessinioti C, Geller AC, Stergiopoulou A, Dimou N, Lo S, Keim U, Gershenwald JE, Haydu LE, Dummer R, Mangana J, Hauschild A, Egberts F, Vieira R, Brinca A, Zalaudek I, Deinlein T, Evangelou E, Thompson JF, Scolyer RA, Peris K, Garbe C, Stratigos AJ. Br J Dermatol. 2021 Jul;185(1):101-109.

Characterizing the Clinical Implications of Histologic Regression in Melanoma Requires Clear Diagnostic Criteria That Are Consistently Applied-Reply.

MIA Media2022-07-25T21:47:59+10:00June 30th, 2021|

Scolyer RA, El Sharouni MA, Thompson JF. JAMA Dermatol. (Epub 30 June 2021)

Clinical and Molecular Heterogeneity in Patients with Innate Resistance to Anti-PD-1 +/- Anti-CTLA-4 Immunotherapy in Metastatic Melanoma Reveals Distinct Therapeutic Targets.

MIA Media2022-07-25T21:44:37+10:00June 25th, 2021|

Gide TN, Pires da Silva I, Quek C, Ferguson PM, Batten M, Shang P, Ahmed T, Menzies AM, Carlino MS, Saw RPM, Thompson JF, Scolyer RA, Long GV, Wilmott JS. Cancers (Basel). 2021 Jun 25;13(13):3186.

Hyperacute toxicity with combination ipilimumab and anti-PD1 immunotherapy.

MIA Media2022-07-25T21:35:49+10:00June 25th, 2021|

Dearden H, Au L, Wang DY, Zimmer L, Eroglu Z, Smith JL, Cuvietto M, Khoo C, Atkinson V, Lo S, Long GV, Sandhu S, Ascierto PA, Carlino MS, Johnson DB, Larkin J, Menzies AM. Eur J Cancer. 2021 Jun 25;153:168-178.

Risk of radiation necrosis after stereotactic radiosurgery for melanoma brain metastasis by anatomical location.

MIA Media2022-07-23T21:57:15+10:00June 19th, 2021|

Choi S, Hong A, Wang T, Lo S, Chen B, Silva I, Kapoor R, Hsiao E, Fogarty GB, Carlino MS, Menzies AM, Long GV, Shivalingam BS. Strahlenther Onkol. (Epub 19 June 2021)

Lysine Demethylases: Promising Drug Targets in Melanoma and Other Cancers.

MIA Media2022-07-25T21:27:36+10:00June 16th, 2021|

Punnia-Moorthy G, Hersey P, Emran AA, Tiffen J. Front Genet. 2021 Jun 16;12:680633.

Bilateral facial neuritis associated with dabrafenib and trametinib after failure of neoadjuvant immunotherapy for stage III melanoma.

MIA Media2022-07-25T21:24:51+10:00June 14th, 2021|

Li AT, Maw AM, Hsiao E, Ch’ng S, Long GV, Shannon KF, Morrison EJ. ANZ J Surg. (Epub 14 June 2021)

Re-defining the role of surgery in the management of patients with oligometastatic stage IV melanoma in the era of effective systemic therapies.

MIA Media2022-07-25T21:21:25+10:00June 11th, 2021|

Ch’ng S, Uyulmaz S, Carlino MS, Pennington TE, Shannon KF, Rtshiladze M, Stretch JR, Nieweg OE, Varey AHR, Hsiao E, Kapoor R, Pires da Silva I, Lo SN, Spillane AJ, Scolyer RA, Long GV, Hong AM, Saw RPM, Thompson JF, Menzies AM. Eur J Cancer. (Epub 11 June 2021)

Role of Tumor-Infiltrating B Cells in Clinical Outcome of Patients with Melanoma Treated With Dabrafenib Plus Trametinib

MIA Media2022-07-23T22:00:01+10:00June 9th, 2021|

Brase JC, Walter RFH, Savchenko A, Gusenleitner D, Garrett J, Schimming TT, Váraljai R, Castelletti D, Kim JY, Dakappagari NK, Schultz K, Robert C, Long GV, Nathan PD, Ribas A, Flaherty KT, Karaszewska B, Schachter J, Sucker A, Schmid KW, Zimmer L, Livingstone E, Gasal E, Schadendorf D, Roesch A. Clin Cancer Res. (Epub 9 June 2021)

PDCD1 Polymorphisms May Predict Response to Anti-PD-1 Blockade in Patients With Metastatic Melanoma.

MIA Media2022-07-25T21:10:57+10:00June 9th, 2021|

Parakh S, Musafer A, Paessler S, Witkowski T, Suen CSNLW, Tutuka CSA, Carlino MS, Menzies AM, Scolyer RA, Cebon J, Dobrovic A, Long GV, Klein O, Behren A. Front Immunol. 2021 Jun 9;12:672521.

Identifying the ‘Active Ingredients’ of an Effective Psychological Intervention to Reduce Fear of Cancer Recurrence: A Process Evaluation.

MIA Media2022-07-25T21:31:38+10:00June 7th, 2021|

Kan JM, Dieng M, Butow PN, Mireskandari S, Tesson S, Menzies SW, Costa DSJ, Morton RL, Mann GJ, Cust AE, Kasparian NA. Front Psychol. (Epub 7 June 2021)

Evolutionary predictability of genetic versus nongenetic resistance to anticancer drugs in melanoma.

MIA Media2022-07-25T21:14:53+10:00June 7th, 2021|

Marin-Bejar O, Rogiers A, Dewaele M, Femel J, Karras P, Pozniak J, Bervoets G, Van Raemdonck N, Pedri D, Swings T, Demeulemeester J, Borght SV, Lehnert S, Bosisio F, van den Oord JJ, Bempt IV, Lambrechts D, Voet T, Bechter O, Rizos H, Levesque MP, Leucci E, Lund AW, Rambow F, Marine JC. Cancer Cell. (Epub 7 June 2021)

Neoadjuvant Immunotherapy in Melanoma – The New Frontier

MIA Media2022-07-23T21:46:48+10:00June 3rd, 2021|

Menzies AM, Scolyer RA, Long GV. Clin Cancer Res. (Epub 3 Jun 2021)

Neoadjuvant immunotherapy in melanoma – the new frontier

MIA Media2022-07-23T21:34:18+10:00June 3rd, 2021|

Menzies AM, Scolyer RA, Long GV. Clin Cancer Res. (Epub 3 June 2021)

Evaluation of Crizotinib Treatment in a Patient With Unresectable GOPC-ROS1 Fusion Agminated Spitz Nevi

MIA Media2022-07-23T21:43:01+10:00June 2nd, 2021|

Robertson SJ, Orme L, Teixeira R, Shamassi M, Newell F, Patch AM, Yeh I, Gard G, Wilmott J, Jackett L, LeBoit P, Fellowes A, MacArthur G, Fox S, Hayward NK, Bastian B, Scolyer R, Waddell N, Penington A, Shackleton M. JAMA Dermatol. (Epub 2 June 2021)

Counting mitoses: SI(ze) matters!

MIA Media2022-07-23T21:39:14+10:00June 2nd, 2021|

Cree IA, Tan PH, Travis WD, Wesseling P, Yagi Y, White VA, Lokuhetty D, Scolyer RA. Mod Pathol. (Epub 2 June 2021)

Melanoma with osseous or chondroid differentiation: a report of eight cases including SATB2 expression and mutation analysis.

MIA Media2022-07-23T21:30:04+10:00June 2nd, 2021|

Gallagher SJ, Bailey T, Rawson RV, Mahar AM, Thompson JF, Long GV, Wilmott JS, Scolyer RA. Pathology. (Epub 2 June 2021)

Risk factors for melanoma by anatomical site: an evaluation of aetiological heterogeneity.

MIA Media2022-07-23T22:03:24+10:00June 1st, 2021|

Laskar R, Ferreiro-Iglesias A, Bishop DT, Iles MM, Kanetsky PA, Armstrong BK, Law MH, Goldstein AM, Aitken JF, Giles GG; Australian Melanoma Family Study Investigators; Leeds Case-Control Study Investigators, Robbins HA, Cust AE. Br J Dermatol. 2021 Jun;184(6):1085-1093.

Current Challenges in Access to Melanoma Care: A Multidisciplinary Perspective.

MIA Media2022-07-23T21:53:30+10:00June 1st, 2021|

Khushalani NI, Truong TG, Thompson JF. Am Soc Clin Oncol Educ Book. 2021 Jun;41:e295-e303.

Validation of the American Joint Committee on Cancer Staging in Squamous Cell Carcinoma of the Vermilion Lip

MIA Media2022-07-23T21:26:14+10:00June 1st, 2021|

Yung AE, Que MS, Lo S, Aggarwal S, Hong AM, Tin MM, Clark JR, Gupta R, Ch’ng S. Ann Surg Oncol. 2021 Jun;28(6):3092-3099.

Immunotherapy in advanced Merkel cell carcinoma: Sydney west cancer network experience.

MIA Media2022-07-25T21:50:40+10:00May 30th, 2021|

Hasmat S, Howle JR, Karikios DJ, Carlino MS, Veness MJ. J Med Imaging Radiat Oncol. (Epub 30 May 2021)

Predicting recurrence in patients with sentinel node-negative melanoma: validation of the EORTC nomogram using population-based data.

MIA Media2022-07-25T22:03:57+10:00May 27th, 2021|

El Sharouni MA, Ahmed T, Witkamp AJ, Sigurdsson V, van Gils CH, Nieweg OE, Scolyer RA, Thompson JF, van Diest PJ, Lo SN. Br J Surg. 2021 May 27;108(5):550-553.

Melanoma Cell State-Specific Responses to TNFα

MIA Media2022-07-25T22:10:49+10:00May 26th, 2021|

Lim SY, Alavi S, Ming Z, Shklovskaya E, Fung C, Stewart A, Rizos H. Biomedicines. (Epub 26 May 2021)

An independent external validation of melanoma risk prediction models using the Australian Melanoma Family Study.

MIA Media2022-07-25T22:14:15+10:00May 1st, 2021|

Vuong K, Armstrong BK, Espinoza D, Hopper JL, Aitken JF, Giles GG, Schmid H, Mann GJ, Cust AE, McGeechan K. Br J Dermatol. 2021 May;184(5):957-960.

Pembrolizumab versus placebo as adjuvant therapy in completely resected stage IIB or IIC melanoma (KEYNOTE-716): a randomised, double-blind, phase 3 trial

MIA Media2022-07-25T21:12:03+10:00April 30th, 2021|

Jason J Luke, Prof Piotr Rutkowski, Paola Queirolo, Michele Del Vecchio, Prof Jacek Mackiewicz, Vanna Chiarion-Sileni, Luis de la Cruz Merino, Prof Muhammad A Khattak, Prof Dirk Schadendorf, Prof Georgina V Long, Paolo A Ascierto, Mario Mandala, Federica De Galitiis, Andrew Haydon, Reinhard Dummer, Prof Jean-Jacques Grob, Caroline Robert, Matteo S Carlino, Peter Mohr, Andrew Poklepovic, Prof Vernon K Sondak, Prof Richard A Scolyer, John M Kirkwood, Ke Chen, Scott J Diede, Sama Ahsan, Nageatte Ibrahim, Prof Alexander M M. Lancet. (30 Apr 2022)

Pathological response and survival with neoadjuvant therapy in melanoma: a pooled analysis from the International Neoadjuvant Melanoma Consortium (INMC)

MIA Media2022-06-09T10:58:09+10:00February 9th, 2021|

Alexander M. Menzies, Rodabe N. Amaria, Elisa A. Rozeman, Alexander C. Huang, Michael T. Tetzlaff, Bart A. van de Wiel, Serigne Lo, Ahmad A. Tarhini, Elizabeth M. Burton, Thomas E. Pennington, Robyn P. M. Saw, Xiaowei Xu, Giorgos C. Karakousis, Paolo A. Ascierto, Andrew J. Spillane, Alexander C. J. van Akkooi, Michael A. Davies, Tara C. Mitchell, Hussein A. Tawbi, Richard A. Scolyer, Jennifer A. Wargo, Christian U. Blank & Georgina V. Long. Nat Med (2021).

Melanoma recurrence patterns and management after adjuvant targeted therapy: a multicentre analysis.

MIA Media2022-07-25T22:17:12+10:00February 1st, 2021|

Bhave P, Pallan L, Long GV, Menzies AM, Atkinson V, Cohen JV, Sullivan RJ, Chiarion-Sileni V, Nyakas M, Kahler K, Hauschild A, Plummer R, Trojaniello C, Ascierto PA, Zimmer L, Schadendorf D, Allayous C, Lebbe C, Maurichi A, Santinami M, Roy S, Robert C, Lesimple T, Patel S, Versluis JM, Blank CU, Khattak A, Van der Westhuizen A, Carlino MS, Shackleton M, Haydon A. Br J Cancer. 2021 Feb;124(3):574-580.

Distinct Immune Cell Populations Define Response to Anti-PD-1 Monotherapy and Anti-PD-1/Anti-CTLA-4 Combined Therapy

MIA Media2022-11-09T10:00:00+11:00February 11th, 2019|

Tuba N. Gide, Camelia Quek, Alexander M. Menzies, Annie T. Tasker, Ping Shang, Jeff Holst, Jason Madore, Su Yin Lim, Rebecca Velickovic, Matthew Wongchenko, Yibing Yan, Serigne Lo, Matteo S. Carlino, Alexander Guminski, Robyn P.M. Saw, Angel Pang, Helen M. McGuire, Umaimainthan Palendira, John F. Thompson, Helen Rizos, Ines Pires da Silva,
Marcel Batten, Richard A. Scolyer, Georgina V. Long, James S. Wilmott. Cancer Cell Volume 35, Issue 2, P238-255.E6

For earlier research papers, prior to 2021, please email digital@melanoma.org.au.